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FOREWORD
This toxicological profile is prepared in accordance with guidelines developed by the Agency for Toxic 
Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The 
original guidelines were published in the Federal Register on April 17, 1987. Each profile will be revised 
and republished as necessary.
The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects 
information for the hazardous substance described therein. Each peer-reviewed profile identifies and 
reviews the key literature that describes a substance’s toxicologic properties. Other pertinent literature is 
also presented, but is described in less detail than the key studies. The profile is not intended to be an 
exhaustive document; more comprehensive sources o f specialty information are referenced.
The focus o f the profiles is on health and toxicologic information. Each toxicological profile begins with 
a public health statement that describes, in nontechnical language, a substance’s relevant toxicological 
properties. Following the public health statement is information concerning levels o f significant human 
exposure and, where known, significant health effects. The adequacy o f information to determine a 
substance’s health effects is described in a health effects summary. Data needs that are o f significance to 
protection o f public health are identified by ATSDR and EPA.
Each profile includes the following:
(A) The examination, summary, and interpretation of available toxicologic information and 
epidemiologic evaluations on a toxic substance to ascertain the levels of significant human 
exposure for the substance and the associated acute, subacute, and chronic health effects;
(B) A determination o f whether adequate information on the health effects o f each substance 
is available or in the process of development to determine levels of exposure that present a 
significant risk to human health of acute, subacute, and chronic health effects; and
(C) Where appropriate, identification of toxicologic testing needed to identify the types or 
levels o f exposure that may present significant risk o f adverse health effects in humans.
The principal audiences for the toxicological profiles are health professionals at the Federal, State, and 
local levels; interested private sector organizations and groups; and members o f the public. We plan to 
revise these documents in response to public comments and as additional data become available. 
Therefore, we encourage comments that will make the toxicological profile series o f the greatest use.
Christopher J. Portier, Ph.D.
Assistant Administrator 
Agency for Toxic Substances and Disease Registry
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QUICK REFERENCE FOR HEALTH CARE PROVIDERS
Toxicological Profiles are a unique compilation of toxicological information on a given hazardous 
substance. Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation 
o f available toxicologic and epidemiologic information on a substance. Health care providers treating 
patients potentially exposed to hazardous substances will find the following information helpful for fast 
answers to often-asked questions.
Prim ary Chapters/Sections o f  Interest
Chapter 1: Public Health Statement: The Public Health Statement can be a useful tool for educating 
patients about possible exposure to a hazardous substance. It explains a substance’s relevant 
toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of 
the general health effects observed following exposure.
Chapter 2: Relevance to Public Health: The Relevance to Public Health Section evaluates, interprets, 
and assesses the significance o f toxicity data to human health.
Chapter 3: Health Effects: Specific health effects o f a given hazardous compound are reported by type 
o f health effect (death, systemic, immunologic, reproductive), by route o f exposure, and by length 
o f exposure (acute, intermediate, and chronic). In addition, both human and animal studies are 
reported in this section.
N O T E : Not all health effects reported in this section are necessarily observed in the clinical 
setting. Please refer to the Public Health Statement to identify general health effects observed 
following exposure.






How Can (Chemical X) Affect Children?
How Can Families Reduce the Risk of Exposure to (Chemical X)? 
Children’s Susceptibility 
Exposures of Children
Other Sections of Interest:
Section 3.8 Biomarkers of Exposure and Effect
Section 3.11 Methods for Reducing Toxic Effects
A T S D R  Inform ation Center
P h on e : I-8OO-CDC-INFO (800-232-4636) or 1-888-232-6348 (TTY) F a x : (770) 488-4178
E-m ail: cdcinfo@cdc.gov In ternet: http://www.atsdr.cdc.gov
The following additional material can be ordered through the ATSDR Information Center:
Case Studies in Environmental Medicine: Taking an Exposure History—The importance o f taking an
exposure history and how to conduct one are described, and an example of a thorough exposure 
history is provided. Other case studies o f interest include Reproductive and Developmental
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Hazards; Skin Lesions and Environmental Exposures; Cholinesterase-Inhibiting Pesticide 
Toxicity; and numerous chemical-specific case studies.
Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene
(prehospital) and hospital medical management of patients exposed during a hazardous materials 
incident. Volumes I and II are planning guides to assist first responders and hospital emergency 
department personnel in planning for incidents that involve hazardous materials. Volume III— 
Medical Management Guidelines fo r  Acute Chemical Exposures—is a guide for health care 
professionals treating patients exposed to hazardous materials.
Fact Sheets (ToxFAQs) provide answers to frequently asked questions about toxic substances.
Other Agencies and Organizations
The National Center fo r  Environmental Health (NCEH) focuses on preventing or controlling disease,
injury, and disability related to the interactions between people and their environment outside the 
workplace. Contact: NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta,
GA 30341-3724 • Phone: 770-488-7000 • FAX: 770-488-7015.
The National Institute fo r  Occupational Safety and Health (NIOSH) conducts research on occupational 
diseases and injuries, responds to requests for assistance by investigating problems o f health and 
safety in the workplace, recommends standards to the Occupational Safety and Health 
Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains 
professionals in occupational safety and health. Contact: NIOSH, 200 Independence Avenue, 
SW, Washington, DC 20201 • Phone: 800-356-4674 or NIOSH Technical Information Branch, 
Robert A. Taft Laboratory, Mailstop C-19, 4676 Columbia Parkway, Cincinnati, OH 45226-1998 
• Phone: 800-35-NIOSH.
The National Institute o f  Environmental Health Sciences (NIEHS) is the principal federal agency for
biomedical research on the effects o f chemical, physical, and biologic environmental agents on 
human health and well-being. Contact: NIEHS, PO Box 12233, 104 T.W. Alexander Drive, 
Research Triangle Park, NC 27709 • Phone: 919-541-3212.
Referrals
The Association o f  Occupational and Environmental Clinics (AOEC) has developed a network o f clinics 
in the United States to provide expertise in occupational and environmental issues. Contact: 
AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone: 202-347-4976 
• FAX: 202-347-4950 • e-mail: AOEC@AOEC.ORG • Web Page: http://www.aoec.org/.
The American College o f  Occupational and Environmental Medicine (ACOEM) is an association of 
physicians and other health care providers specializing in the field of occupational and 
environmental medicine. Contact: ACOEM, 25 Northwest Point Boulevard, Suite 700, Elk 






ATSDR, Division o f Toxicology and Human Health Sciences (proposed), Atlanta, GA
Lisa Ingerman, Ph.D., DABT 
Fernando T. Llados, Ph.D.
Lynn E. Barber, M.S.
Daniel Plewak, B.S.
Gary L. Diamond, Ph.D.
SRC, Inc., North Syracuse, NY
THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS:
1. Health Effects Review. The Health Effects Review Committee examines the health effects 
chapter o f each profile for consistency and accuracy in interpreting health effects and classifying 
end points.
2. Minimal Risk Level Review. The Minimal Risk Level Workgroup considers issues relevant to 
substance-specific Minimal Risk Levels (MRLs), reviews the health effects database o f each 
profile, and makes recommendations for derivation o f MRLs.
3. Data Needs Review. The Environmental Toxicology Branch (proposed) reviews data needs 
sections to assure consistency across profiles and adherence to instructions in the Guidance.
4. Green Border Review. Green Border review assures the consistency with ATSDR policy.
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PEER REVIEW
A peer review panel was assembled for RDX. The panel consisted o f the following members:
1. Ping Gong, Ph.D., Senior Scientist, SpecPro, Inc., Vicksburg, Mississippi;
2. Sam Kacew, Ph.D., Associate Director of Toxicology, McLauglin Centre for Population Health 
Risk Assessment, University o f Ottawa, Ottawa, Ontario; and
3. Sharon A. Meyer, Ph.D., Associate Professor, Department o f Toxicology, College o f Health 
Sciences, University o f Louisiana at Monroe, Monroe, Louisiana.
These experts collectively have knowledge o f RDX’s physical and chemical properties, toxicokinetics, 
key health end points, mechanisms o f action, human and animal exposure, and quantification o f risk to 
humans. All reviewers were selected in conformity with the conditions for peer review specified in 
Section 104(I)(13) o f the Comprehensive Environmental Response, Compensation, and Liability Act, as 
amended.
Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer 
reviewers' comments and determined which comments will be included in the profile. A listing o f the 
peer reviewers' comments not incorporated in the profile, with a brief explanation o f the rationale for their 
exclusion, exists as part o f the administrative record for this compound.
The citation o f the peer review panel should not be understood to imply its approval o f the profile's final 
content. The responsibility for the content o f this profile lies with the ATSDR.
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1. PUBLIC HEALTH STATEMENT
This public health statement tells you about hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) and the effects 
o f exposure to it.
The Environmental Protection Agency (EPA) identifies the most serious hazardous waste sites in the 
nation. These sites are then placed on the National Priorities List (NPL) and are targeted for long-term 
federal clean-up activities. RDX has been found in at least 31 o f the 1,699 current or former NPL sites. 
Although the total number o f NPL sites evaluated for this substance is not known, the possibility exists 
that the number o f sites at which RDX is found may increase in the future as more sites are evaluated. 
This information is important because these sites may be sources of exposure and exposure to this 
substance may be harmful.
When a substance is released either from a large area, such as an industrial plant, or from a container, 
such as a drum or bottle, it enters the environment. Such a release does not always lead to exposure. You 
can be exposed to a substance only when you come in contact with it. You may be exposed by breathing, 
eating, or drinking the substance, or by skin contact.
If  you are exposed to RDX, many factors will determine whether you will be harmed. These factors 
include the dose (how much), the duration (how long), and how you come in contact with it. You must 
also consider any other chemicals you are exposed to and your age, sex, diet, family traits, lifestyle, and 
state o f health.
1.1 WHAT IS RDX?
Other nam es for RDX RDX stands for Royal Demolition Explosive, 
also known as cyclonite, hexogen, and 
hexahydro-1,3,5-trinitro-1,3,5-triazine.
White crystalline solid RDX is an explosive on its own, and can be 
combined with other ingredients to make plastic 
explosives (C-4 contains 91% RDX). Its odor 
and taste are unknown. When heated, acrid 
fumes may be released.
RDX 2
1. PUBLIC HEALTH STATEMENT
Used in exp losives RDX is used as an explosive. It is a synthetic 
product that does not occur naturally in the 
environment.
1.2 WHAT HAPPENS TO RDX WHEN IT ENTERS THE ENVIRONMENT?
Found in water, so il, and air RDX particles can enter air when it is disposed 
of by burning. RDX can enter water from 
disposal of waste water from ammunition 
plants. RDX can enter water or soil from spills 
or leaks from improper disposal at plants or 
hazardous waste sites and at current and 
former military installations.
Rem oval from so il, water, and air RDX is slow dissolving in water. It does not 
bind significantly to soils and can leach to 
groundwater from soil. In water and air, RDX 
can break down in hours, but breaks down 
more slowly in soil. It does not build up in fish 
or people.
1.3 HOW MIGHT I BE EXPOSED TO RDX?
Air You may be exposed to RDX by the inhalation, 
oral, or dermal routes, or by any combination of 
these routes. Typically, only people who work 
with RDX can potentially breathe RDX dust or 
get it on their skin. You can be exposed if you 
breathe RDX fumes from explosions or bombing 
ranges of burning RDX.
W ater and so il You may be exposed to RDX by drinking 
contaminated water or by touching 
contaminated soil if you live near facilities that 
produce or use RDX. RDX has been found in 
water and soil near some ammunition plants, 
current or former military installations and 
storage areas.
Food You may be exposed to RDX by ingesting 
agricultural crops grown in contaminated soils 
irrigated with contaminated water.
1. P U B L IC  H E A L T H  S T A T E M E N T






RDX can enter your body if you breathe in fumes of burning 
RDX or from the detonation of munitions containing RDX or if 
you breath in the dust from powdered RDX.
It can also enter the body if you drink water contaminated with 
RDX or accidentally or intentionally ingest explosives 
containing RDX.
Much less RDX can enter the body through the skin if you 
come in contact with dusts of RDX or with liquids containing 
RDX.
Leave your body Based on observations made in humans and results from 
studies in animals, most of the RDX appears to be broken 
down rapidly in the body. These products, as well as 
unchanged RDX, are eliminated in the urine and exhaled air in 
a few days. RDX is not expected to accumulate in the body.
1.5 HOW CAN RDX AFFECT MY HEALTH?
Hum ans If you breathe in dusts of RDX or intentionally or accidentally 
swallow large amounts of RDX, you may develop seizures. 
The seizures are temporary and will stop after the RDX is 
eliminated from your body.
Some people exposed to large amounts of RDX also have 
alterations in blood pressure and in some components of the 
blood, but these effects may be secondary to the seizures.
We do not know the effects of long-term, low-level exposure to 
RDX.
Laboratory an im als Animals that had large amounts of RDX placed in the stomach 
with a tube or that ate food mixed with RDX for longer periods 
of time suffered seizures.
Rats and mice that ate RDX for 3 months or longer had 
decreased body weights and slight liver and kidney damage.
C ancer There are no studies reported of cancer in people exposed to 
RDX.
The EPA has determined that RDX is a possible human 
carcinogen based on the presence of liver tumors in mice that 
were exposed to RDX in the food for 1-2 years.
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1.6 HOW CAN RDX AFFECT CHILDREN?
This section discusses potential health effects in humans from exposures during the period from 
conception to maturity at 18 years o f age.
1. PUBLIC HEALTH STATEMENT
Effects in children There are no studies of children exposed to RDX, but a child 
who accidentally ingested RDX had seizures, which is the 
same effect that occurs in adults exposed to high amounts of 
RDX.
We do not know whether children are more susceptible to the 
effects of RDX than adults.
We do not know whether RDX causes birth defects in humans.
Laboratory anim als Exposure of animals to RDX during pregnancy has not caused 
birth defects in newborn animals. However, rats exposed to 
RDX during gestation gave birth to babies with smaller weight 
and length than rats not exposed to RDX.
In rats exposed to RDX during pregnancy, RDX was able to 
pass through the placenta and reached the fetus.
Young deer mice (21 days old) were more sensitive than older 
deer mice (50 days old) to the acute toxic effects of RDX.
Breast milk There are no studies that looked for RDX in human breast milk. 
However, rats exposed to RDX during pregnancy had RDX in 
their milk, suggesting that the same can occur in humans. This 
means that women exposed to RDX who nurse their babies 
could transfer RDX to the babies in the milk.
1.7 HOW CAN FAMILIES REDUCE THE RISK OF EXPOSURE TO RDX?
Consum er products RDX is not found in consumer products. Therefore, families 
are not expected to have contact with RDX through the use of 
consumer products.
Drinking water Families whose tap or well water may be contaminated with 
RDX may choose to drink or cook with bottled water or to install 
activated carbon water filters.
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1. PUBLIC HEALTH STATEMENT
IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO 
RDX?
Detecting exposure RDX can be measured in blood and urine, but these are not 
routine tests that can be performed in a doctor’s office.
We do not know whether the presence of RDX in the blood 
indicates that you were exposed briefly a few days before the 
blood was collected or that you are experiencing constant 
exposure.
M easuring exposure The tests for RDX in blood and urine cannot be used to 
determine how much RDX entered your body.
The presence of RDX in your blood does not necessarily mean 
that you will suffer adverse health effects. The usual immediate 
health effects are seizures, muscle twitching, or vomiting from 
very high exposures. These would probably occur before you 
had the blood or urine test.
1.9 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO 
PROTECT HUMAN HEALTH?
The federal government develops regulations and recommendations to protect public health. Regulations 
can be enforced by law. The EPA, the Occupational Safety and Health Administration (OSHA), and the 
Food and Drug Administration (FDA) are some federal agencies that develop regulations for toxic 
substances. Recommendations provide valuable guidelines to protect public health, but cannot be 
enforced by law. The Agency for Toxic Substances and Disease Registry (ATSDR) and the National 
Institute for Occupational Safety and Health (NIOSH) are two federal organizations that develop 
recommendations for toxic substances.
Regulations and recommendations can be expressed as “not-to-exceed” levels. These are levels o f a toxic 
substance in air, water, soil, or food that do not exceed a critical value. This critical value is usually based 
on levels that affect animals; they are then adjusted to levels that will help protect humans. Sometimes 
these not-to-exceed levels differ among federal organizations because they used different exposure times 
(an 8-hour workday or a 24-hour day), different animal studies, or other factors.
Recommendations and regulations are also updated periodically as more information becomes available. 
For the most current information, check with the federal agency or organization that provides it.
RDX
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Some regulations and recommendations for RDX include the following:
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Leve ls  in drinking w ater set by EP A The EPA has determined that exposure to RDX in 
drinking water at concentrations of 0.1 mg/L for one 
day or 0.1 mg/L for 10 days is not expected to cause 
any adverse effects in a child.
The EPA has determined that lifetime exposure to 
0.002 mg/L RDX is not expected to cause any 
adverse effects.
Leve ls  in w orkplace air se t by O SH A OSHA had previously set a legal limit of 1.5 mg/m3 for 
RDX in March 1989; however, the standard was 
vacated in 1992.
NIOSH has set a 10-hour time-weighted average 
recommended exposure limit of 1.5 mg/m3.
1.10 WHERE CAN I GET MORE INFORMATION?
I f  you have any more questions or concerns, please contact your community or state health or 
environmental quality department, or contact ATSDR at the address and phone number below.
ATSDR can also tell you the location o f occupational and environmental health clinics. These clinics 
specialize in recognizing, evaluating, and treating illnesses that result from exposure to hazardous 
substances.
Toxicological profiles are also available on-line at www.atsdr.cdc.gov and on CD-ROM. You may 
request a copy o f the ATSDR ToxProfiles™ CD-ROM by calling the toll-free information and technical 
assistance number at 1-800-CDCINFO (1-800-232-4636), by e-mail at cdcinfo@cdc.gov, or by writing
Agency for Toxic Substances and Disease Registry
Division o f Toxicology and Human Health Sciences (proposed)
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Organizations for-profit may request copies o f final Toxicological Profiles from the following:
National Technical Information Service (NTIS) 
5285 Port Royal Road 
Springfield, VA 22161 
Phone: 1-800-553-6847 or 1-703-605-6000 
Web site: http://www.ntis.gov/
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2. RELEVANCE TO PUBLIC HEALTH
2.1 BACKGROUND AND ENVIRONMENTAL EXPOSURES TO RDX IN THE UNITED 
STATES
RDX is a military explosive produced by the nitrolysis o f hexamine with nitric acid. It is a synthetic 
compound that does not occur naturally in the environment. Effluents and emissions from Army 
ammunition plants and many current and former military installations are responsible for the release of 
RDX into the environment. RDX can enter the air, water, and soil as a consequence o f these releases. 
RDX is expected to exist as a particulate in the atmosphere. RDX has low water solubility and is subject 
to photolysis (half-life o f 9-13 hours). RDX undergoes biodegradation in water and soil under anaerobic 
conditions to form several biodegradation products. RDX is mobile in soil and can leach into 
groundwater, and can be transported from soils or water to terrestrial and aquatic plants. RDX is not very 
lipid soluble, and therefore, has a low potential for bioaccumulation in aquatic species.
RDX has been identified in environmental samples, primarily near army munitions depots. Indoor air 
samples collected at ammunition plants were found to contain RDX in concentrations ranging from 
0.032 to 60 mg/m3. In water, RDX has been identified in a variety o f groundwater samples from 
ammunition plants in the United States (<20-13,200 ^g/L) and Germany (21-3,800 ^g/L). Sediment 
samples from Army depots have been found to contain RDX in concentrations ranging from <0.1 to 
3,574 mg/kg and in composts prepared from contaminated sediments (>2.9-896 mg/kg). Additionally, 
RDX was identified in plant species irrigated with or grown in contaminated water (<20-3,196 ^g/L).
For the general population, including children, exposure to RDX is limited to areas around Army 
ammunition plants where it is manufactured, used in munitions, packed, loaded, or released through the 
demilitarization o f antiquated munitions. The most likely route o f exposure is ingestion o f contaminated 
drinking water or agricultural crops irrigated with contaminated water. Exposure can also occur though 
dermal contact with soil containing RDX or by inhaling contaminated particulate matter produced during 
incineration o f RDX-containing waste material. Children playing in contaminated water or soil may also 
be exposed via ingestion. Children can also be exposed if  workers inadvertently bring home RDX 
adhered to shoes or clothing.
Occupational exposure to RDX can occur when workers handle RDX at Army ammunition plants. Under 
these conditions, exposure can occur as a result o f release o f dust into the workroom air, principally
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during dumping o f dried RDX powder, screening and blending, and clean-up o f spilled material.
Exposure to RDX can also occur through dermal contact during manufacture, handling, and clean-up of 
RDX. RDX was detected at a concentration o f 0.052 mg/m3 (0.47 ppm) in the particulate fraction o f only 
one o f eight indoor air samples taken from the incorporation area o f Holston Army Ammunition Plant in 
Tennessee in 1986. Based on the observed concentration, the potential for exposure to RDX is considered 
to be negligible.
2.2 SUMMARY OF HEALTH EFFECTS
There is limited information on the toxicity o f RDX in humans; the database consists o f studies of 
workers exposed to RDX dust, soldiers using C-4 (a plasticized explosive containing 91% RDX) as a 
cooking fuel, and case reports o f individuals ingesting RDX. Most o f these studies involve acute 
exposure to RDX and provide limited exposure information. Neurologic dysfunction, primarily seizures 
and convulsions, was the most commonly reported effect. The seizures/convulsions typically occurred 
within several hours o f exposure, and in some cases, convulsions were noted for several days after 
exposure. Other neurological symptoms that have been observed in humans include disorientation, 
lethargy, muscle twitching, and marked hyperirritability.
Studies in laboratory animals support neurological effects as a sensitive end point o f RDX. Seizures, 
convulsions, and tremors have been reported in rats, deer mice, dogs, and monkeys orally exposed to 
RDX for acute, intermediate, or chronic durations. As with human exposure, the clonic-tonic convulsions 
and seizures are often observed shortly after exposure; however, a study in monkeys did not report 
seizures in some o f the animals until after 34-57 doses o f 10 mg/kg/day. In acute-exposure studies, the 
lowest adverse effect level for seizures and convulsions was 17 mg/kg/day, with no seizures at
12.5 mg/kg/day. In addition to these neurological effects, decreases in motor activity and impaired 
learning were observed in rats following administration o f a single gavage dose of 12.5 mg/kg/day; 
however, no alterations in motor activity were observed in rats administered 10 mg/kg/day for 16 or 
30 days. A lower adverse effect level (8 mg/kg/day) was reported in an intermediate-duration study, with 
a no-observed-adverse-effect level (NOAEL) of 4 mg/kg/day. At higher doses (>40 mg/kg/day), 
hyperactivity, hyperirritability, hyperreactivity, and increased fighting have been observed in rats. 
Although the database is mostly comprised o f studies in rats, intermediate-duration studies in monkeys 
and dogs do not suggest species differences in RDX-induced seizures/convulsions. In chronic-duration 
oral studies, seizures and convulsions were observed at 40 mg/kg/day; this dose was also associated with 
88% lethality. No neurological effects were observed in rats chronically exposed to 8 or 10 mg/kg/day.
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The animal data suggest that there may be other targets o f RDX toxicity, including the hematological 
system and liver following oral exposure. Small, although significant, decreases in hemoglobin and 
erythrocyte levels were observed following intermediate-duration exposure, but this was not consistently 
found in other intermediate or chronic studies. Several studies found minor changes in serum chemistry 
parameters suggestive o f a slight impairment o f liver function. These alterations include decreases in 
alanine aminotransferase and in serum triglyceride and/or cholesterol levels and increases in serum 
cholesterol levels. A decrease in blood glucose levels observed in one study o f rats may also be related to 
impaired liver function. Hepatomegaly and hepatocellular vacuolization have been reported in rats; 
however, most studies did not report histological alterations in the liver. An intermediate-duration study 
in monkeys reported an increase in vomiting following gavage administration of 10 mg/kg/day RDX; the 
occurrence o f vomiting at 0.1 or 1 mg/kg/day was similar to controls.
There is limited information to suggest that RDX is a reproductive toxicant following oral exposure. An 
increased incidence o f spermatic granuloma in the prostate was observed in rats following exposure to 
40 mg/kg/day for 6 months; however, this effect was not observed at longer durations (1 or 2 years) in the 
same study. A nonsignificant increase in testicular degeneration was also observed in this study in rats 
exposed for 6 months to 40 mg/kg/day, but testicular effects were not observed in another study o f rats 
exposed to 100 mg/kg/day for 13 weeks. Adverse developmental effects have been observed in rats, 
particularly at maternally toxic doses. Decreases in pup survival and increases in the occurrence of 
stillbirths were observed at 50 mg/kg/day; this dose also resulted in maternal deaths. A decrease in pup 
body weight and an increase in the incidence of renal cysts were observed in F2 pups at 16 mg/kg/day in a 
two-generation study o f rats and a decrease in fetal body weight and length were observed in the offspring 
o f rats administered 20 mg/kg/day on gestation days 6-15. No adverse developmental (or maternal) 
effects were observed in rabbits.
The carcinogenic potential o f RDX was evaluated in orally exposed rats and mice; no evidence of 
carcinogenicity was observed in two rat studies. In mice, an increase in the combined incidence of 
hepatocellular adenomas and carcinomas was observed in females only. However, a re-evaluation of 
these data using current diagnostic criteria resulted in a reclassification of some hepatocellular adenomas 
as foci o f cytoplasmic alterations. As a result o f the re-analysis, the combined incidence was significantly 
higher than concurrent controls at 35 mg/kg/day, but not at 100 mg/kg/day and the incidence in the 
35 mg/kg/day group was within the range o f historical control data. The investigators suggested that the 
study provided equivocal evidence of carcinogenicity. The International Agency for Research on Cancer
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(IARC) and the Department o f Health and Human Services (DHHS) have not classified the 
carcinogenicity o f RDX. EPA classified RDX as a group C carcinogen, possibly carcinogenic to humans; 
however, this evaluation was done prior to the re-evaluation o f mouse tumor data. EPA is currently re­
evaluating RDX.
2.3 MINIMAL RISK LEVELS (MRLs)
ATSDR has made estimates o f exposure levels posing minimal risk to humans (MRLs) for RDX. An 
MRL is defined as an estimate o f daily human exposure to a substance that is likely to be without an 
appreciable risk o f adverse effects (noncarcinogenic) over a specified duration o f exposure. MRLs are 
derived when reliable and sufficient data exist to identify the target organ(s) o f effect or the most sensitive 
health effect(s) for a specific duration within a given route of exposure. MRLs are based on 
noncancerous adverse health effects only and do not consider carcinogenic effects. MRLs can be derived 
for acute, intermediate, and chronic duration exposures for inhalation and oral routes. Appropriate 
methodology does not exist to develop MRLs for dermal exposure.
Although methods have been established to derive levels posing minimal risks to humans (Barnes and 
Dourson 1988; EPA 1990b), uncertainties are associated with these techniques. Furthermore, ATSDR 
acknowledges additional uncertainties inherent in the application o f the procedures to derive less than 
lifetime MRLs. As an example, acute inhalation MRLs may not be protective for adverse health effects 
that are delayed in development or are acquired following repeated acute insults, such as hypersensitivity 
reactions, asthma, or chronic bronchitis. As these kinds o f health effects data become available and 
methods to assess levels o f significant human exposure improve, these MRLs will be revised.
Inhalation M R L s
ATSDR has not derived inhalation MRLs due to the limited data available on the toxicity o f RDX 
following inhalation exposure. Several studies reported convulsions in humans acutely exposed to 
unspecified amounts o f RDX (Hollander and Colbach 1969; Kaplan et al. 1965; Testud et al. 1996a). 
Nausea and vomiting have also been reported in humans (Hollander and Colbach 1969; Ketel and Hughes 
1972); however, these individuals may have been exposed to RDX via inhalation and ingestion. Deaths 
due to bronchopneumonia, pneumonia, or pulmonary congestion were observed in rabbits and guinea pigs 
exposed to an unspecified concentration of RDX (Sunderman 1944). The lack o f dose-response data for 
the human and animal studies precludes derivation o f inhalation MRLs.
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Oral M R L s  
Acute-Duration
• ATSDR has derived an MRL o f 0.2 mg/kg/day for acute-duration oral exposure (14 days or less) 
to RDX. This MRL is based on a NOAEL o f 8.5 mg/kg/day and LOAEL o f 17 mg/kg/day for 
convulsions/seizures observed in rats administered RDX via gavage 7 days/week for 14 days 
(U.S. Army 2006). A PBPK model was used to predict peak brain concentrations in the rat and to 
estimate human equivalent doses (HEDs). The NOAELhed o f 6.45 mg/kg/day was divided by an 
uncertainty factor of 30 (3 for extrapolation from animals to humans with dosimetric adjustments 
and 10 for human variability).
The acute toxicity database consists o f several human exposure studies reporting convulsions and seizures 
following oral exposure to RDX (Hollander and Colbach 1969; Kasuske et al. 2009; Ketel and Hughes 
1972; Küçükardalï et al. 2003; Merrill 1968; Stone et al. 1969; Woody et al. 1986). Although some 
studies provide exposure estimates, these values are not considered reliable. Animal studies have also 
identified convulsions and seizures as the most sensitive effect following acute-duration oral exposure 
(Burdette et al. 1988; Meyer et al. 2005; Schneider et al. 1977; U.S. Army 1980b, 1986d, 2006). The 
lowest adverse effect level for convulsions/seizures was 17 mg/kg/day in rats administered RDX via 
gavage for 14 days (U.S. Army 2006); an increase in the incidence o f mortality was also observed at this 
dose level (U.S. Army 2006). Several other studies have identified similar lowest-observed-adverse- 
effect levels (LOAELs); convulsions were observed in rat dams administered via gavage 20 mg/kg/day on 
gestation days 6-15 or 19 (U.S. Army 1980b, 1986d) and seizures were observed in rats administered a 
single gavage dose o f 25 mg/kg (Burdette et al. 1988). The dose-response curve for seizures/convulsions 
appears to be fairly steep, with no effects at 8.5 (U.S. Army 2006) or 12.5 (U.S. Army 1985b) mg/kg/day 
and seizures at 17 mg/kg/day (U.S. Army 2006). Additionally, decreases in motor activity and learning 
were observed at a lower dose (12.5 mg/kg/day) in rats receiving a single gavage dose (U.S. Army 
1985b).
There are limited data on the non-neurological toxicity o f RDX following acute-duration exposure. U.S. 
Army (2006) monitored body weight, hematological parameters, clinical chemistry parameters, and organ 
weight in male and female rats administered gavage doses of 2-17 mg/kg/day for 14 days. No 
biologically relevant alterations in these systemic toxicity end points were observed. Decreases in fetal 
weight and length were observed in the offspring o f rats administered 20 mg/kg/day on gestation days 6­
15 (U.S. Army 1986d); however, this exposure was associated with maternal convulsions/seizures and 
death.
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Based on the available data, impaired neurological function was identified as the critical effect for 
derivation o f an acute-duration oral MRL. Although the acute database lacks studies adequately assessing 
systemic toxicity, intermediate-duration studies have found no systemic effects at doses lower than those 
affecting the nervous system. The lowest adverse effect level for neurological effects is 12.5 mg/kg/day 
for decreases in motor activity and learning in rats following a single gavage dose (U.S. Army 1985b); 
this study did not identify a NOAEL. In a repeated exposure study by this group (U.S. Army 1985b), no 
significant alterations in motor activity were observed in rats following 15 or 30 days o f exposure to 
doses as high as 10 mg/kg/day. At a slightly higher dose (17 mg/kg/day), convulsions and tremors were 
observed in rats administered RDX for 14 days (U.S. Army 2006); no neurological effects were observed 
at 8.5 mg/kg/day. The U.S. Army (2006) study was selected as the principal study because it identified a 
NOAEL and involved repeated exposure, and it is likely that an MRL based on this study would be 
protective for the neurobehavioural effects observed at 12.5 mg/kg/day in the U.S. Army (1985b) study.
In the U.S. Army (2006) study, groups o f 6 male and 6 female Sprague-Dawley rats were administered 
via gavage 0, 2.125, 4.25, 8.5, 17.00, 25.50, 34.00, or 42.5 mg/kg/day as a suspension o f RDX/1% 
methylcellulose/0.2% Tween 80 in distilled water 7 days/week for 14 days. Rats were monitored daily 
for toxic signs and morbidity. Body weights and feed consumption were measured on days 0, 1, 3, 7, and 
14. Additional parameters used to assess toxicity included clinical chemistry and hematology values, 
organ weights, and gross necropsies. A significant increase in early deaths was observed at 
>25.5 mg/kg/day. Tremors and convulsions were observed in rats exposed to >17 mg/kg/day. In the 
males exposed to >17 mg/kg/day, blood stains around the mouth and nose and low arousal were also 
observed. Increased arousal, blood around the mouth and nose, barbering, and lacrimation were observed 
in females exposed to >17 mg/kg/day. No signs o f neurological alterations were observed in rats exposed 
to <8.5 mg/kg/day. Significant decreases in body weight were observed in male rats exposed to 
>17 mg/kg/day on days 1 and 7, but there were no significant alterations in male body weight at 
termination. In female rats, significant decreases in body weight gain were observed at >34 mg/kg/day on 
day 1 and in the 8.5 mg/kg/day group on day 14; however, the magnitude o f the decreased body weight 
was <10% and no significant alterations were observed at higher dose levels. Significant decreases in 
food consumption were also observed during the first 7 days o f exposure in males and females exposed to 
>8.5 mg/kg/day. Significant decreases in absolute liver weights and liver-to-brain weights and increases 
in blood cholesterol levels were observed in females exposed to 8.5 mg/kg/day; these effects were not 
observed at higher dose levels or in males. Due to the lack o f dose-response relationships for the 
alterations in liver weight and blood cholesterol levels, these changes observed in the 8.5 mg/kg/day
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female group were not considered biologically relevant. No significant alterations in hematological 
parameters or other clinical chemistry parameters or organ weights were observed.
The acute-duration oral MRL was derived using the NOAEL/LOAEL approach; the lack o f incidence 
data for the neurological effects precluded using a benchmark dose approach. The MRL is based on the 
NOAEL o f 8.5 mg/kg/day and a LOAEL o f 17 mg/kg/day identified in the U.S. Army (2006) study. The 
available mode o f action data suggest that the induction o f seizures and/or convulsions is likely associated 
with the binding o f RDX to GABA receptors in the brain and the onset o f seizures is directly related to 
the levels of RDX in the brain (Gust et al. 2009; Williams et al. 2011). A physiologically based 
pharmacokinetic (PBPK) model (Sweeney et al. 2012) was used to predict peak brain RDX concentration 
and mean brain RDX concentration for each administered dose in the U.S. Army (2006) study. Based on 
a comparison o f predicted brain RDX concentrations to the NOAEL and LOAEL values for 
seizures/convulsions observed in intermediate and chronic studies, ATSDR determined that peak brain 
RDX concentration was a more appropriate internal dose metric for derivation o f the MRL than mean 
brain RDX concentration. To determine the point o f departure for the MRL, the PBPK model was used 
to predict HEDs from peak brain concentration data. Detailed discussions o f the PBPK model and 
support for using peak brain concentration as the internal dose metric are presented in Appendix A. The 
PBPK model predicted a peak brain concentration o f 6.19 mg/L in rats administered 8.5 mg/kg/day 7 
days/week for 14 days and a HED o f 6.455 mg/kg/day. The MRL o f 0.2 mg/kg/day was calculated by 
dividing the NOAELhed o f 6.45 mg/kg/day for neurological effects (U.S. Army 2006) by an uncertainty 
factor o f 30 (3 for extrapolation from animals to humans with dosimetric adjustment and 10 for human 
variability).
Intermediate-Duration
• ATSDR has derived an MRL o f 0.1 mg/kg/day for intermediate-duration oral exposure (15­
364 days) to RDX. The MRL is based on a 90-day study which identified a NOAEL of 
4 mg/kg/day and LOAEL o f 8 mg/kg/day for seizures/convulsions in rats receiving gavage doses 
o f RDX 7 days/week (U.S. Army 2006). ATSDR derived the MRL using benchmark dose 
modeling o f seizure/convulsion incidence data and PBPK modeling to predict peak brain 
concentrations in the rat and to estimate HEDs. The BMCLHED of 4.13 mg/kg/day was divided by 
an uncertainty factor o f 30 (3 for extrapolation from animals to humans with dosimetric 
adjustments and 10 for human variability).
No human studies have examined the toxicity o f RDX following intermediate-duration exposure. Data 
from laboratory animal studies suggest that the nervous system is the most sensitive target o f RDX 
toxicity. Convulsions, seizures, and/or tremors have been observed in rats at doses o f >8 mg/kg/day (U.S.
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Army 1983a, 2006; von Oettingen et al. 1949), monkeys at 10 mg/kg/day (U.S. Navy 1974b), and dogs at 
50 mg/kg/day (von Oettingen et al. 1949). In addition, hyperactivity was noted in rats exposed to 
100 mg/kg/day (Levine et al. 1981, 1990). The results o f the U.S. Army (2006) study suggest that there is 
a steep dose-response curve for seizure induction. The occurrences o f seizures were 0% at 4 mg/kg/day, 
20-30%  at 8 mg/kg/day, 45-50%  at 10 mg/kg/day, and 80-90%  at 12 or 15 mg/kg/day. An increase in 
mortality was often reported at the lowest doses associated with seizures. Less serious adverse health 
effects have been observed at similar or higher dose levels. Several studies have found changes in serum 
chemistry parameters suggestive o f impaired liver function, although histological alterations were not 
generally found in the liver. Decreases in serum cholesterol and/or triglycerides were observed at 
>8 mg/kg/day (U.S. Army 1983a, 2006; Levine et al. 1981) and decreases in serum alanine 
aminotransferase activity levels were observed at 28 mg/kg/day (U.S. Army 1980b). The magnitude of 
these alterations was small and not likely to be biologically significant. Small, although significant, 
decreases in erythrocyte and hemoglobin levels were also observed in rats exposed to 40 mg/kg/day (U.S. 
Army 1983a) and mice exposed to 160 mg/kg/day (U.S. Army 1980b), but this finding has not been 
consistently found in intermediate-duration studies (U.S. Army 1980b, 2006; von Oettingen et al. 1949). 
Emesis was observed in monkeys administered via gavage 10 mg/kg/day for 90 days (U.S. Navy 1974b); 
the incidence in monkeys administered 1 mg/kg/day was not considered to be different from the controls. 
There is limited evidence that RDX is a reproductive toxicant. An increased incidence o f spermatic 
granuloma was observed in the prostate o f rats exposed to 40 mg/kg/day for 6 months (U.S. Army 
1983a). In a two-generation study in rats, decreases in F2 pup body weight and increases in the incidence 
o f renal cysts were observed at 16 mg/kg/day and increases in the number o f stillbirths and decreases in 
pup survival were observed in the Fj generation exposed to 50 mg/kg/day (U.S. Army 1980b).
Impaired neurological function was identified as the critical effect for derivation o f an intermediate- 
duration oral MRL. The lowest adverse effect level for this end point is 8 mg/kg/day with a NOAEL of 
4 mg/kg/day (U.S. Army 2006). A slightly higher LOAEL o f 10 mg/kg/day was identified in monkeys 
(U.S. Navy 1974b); a NOAEL was not identified in this study. The rat study (U.S. Army 2006) was 
selected as the principal study. In this study, groups of 10 male and 10 female F344 rats were 
administered via gavage 0, 4, 8, 10, 12, or 15 mg/kg/day as a suspension of RDX/1% methylcellulose/ 
0.2% Tween 80 in distilled water 7 days/week for 90 days. Rats were monitored weekly for toxic signs 
and functional observational battery (FOB) observations (home-cage, hand held, and open arena 
observations), and body weights and feed consumption were measured weekly. Additional parameters 
used to assess toxicity included neurobehavioral tests after week 11 (motor activity, grip strength, and 
sensory reactivity to different types o f stimuli), ophthalmic examination, urinalysis, clinical chemistry,
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hematology, coagulation, organ weights, gross necropsies, and histopathological examination o f major 
tissues and organs from rats exposed to 0 or 15 mg/kg/day. Significant increases in mortality rates were 
observed at >10 mg/kg/day. Convulsions were observed in most animals dying early. Transient clinical 
signs included changes in arousal, inflammation o f eyelash follicles, increased salivation, blood stains 
around mouth and nose, rough haircoat, tremors, and convulsions; the incidence and severity increased 
with dose. The incidences o f convulsions were 0/20, 0/20, 3/20, 6/20, 13/20, and 12/20 in rats exposed to 
0, 4, 8, 10, 12, and 15 mg/kg/day, respectively. Although the incidence o f convulsions was not 
statistically significant at 8 mg/kg/day, the increased incidence of seizures was considered biologically 
significant and the 8 mg/kg/day dose level was considered a LOAEL. The tremors/convulsions were 
observed within the first week o f exposure in the 12 or 15 mg/kg/day groups and persisted throughout the 
study. No significant RDX-related alterations in foot splay, front limb grip strength, or response to 
stimuli were found. Hematological tests showed significant increases in erythrocyte mean cell volume at 
8 (males only), 10, and 12 mg/kg/day and significant decrease in serum cholesterol in males exposed to 
>8 mg/kg/day. No significant increases in the incidence o f histopathological alterations were observed.
The intermediate-duration oral MRL was derived using benchmark dose modeling and PBPK modeling. 
As discussed for the acute-duration oral MRL, a PBPK model (Sweeney et al. 2012) was used to predict 
peak and mean brain RDX concentrations. Comparisons with empirical seizure data following 
intermediate- or chronic-duration exposure with predicted brain RDX levels provided support for using 
peak brain concentration as the internal dose metric for the MRL derivation. The incidence data for 
convulsions in rats were fit to several dichotomous models using a benchmark response (BMR) o f 10% 
and the internal dose metric o f peak brain concentration. Detailed discussion o f the benchmark dose 
modeling, the PBPK model, and support for the selection o f the internal dose metric are presented in 
Appendix A. The log-probit model provided the best fit to the data and was used to estimate a 95% lower 
confidence limit on the benchmark dose (BMDL10) of 3.9624 mg/L. Using PBPK modeling, a HED of 
4.1308 mg/kg/day was predicted from the BMDL10. The MRL of 0.1 mg/kg/day was calculated by 
dividing the BMDLhed o f 4.1308 mg/kg/day for neurological effects by an uncertainty factor o f 30 (3 for 
extrapolation from animals to humans with dosimetric adjustments and 10 for human variability).
Chronic-Duration
• ATSDR has derived an MRL o f 0.1 mg/kg/day for chronic-duration oral exposure (>365 days) to 
RDX. This MRL is based on a NOAEL o f 8 mg/kg/day and LOAEL o f 40 mg/kg/day for 
convulsions/seizures observed in rats exposed to RDX in the diet for 2 years (U.S. Army 1983a). 
A PBPK model was used to predict peak brain concentrations in the rat and to estimate HEDs.
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The NOAELhed o f 4.223 mg/kg/day was divided by an uncertainty factor o f 30 (3 for
extrapolation from animals to humans with dosimetric adjustments and 10 for human variability).
The chronic oral toxicity o f RDX has been evaluated in two rat studies (U.S. Army 1983a; U.S. Navy 
1976) and a mouse study (U.S. Army 1984c). A number of adverse health effects have been observed in 
rats exposed to 40 mg/kg/day including tremors, convulsions, and hyperresponsiveness; decreased 
hematocrit, hemoglobin, and erythrocyte levels; hepatomegaly and decreased serum cholesterol and 
triglycerides; renal papillary necrosis and increased blood urea nitrogen levels; testicular degeneration; 
and cataracts (females only) (U.S. Army 1983a); no adverse effects were observed in rats exposed to 
8 mg/kg/day. The 40 mg/kg/day dose was also associated with an 88% mortality rate. In addition to 
these effects, significant increases in the incidence o f suppurative inflammation were observed in the 
prostate o f rats exposed to >1.5 mg/kg/day (U.S. Army 1983a). U.S. Army (2006) noted that 
inflammation o f the prostate gland is a common condition in older rodents and is generally not due to 
toxicity; additionally, the prostate effects in the U.S. Army (1983a) study were predominantly found in 
rats dying early.
In the U.S. Navy (1976) rat study, no adverse effects were observed at doses as high as 10 mg/kg/day. 
This study did not include a histological examination of the prostate and the animals were monitored 
weekly for overt signs o f toxicity. In mice, increases in serum cholesterol levels were observed in 
females exposed to 35 mg/kg/day and increased relative kidney weights and cytoplasmic vacuolization in 
the kidney were observed at 100 mg/kg/day (U.S. Army 1984c). The toxicological significance o f the 
increased serum cholesterol level in the absence o f other indications o f hepatic damage is not known.
The lowest LOAEL identified in chronic-duration studies is 1.5 mg/kg/day for prostate inflammation; the 
NOAEL for this effect is 0.3 mg/kg/day. However, U.S. Army (1983a) suggested that this effect is likely 
secondary to a bacterial infection in older rats dying early; thus, it was not considered an appropriate basis 
o f a chronic-duration MRL. The effects observed in rats (including convulsions/tremors, hematological 
alterations, impaired hepatic function, and renal lesions) exposed to 40 mg/kg/day (NOAEL of 
8 mg/kg/day) were considered as the basis o f a chronic-duration MRL. Based on a comparison o f the 
effects observed in rats exposed to 40 mg/kg/day and those observed in mice exposed to 35 mg/kg/day, 
rats appear to be more sensitive to the toxicity o f RDX than mice; thus, the mouse study was not 
considered for MRL derivation.
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In the U.S. Army (1983a) study, groups o f male and female Fischer 344 rats (75/sex/group) were exposed 
to 0, 0.3, 1.5, 8.0, or 40.0 mg/kg/day RDX in the diet for 2 years. The following parameters were used to 
assess toxicity: daily observations, ophthalmic examinations, hematology, clinical chemistry, organ 
weights, and complete histopathology o f major tissues and organs o f rats in the 0 or 40.0 mg/kg/day groups, 
and histopathological examination o f the brain, gonads, heart, liver, kidneys, spleen, and spinal cord o f rats 
in the 0.3, 1.5, and 8.0 mg/kg/day groups. Actual RDX doses were within 3% o f the intended dose. Deaths 
were observed at 40 mg/kg/day; 88% of males and 41% o f females died by week 88. The mean survival 
time for the 40 mg/kg/day males was 14.6 months compared with 22.3 months for the control males. A 
20.6 month survival time was seen for the 40 mg/kg/day females vs. 22.0 months for the control females at 
40 mg/kg/day. A significant decrease in survival time was also observed in the males exposed to
1.5 mg/kg/day (21.0 months); however, no alterations in survival time was observed in the females exposed 
to 1.5 mg/kg/day (22.2 months) or in the males (22.2 months) or females (22.4 months) exposed to 
8 mg/kg/day. Additionally, there were no significant differences in mortality incidence in the 1.5 or 
8 mg/kg/day groups, as compared to controls. Statistically decreased body weight gain was observed in 
males (20-30%) and females (10-15%) exposed to 40.0 mg/kg/day; statistically significant decreases in 
body weight gain were also observed at 8.0 mg/kg/day, but the body weight was within 10% o f controls. 
Tremors and convulsions were observed prior to death at 40 mg/kg/day; the animals were hyperactive to 
approach and had increased fighting. No adverse clinical signs were noted for the lower dose groups. 
Significant decreases in hemoglobin and erythrocyte counts were observed in the 40 mg/kg/day group 
beginning at week 26; the study investigators noted that the anemic state was considered slight and there 
was no evidence o f physiologic compensatory responses. Thrombocytosis was observed in rats exposed to 
40 mg/kg/day and elevated platelet counts were observed in 8 mg/kg/day males during weeks 13 and 26. 
Significant decreases in blood glucose, total cholesterol, and triglyceride levels were observed in the 
40 mg/kg/day group starting at week 13. Significant decreases in serum alanine aminotransferase levels 
were observed in males exposed to 8 or 40 mg/kg/day at weeks 26 and 52 and in females at 40 mg/kg/day at 
week 26. Other clinical chemistry alterations included decreases in globulin and albumin levels at weeks 52 
and 78 and increases in serum potassium levels at weeks 26, 52, and 78. A significant increase in the 
incidence of cataracts was observed in females in the 40 mg/kg/day group during weeks 78 and 104. 
Histological alterations observed after 2 years o f exposure included suppurative inflammation o f the 
prostate in the 1.5, 8, and 40 mg/kg/day groups; renal medullary papillar necrosis, renal pyelitis, and urinary 
bladder luminal distension and cystitis in males exposed to 40 mg/kg/day; splenic extramedullary 
hematopoiesis in female rats exposed to 40 mg/kg/day; and hemosiderin-like pigment in males exposed to 
1.5, 8, or 40 mg/kg/day. In the absence of altered hematological parameters or other effects on the spleen, 
the increased pigment levels observed at 1.5 or 8 mg/kg/day were not considered adverse.
2. RELEVANCE TO PUBLIC HEALTH
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2. RELEVANCE TO PUBLIC HEALTH
The U.S. Army (19S3a) study identified a NOAEL o f S mg/kg/day and a LOAEL o f 40 mg/kg/day for 
tremors and convulsions in rats exposed to RDX in the diet for 2 years. ATSDR derived a chronic- 
duration oral MRL using the NOAEL/LOAEL approach; benchmark dose modeling could not be utilized 
because the investigators did not report incidence data for neurological signs. As discussed for the acute- 
duration oral MRL, a PBPK model (Sweeney et al. 2012) was used to predict peak and mean brain RDX 
concentrations. Comparisons with empirical seizure data following intermediate- or chronic-duration 
exposure with predicted brain RDX levels provided support for using peak brain concentration as the 
internal dose metric for the MRL derivation. To determine the point o f departure for the MRL, the PBPK 
model was also used to predict the HED for a given rat peak brain RDX concentration; detailed 
discussions o f the PBPK model and support for selecting peak brain RDX concentration as the internal 
dose metric are presented in Appendix A. The NOAEL from the U.S. Army (19S3a) study corresponds to 
peak brain concentrations of 4.051 mg/L and a HED o f 4.223 mg/kg/day. The MRL o f 0.1 mg/kg/day 
was calculated by dividing the NOAELhed o f 4.223 mg/kg/day by an uncertainty factor o f 30 (3 for 




The primary purpose of this chapter is to provide public health officials, physicians, toxicologists, and 
other interested individuals and groups with an overall perspective on the toxicology o f RDX. It contains 
descriptions and evaluations o f toxicological studies and epidemiological investigations and provides 
conclusions, where possible, on the relevance o f toxicity and toxicokinetic data to public health.
A glossary and list o f acronyms, abbreviations, and symbols can be found at the end o f this profile.
3.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE
To help public health professionals and others address the needs o f persons living or working near 
hazardous waste sites, the information in this section is organized first by route o f exposure (inhalation, 
oral, and dermal) and then by health effect (death, systemic, immunological, neurological, reproductive, 
developmental, genotoxic, and carcinogenic effects). These data are discussed in terms o f three exposure 
periods: acute (14 days or less), intermediate (15-364 days), and chronic (365 days or more).
Levels o f significant exposure for each route and duration are presented in tables and illustrated in 
figures. The points in the figures showing no-observed-adverse-effect levels (NOAELs) or lowest- 
observed-adverse-effect levels (LOAELs) reflect the actual doses (levels o f exposure) used in the studies. 
LOAELs have been classified into "less serious" or "serious" effects. "Serious" effects are those that 
evoke failure in a biological system and can lead to morbidity or mortality (e.g., acute respiratory distress 
or death). "Less serious" effects are those that are not expected to cause significant dysfunction or death, 
or those whose significance to the organism is not entirely clear. ATSDR acknowledges that a 
considerable amount o f judgment may be required in establishing whether an end point should be 
classified as a NOAEL, "less serious" LOAEL, or "serious" LOAEL, and that in some cases, there will be 
insufficient data to decide whether the effect is indicative o f significant dysfunction. However, the 
Agency has established guidelines and policies that are used to classify these end points. ATSDR 
believes that there is sufficient merit in this approach to warrant an attempt at distinguishing between 
"less serious" and "serious" effects. The distinction between "less serious" effects and "serious" effects is 
considered to be important because it helps the users of the profiles to identify levels o f exposure at which 
major health effects start to appear. LOAELs or NOAELs should also help in determining whether or not
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the effects vary with dose and/or duration, and place into perspective the possible significance o f these 
effects to human health.
The significance o f the exposure levels shown in the Levels o f Significant Exposure (LSE) tables and 
figures may differ depending on the user's perspective. Public health officials and others concerned with 
appropriate actions to take at hazardous waste sites may want information on levels o f exposure 
associated with more subtle effects in humans or animals (LOAELs) or exposure levels below which no 
adverse effects (NOAELs) have been observed. Estimates o f levels posing minimal risk to humans 
(Minimal Risk Levels or MRLs) may be o f interest to health professionals and citizens alike.
Levels o f exposure associated with carcinogenic effects (Cancer Effect Levels, CELs) o f RDX are 
indicated in Table 3-1 and Figure 3-1. Because cancer effects could occur at lower exposure levels, 
Figure 3-1 also shows a range for the upper bound o f estimated excess risks, ranging from a risk o f 1 in 
10,000 to 1 in 10,000,000 (10-4 to 10-7), as developed by EPA.
A User's Guide has been provided at the end of this profile (see Appendix B). This guide should aid in 
the interpretation o f the tables and figures for Levels o f Significant Exposure and the MRLs.
3.2.1 Inhalation Exposure
3.2.1.1 Death
No studies were located regarding death in humans after inhalation exposure to RDX. Death attributed to 
impairment o f the respiratory system was observed in rabbits and guinea pigs exposed to an unspecified 
concentration of RDX (Sunderman 1944).
3.2.1.2 System ic Effects
Four studies were located regarding systemic effects in humans after inhalation exposure to RDX alone. 
The available studies have reported adverse gastrointestinal, hematological, hepatic, and renal effects in 
workers exposed to C-4 (an explosive composed o f 91% RDX) or RDX dusts via inhalation. Since the 
exposure concentration and/or duration were not described for these studies, they are not presented in 
tables or figures. No studies were located regarding respiratory, cardiovascular, musculoskeletal, dermal, 
ocular, or other systemic effects in humans after inhalation exposure to RDX. Case reports are available 
regarding systemic effects in workers exposed to unknown levels o f RDX via the inhalation or oral routes
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(Ketel and Hughes 1972). These studies are also discussed in Section 3.2.2.2. Only one study is 
available regarding systemic effects in animals after inhalation exposure to RDX (Sunderman 1944).
This study is limited by insufficient numbers of animals tested, no controls, and no data on exposure 
levels. No studies were located regarding gastrointestinal, hepatic, or dermal effects in animals.
Respiratory Effects. Three o f 6 rabbits died from bronchopneumonia; death o f 7 o f 18 guinea pigs 
was attributed to pneumonia and pulmonary congestion (Sunderman 1944).
Cardiovascular Effects. Histopathology revealed the absence o f striations in the cardiac muscle of 
guinea pigs exposed to unspecified levels o f RDX for 4-67 days (Sunderman 1944).
Gastrointestinal Effects. Soldiers who were exposed to an unspecified amount of C-4 (91% RDX) 
as a cooking fuel for an unknown duration experienced nausea and vomiting (Hollander and Colbach 
1969; Ketel and Hughes 1972); the soldiers were exposed to RDX via the inhalation and/or oral routes.
Hematological Effects. Two studies o f workers exposed to RDX dusts are available, but neither 
revealed any adverse hematological effects. In one study, workers who were presumably exposed acutely 
to unknown levels o f RDX dusts had normal blood counts (Kaplan et al. 1965). In the other study, 
workers exposed to an average o f 0.28 mg/m3 o f RDX dusts in the workplace, presumably for a chronic 
period, showed no hematological changes compared to controls (Hathaway and Buck 1977). Transient 
elevation o f the white blood count was frequently observed in individuals exposed to C-4 (91% RDX). 
Normal red blood count, leukocytes, and hemoglobin were reported in rats following intermediate 
exposure to RDX. However, in the same study, hemoglobin counts were decreased in guinea pigs 
(Sunderman 1944).
Hepatic Effects. No liver toxicity was revealed by blood or urine analyses of workers exposed to 
RDX in the air; the duration o f exposure was not reported (Hathaway and Buck 1977).
Renal Effects. Blood and urine analyses o f workers exposed to RDX in the air for acute (Kaplan et al. 
1965) or chronic durations (Hathaway and Buck 1977) did not reveal any kidney toxicity. Although no 
renal toxicity was observed after exposure to RDX dust, there were some manifestations o f renal damage 
after possible inhalation exposure to C-4 (91% RDX): transient oliguria and proteinuria in two patients 
and acute renal failure in one case (Ketel and Hughes 1972).
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There was no kidney pathology in rats or guinea pigs exposed to RDX, but degeneration of the kidneys 
was found in rabbits exposed to unspecified levels o f RDX for an intermediate period (Sunderman 1944). 
This study is limited in that no controls were used, and details o f the study were not specified.
3.2.1.3 Immunological and Lymphoreticular Effects
Workers at an Army ammunition plant who were exposed to an average o f 0.28 mg/m3 o f RDX dusts for 
an unknown period o f time showed no significant differences in a test for antinuclear antibodies as 
compared to nonexposed workers. The results o f this test provide no evidence o f autoimmune disease 
(Hathaway and Buck 1977). No other immunological function tests were performed.
No studies were located regarding immunological effects in animals after inhalation exposure to RDX.
3.2.1.4 Neurological Effects
Convulsions and unconsciousness, accompanied by headache, dizziness, and vomiting, were noted in 
5 out o f 26 workers who were exposed to unknown levels o f RDX dust in the air (Kaplan et al. 1965). 
Similar findings, such as convulsions, muscle twitching, and confusion, have been reported in five case 
studies o f men exposed to C-4 fumes (91% RDX) when it was used as a cooking fuel (Hollander and 
Colbach 1969), and in a worker hand-sieving RDX (Testud et al. 1996a). The workers recovered a few 
days after they were removed from the source o f exposure. Testud et al. (1996a) noted that CT scan and 
MRI (performed 1 week after exposure) were normal and electroencephalogram only showed signs o f the 
administered anticonvulsant therapy; in the other studies, tests o f neurological function were not 
performed. In a study o f workers at an RDX facility, no increases in the occurrence o f subjective 
symptoms were reported (Ma and Li 1993). Significant differences in performance on tests o f memory 
retention and block design were found in workers exposed to 0.407 or 0.672 mg/m3, as compared to 
controls; however, no differences were found between the two exposed groups. No significant alterations 
in performance on tests o f reaction time were noted.
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No studies were located regarding neurological effects in animals after inhalation exposure to RDX.
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No studies were located regarding death in humans after oral exposure to RDX.
Deaths were reported in animals following acute, intermediate, and chronic exposures to RDX. Three out 
o f 12 rats died during induced seizures following acute exposure to 50 mg/kg RDX, which was 
administered by gavage (Burdette et al. 1988). LD50 values for single gavage doses were 71-118 mg/kg 
in rats (U.S. Army 1978b, 1980b), 86-97 mg/kg in mice (U.S. Army 1978b, 1980b), and 136-319 mg/kg 
in deer mice (Smith 2007). Apparent age-related differences in LD50 values were found in deer mice; the 
LD50 values were 136, 319, and 158 mg/kg in 21-, 50-, and 200-day-old mice (Smith et al. 2007). 
Miniature swine died (2/10) following single gavage doses o f 100 mg/kg (Schneider et al. 1977). Rat 
dams that were fed 20 mg/kg/day o f RDX during gestation had mortality rates o f 24% (U.S. Army 1980b, 
1986d).
In 90-day feeding studies, levels as low as 25 mg/kg/day (von Oettingen et al. 1949) and 100 mg/kg/day, 
produced deaths in rats (Levine et al. 1990), and levels o f 320 mg/kg/day produced deaths in mice (U.S. 
Army 1980b). Increased mortality (25%) was observed in rats administered via gavage 10 mg/kg/day 
(U.S. Army 2006); however, no deaths were observed in dogs (U.S. Navy 1974a) or monkeys (U.S. Navy 
1974b) also administered 10 mg/kg/day. In chronic-duration studies, an excessive number o f deaths was 
observed in rats exposed to 40 mg/kg/day for 1-2 years compared to controls (U.S. Army 1983a). 
However, an excessive number o f deaths was not observed in rats administered 10 mg/kg/day o f RDX 
(U.S. Navy 1976). The LD50 values and all reliable LOAEL values for death are recorded in Table 3-1 
and plotted in Figure 3-1.
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Table Z-1 Levels o f  S ig n ifica n t Exposure  to  RDX - Oral
K e y  to  S p e c ie s  
F ig u re  (S tra in )
E x p o s u re /
D u ra t io n /
F re q u e n c y
(R o u te )
L O A E L
N O A E L  L e s s  S e rio u s  
S y s te m  (m g /k g /d a y ) (m g /k g /d a y )
S e rio u s
(m g /k g /d a y )
R e fe re n c e  
C h e m ic a l F o rm C o m m e n ts
A C U T E  E X P O S U R E
D e a th
1 Rat once
(Long- Evans) (G W )
5G M (3 /1 2  died during  
seizures)
Burdette et al. 1 98 8
Rat









R at Gd 6 -1 9
(F ischer 3 4 4 ) (G W )
R at once
(F ischer 3 4 4 ) (G )
Rat
(S p rag u e-
D aw ley)
Gd 6 -1 5  
(G W )
7 Rat
(S p rag u e-
D aw ley)
7  d/w k  
1 4  d 
(G W )
5G (2/1G  died) S chne id er et al. 1977
71 M (LD5G )
7 5  F (9/1G  rats died)
U .S . A rm y 1978b
2G F (6 /2 5  died) U .S . A rm y 198Gb
119  (LD5G) U .S . A rm y 198Gb
2G F (3 1 %  died) U .S . A rm y 1986d







(N S ) (G W )









Table 3-1 Levels o f  S ig n ifica n t Exposure  to  RDX _ Oral (continued)
E x p o s u re / L O A E L
D u ra t io n /
K e y  to' S p e c ie s  F re q u e n c y  N O A E L  L e s s  S e r io u s  S e rio u s  R e fe re n c e
F ig u re  (S tra in ) (_______)___________ S y s te m  (m g /k g /d a y ) (m g /k g /d a y )________________________(m g /k g /d a y )____________________ C h e m ic a l F o rm _______________________ C o m m e n ts
M ouse
(S w iss-
W eb ste r)
once
(G O )
8 6  M (LD5G)
7 5  F (5/1G  m ice died)
U .S . A rm y 1978b
1O M ouse
(B 6 C 3 F 1 )
once
(G )
9 7  M (LD5G) 
5 9  F (LD5G)





S y s te m ic
12 Rat Gd 6 -1 9  
(F ischer 3 4 4 ) (G W )
Bd W t 2 0  F (1 2 %  decrease  in
m aternal body w eight)
1GG F (2/1G  died) S chne id er et al. 1977
U .S . A rm y 1980b
1Z Rat
(S p rag u e-
D aw ley)
7  d/w k  
1 4  d 
(G W )
H em ato 17 U .S . A rm y 2 0 0 6
14  M ouse daily
(P erom yscus 1 4  days
leucopus) (F )
N e u ro lo g ic a l




6 8  F
6 8  F 
6 8  F
E P A  1999
3 5 7  M (seizures) S tone et al. 1969
1e Rat once
(Long- Evans) (G W )










Table 3-1 Levels o f  S ig n ifica n t Exposure  to  RDX - Oral (continued)
E x p o s u re / L O A E L
D u ra t io n /
K e y  to  S p e c ie s  F re q u e n c y  N O A E L  L e s s  S e r io u s  S e rio u s  R e fe re n c e
F ig u re  (S tra in ) (R o u te ) S y s te m  (m g /k g /d a y ) (m g /k g /d a y ) (m g /k g /d a y ) C h e m ic a l F o rm
17 Rat 0nce  8 7  F (convulsions in 2 /2  rats) M e y e r et a l. 2 0 0 5
(S p ra g u e - (G O )
D aw ley)
18 Rat once 5 0  (convulsions) S chne id er et al. 1977
(S p ra g u e - (G W ) '  '
D aw ley)
19 Rat Gd 6 1 9  2  F 2 0  F (convulsions and U S . A rm y 1980b
(F ischer 3 4 4 ) (G W ) hyperactivity in dam s)
2 0  Rat




12 .5  (de c re a s es  in m otor
activity, taste  aversion, 
learning, and auditory  
startle response  
am plitude)
U .S . A rm y 1985b
21 Rat Gd 6 1 5  6  F 2 0  F (convulsions, prostration U S . A rm y 1986d
(S Prag ue- (G W ) in dam s)
D aw ley)
22 Rat
(S p rag u e-
D aw ley)
7  d/w k  
1 4  d 
(G W )
b
8 .5 17 (trem ors and  
convulsions)
U .S . A rm y 2 0 0 6
2 3  Pig once
(N S ) (G W )
100  F (convulsions) S chne id er et al. 1977









Table 3-1 Levels o f  S ig n ifica n t Exposure  to  RDX _ Oral (continued)
Exposure/
D uration /
Key to  Species
F ig u re  (S tra in ) (R o u te )
L O A E L
N O A E L  L e s s  S e rio u s  
S y s te m  (m g /k g /d a y ) (m g /k g /d a y )
S e rio u s
(m g /k g /d a y )
R e fe re n c e  
C h e m ic a l F o rm C o m m e n ts
D e v e lo p m e n ta l
2 4  Rat Gd 6 -1 9
(F ischer 3 4 4 ) (G W )
2  F U .S . A rm y 1980b
2 5  Rat Gd 6 -1 5
(S p ra g u e - (G W ) 
D aw ley)
6  F 2 0  F (9%  d e crease  in fetal
w eight and 5%  decrease  
in fetal length)
U .S . A rm y 1986d
IN TERM ED IATE E X P O S U R E
D e a th
2 6  Rat 13  w k
(F ischer 3 4 4 ) (F )
1GG (6 5 %  m ortality) Levine et al. 1981
2 7  Rat 13  w k
(F ischer 3 4 4 ) (F )
1GG (13/2G  died) Levine et al. 199G
2 8  Rat 7  d/w k
(F ischer- 3 4 4 ) 9G d 
(G W )





2 5  (8/2G  died) von O ettingen et al. 1949
3 0  Rat 1G w k
(N S ) (F )
5G (6G%  m ortality) von O ettingen et al. 1949
31 M ouse
(B 6 C 3 F 1 )
9G d 
(F )









Table 3-1 Levels o f  S ig n ifica n t Exposure  to  RDX - Oral (continued)
Exposure/
D uration /
Key to  Species
F ig u re  (S tra in ) (R o u te ) S y s te m
N O A E L
(m g /k g /d a y )
L e s s  S e rio u s  
(m g /k g /d a y )
L O A E L
S e rio u s
(m g /k g /d a y )
R e fe re n c e  
C h e m ic a l F o rm C o m m e n ts
S y s te m ic
3 2  M on key  9G d 










10 (vom iting in 5 /6  anim als)
10 (necrotic  and degenera te
m eg akaryo cytes  in bone  
m arrow )









3 3  Rat 13  w k








10 F (increased  leukocyte  
counts)
Levine et al. 1981














Table 3-1 Levels o f  S ig n ifica n t Exposure  to  RDX _ Oral (continued)
E x p o s u re / L O A E L
D u ra t io n /
K e y  to' S p e c ie s  F re q u e n c y  N O A E L  L e s s  S e r io u s  S e rio u s  R e fe re n c e
F ig u re  (S tra in ) (_______)___________ S y s te m  (m g /k g /d a y ) (m g /k g /d a y )________________________(m g /k g /d a y )____________________ C h e m ic a l F o rm _______________________ C o m m e n ts
3 4  Rat 3 -1 3  w k










Levine et al. 199G





3 0  M (1 3 %  decrease  in body  
w eight gain)










Table 3-1 Levels o f  S ig n ifica n t Exposure  to  RDX - Oral (continued)
E x p o s u re / L O A E L
D u ra t io n /
K e y  to  S p e c ie s  F re q u e n c y  N O A E L  L e s s  S e r io u s  S e rio u s  R e fe re n c e
F ig u re  (S tra in ) (R o u te ) S y s te m  (m g /k g /d a y ) (m g /k g /d a y ) (m g /k g /d a y ) C h e m ic a l F o rm  C o m m e n ts
3 5  Rat 9 0  d
(F ischer 3 4 4 ) (F )
R esp 4 0 U .S . A rm y 1980b
Cardio 2 8  F 4 0  F (decreased  absolute
heart w eight, m yocardial 
degenera tion)
G astro 4 0
H em ato 4 0
M usc/skel 4 0
H epatic 4 0
R enal 4 0
Endocr 4 0
D erm al 4 0
O cular 4 0









Table 3-1 Levels o f  S ig n ifica n t Exposure  to  RDX _ Oral (continued)
E x p o s u re / L O A E L
D u ra t io n /
K e y  to' S p e c ie s  F re q u e n c y  N O A E L  L e s s  S e r io u s  S e rio u s  R e fe re n c e
F ig u re  (S tra in ) (_______)___________ S y s te m  (m g /k g /d a y ) (m g /k g /d a y )________________________(m g /k g /d a y )____________________ C h e m ic a l F o rm _______________________ C o m m e n ts
3 6  Rat 6  mo








8 4 0  (decreased  hem oglobin  
and erythrocyte levels)




8 4G (decreased  serum  




D erm al 






8 4 0  (1 7 %  decrease  in body
w eight gain)











Table 3-1 Levels o f  S ig n ifica n t Exposure  to  RDX - Oral (continued)
Exposure/
D uration /
Key to  Species
F ig u re  (S tra in ) (R o u te )
N O A E L  L e s s  S e rio u s  
S y s te m  (m g /k g /d a y ) (m g /k g /d a y )
L O A E L
S e rio u s
(m g /k g /d a y )
R e fe re n c e  
C h e m ic a l F o rm C o m m e n ts
3 7  Rat 7  d/w k












U .S . A rm y 2GG6
8 M (decreased  serum  
cholesterol levels)
R enal 









Bd W t 15 2 5  (w eight loss) von O ettingen et al. 1949
39 Rat
(N S )
1G w k  
(F )









Table 3-1 Levels o f  S ig n ifica n t Exposure  to  RDX _ Oral (continued)
E x p o s u re / L O A E L
D u ra t io n /
K e y  to' S p e c ie s  F re q u e n c y  N O A E L  L e s s  S e r io u s  S e rio u s  R e fe re n c e
F ig u re  (S tra in ) (_______)___________ S y s te m  (m g /k g /d a y ) (m g /k g /d a y )________________________(m g /k g /d a y )____________________ C h e m ic a l F o rm _______________________ C o m m e n ts
4 0  M ouse 9 0  d 32Q U .S . A  1980b
(B 6 C 3 F 1 ) (F ) K




3 2 0  
8 0  M 160  M (1 2 %  decrease  in
erythrocyte count and 7%  
decrease  in hem oglobin  
concentration)
H epatic  160  M 3 2 0  M (hepatocellu lar
vacuolization)
R enal 160  M 3 2 0  M (m ild tubu lar nephrosis)
E ndocr 160  M 3 2 0  F (m ild focal subscapular
fibroplasia in adrenal 
gland)









Table 3-1 Levels o f  S ig n ifica n t Exposure  to  RDX - Oral (continued)
E x p o s u re / L O A E L
D u ra t io n /
K e y  to  S p e c ie s  F re q u e n c y  N O A E L  L e s s  S e r io u s  S e rio u s  R e fe re n c e
F ig u re  (S tra in ) (R o u te ) S y s te m  (m g /k g /d a y ) (m g /k g /d a y ) (m g /k g /d a y ) C h e m ic a l F o rm
41 M ouse
(B 6 C 3 F 1 )




















U .S . A rm y 198 4 c
4 2 Dog
(N S )
















U .S . N avy 197 4 a









Table 3-1 Levels o f  S ig n ifica n t Exposure  to  RDX _ Oral (continued)
E x p o s u re / L O A E L
D u ra t io n /
K e y  to' S p e c ie s  F re q u e n c y  N O A E L  L e s s  S e r io u s  S e rio u s  R e fe re n c e
F ig u re  (S tra in ) (_______)___________ S y s te m  (m g /k g /d a y ) (m g /k g /d a y )________________________(m g /k g /d a y )____________________ C h e m ic a l F o rm _______________________ C o m m e n ts
43 Dog
(N S )
6  w k  
6  d/w k  
(C )
Im m u n o / L y m p h o re t
4 4  Rat 7  d/w k
(F ischer- 3 4 4 ) 9 0  d
(G W )
N e u ro lo g ic a l
4 5  M on key  9 0  d









5 0  F
5 0  F 
5 0  F 
5 0  F 
5 0  F 
5 0  F
15
von O ettingen et al. 1949
5 0  F (unspecified w eight loss)
10 (convulsions and  
seizures)
U .S . A rm y 2 0 0 6
U .S . N avy 1 974b
4 6  Rat 13  w k
F ischer 3 4 4  (F )
3 0  100  (hyperreactive  to
approach)
Levine et al. 1981
4 7  Rat 10  w k
(F ischer 3 4 4 ) (F )
3 0  100  (hyperreactive  to
approach)









Table 3-1 Levels o f  S ig n ifica n t Exposure  to  RDX - Oral (continued)
K e y  to  S p e c ie s
F ig u re  (S tra in ) (R o u te )
Exposure/
D uration /
N O A E L  L e s s  S e rio u s  
S y s te m  (m g /k g /d a y ) (m g /k g /d a y )
L O A E L
S e rio u s
(m g /k g /d a y )
R e fe re n c e  
C h e m ic a l F o rm C o m m e n ts
4 8  Rat 2 5  w k
(F ischer 3 4 4 ) (F )
4G (trem or, convulsions, U S . A rm y 198 3 a  
hyperreactive)
4 9  Rat 3G d
(S p ra g u e - (G W ) 
D aw ley)
1G M U .S . A rm y 1985b testing conducted 2 4  
hours a fte r dose  
adm inistration
5 0  Rat 7  d/w k
(F ischer- 3 4 4 ) 9G d 
(G W )
8 (trem ors and  
convulsions)





15 2 5  (convulsions,
hyperirritability and  
fighting)
von O ettingen et al. 1949
5 2  Rat 1G w k
(N S ) (F )
15 5G (hyperirritability and von O ettingen et al. 1949  
convulsions)
5 3  M ouse 9G d 
(B 6 C 3 F 1 ) (F )
16G M 32G M (hyperactivity and /or  
nervousness)
U .S . A rm y 198Gb
5 4  Dog 6  w k
(N S ) 6  d/w k
(C )
5G F (hyperirritability and  
convulsions)










Table 3-1 Levels o f  S ig n ifica n t Exposure  to  RDX _ Oral (continued)
K e y  to  S p e c ie s  
F ig u re  (S tra in )
E x p o s u re /
D u ra t io n /
F re q u e n c y
(R o u te )
L O A E L
N O A E L  L e s s  S e rio u s  
S y s te m  (m g /k g /d a y ) (m g /k g /d a y )
S e rio u s
(m g /k g /d a y )
R e fe re n c e  
C h e m ic a l F o rm C o m m e n ts
R e p ro d u c tiv e
5 5  Rat 3 -1 3  w k
(F ischer 3 4 4 ) (F )
1GG Levine et al. 199G
56 Rat
(F ischer 3 4 4 )
2  generation; 






5G U .S . A rm y 1980b
5 7  Rat 15  w k
(F ischer 3 4 4 ) (F )
16  M 5G M (decreased  fertility) U .S . A rm y 1980b D ecreased  fertility m ay  
be due to R D X -e ffec t 
on genera l w ell-being  
of m ales
5 8  Rat 6  mo
(F ischer 3 4 4 ) (F )
8  M 
4G F
4 0  M (sperm atic  granulom a in 
prostate)
U .S . A rm y 198 3 a
D e v e lo p m e n ta l
5 9  Rat
(F ischer 3 4 4 )
2  generation; 






16 (decrease  in F2 pup body 5 0  (increase in num ber o f U S . A rm y 1980b  
w eight) stillbirths; decrease  in
pup survival in F1)
60 Rabbit
(N S )
Gd 7 -2 9  
(G W )










Table 3-1 Levels o f  S ig n ifica n t Exposure  to  RDX - Oral (continued)
K e y  to  S p e c ie s  
F ig u re  (S tra in )
E x p o s u re /
D u ra t io n /
F re q u e n c y
(R o u te )
L O A E L
S y s te m
N O A E L
(m g /k g /d a y )
L e s s  S e rio u s  
(m g /k g /d a y )
S e rio u s
(m g /k g /d a y )
R e fe re n c e  




CH RO N IC E X P O S U R E
D e a th
61 Rat 2  yr
(F ischer 3 4 4 ) (F )
S y s te m ic
6 2  Rat 1 & 2  yr
(F ischer 3 4 4 ) (F )
R esp 4G
4G M (8 8 %  died) U .S . A rm y 198 3 a











4 0  (de c re a s es  in hem atocrit, 
hem oglobin, and  
erythrocyte levels; 
splenic extram edullary  
hem atopoiesis)
4 0  (hepatom egaly , 
decreased  serum  







R enal 4 0  (renal papillary necrosis  
with increased B U N )
Endocr 
O cular  
Bd W t
4G 
8  F 
8
4G F (cataracts)
4 0  M (2 0 -3 0 %  decrease  in 




Table 3-1 Levels o f  S ig n ifica n t Exposure  to  RDX _ Oral (continued)
E x p o s u re / L O A E L
D u ra t io n /
K e y  to' S p e c ie s  F re q u e n c y  N O A E L  L e s s  S e r io u s  S e rio u s  R e fe re n c e
F ig u re  (S tra in ) (_______)___________ S y s te m  (m g /k g /d a y ) (m g /k g /d a y )________________________(m g /k g /d a y )____________________ C h e m ic a l F o rm _______________________ C o m m e n ts
6 3  Rat 2  yr


















Table 3-1 Levels o f  S ig n ifica n t Exposure  to  RDX - Oral (continued)
E x p o s u re / L O A E L
D u ra t io n /
K e y  to  S p e c ie s  F re q u e n c y  N O A E L  L e s s  S e r io u s  S e rio u s  R e fe re n c e
F ig u re  (S tra in ) (R o u te ) S y s te m  (m g /k g /d a y ) (m g /k g /d a y ) (m g /k g /d a y ) C h e m ic a l F o rm  C o m m e n ts
6 4 M ouse
(B 6 C 3 F 1 )
1 & 2  yr 
(F )
R esp 1GG U .S . A rm y 198 4 c









7 3 5  F (increased  serum  
cholesterol levels)
R enal 3 5  100  (increased  relative kidney
w eights  and reversible
cytoplasm ic
vacuolization)
N e u ro lo g ic a l
6 5  Rat 1 & 2  yr
(F ischer 3 4 4 ) (F )
O cu lar 1GG
Bd W t 1GG
4 0  (trem ors, convulsions; 
hyperresponsive to 
stimuli)
U .S . A rm y 198 3 a
R e p ro d u c tiv e
6 6  Rat 1 & 2  yr 8  M 4 0  M (testicu lar degeneration ) U S . A rm y 198 3 a
(F ischer 3 4 4 ) (F )









Table 3-1 Levels o f  S ig n ifica n t Exposure  to  RDX _ Oral (continued)
E x p o s u re / L O A E L
D u ra t io n /
K e y  to' S p e c ie s  F re q u e n c y  N O A E L  L e s s  S e r io u s  S e rio u s  R e fe re n c e
F ig u re  (S tra in ) (_______)___________ S y s te m  (m g /k g /d a y ) (m g /k g /d a y )________________________(m g /k g /d a y )____________________ C h e m ic a l F o rm _______________________ C o m m e n ts
6 7  M ouse 1 & 2  yr 1GG M U .S . A rm y 198 4 c
(B 6 C 3 F 1 ) (F )
1GG F
C a n c e r
6 8  M ouse
(B 6 C 3 F 1 )
1 & 2  yr 
(F )
3 5  F (C E L: hepatocellu lar  
carc in om as and  
adenom as)
U .S . A rm y 198 4 c
a Th e  num ber corresponds to entries  in Figure 3 -1 .
b U sed to derive an acu te-duration oral m inim al risk level (M R L ) o f 0 .2  m g/kg/day based on a P B P K  m odel predicted internal dose m etric (p e a k  brain R D X  concentration) o f the  
N O A E L  dose; a hum an equ iva len t dose (H E D ) o f the N O A E L  w a s  also estim ated  using a P B P K  m odel. Th e  N O A E L H E D  o f 6 .4 5  m g/kg /day  w a s  divided by an uncertainty factor o f 
3 0  (3  for extrapolation from an im als  to hum an with dosim etric  ad justm ents  and 10 for hum an variability).
c U sed to derive an in term ed iate-duration oral M R L  o f 0.1 m g/kg /day  based  on a B M D L 10  estim ated using using a P B P K  m odel predicted internal dose m etric (peak  brain R D X  
concentration); a hum an equivalen t dose o f the B M D L 10  w a s  also predicted using a P B P K  m odel. Th e  B M D L H E D  o f 4 .1 3 0 8  m g/kg/day w a s  divided by an uncertainty factor o f 3 0  (3  
for extrapolation from an im als  to hum an with dosim etric  ad justm ent and 10 for hum an variability).
d U sed to derive a chronic-duration oral m inim al risk level (M R L ) o f 0.1 m g/kg /day  based on a P B P K  m odel predicted internal dose m etric (peak  brain R D X  concentration) o f the  
N O A E L  dose; a hum an equ iva len t dose (H E D ) o f the N O A E L  w a s  also estim ated  using a P B P K  m odel. Th e  N O A E L H E D  o f 4 .2 2 3  m g/kg /day  w a s  divided by an uncertainty factor of 
3 0  (3  for extrapolation from an im als  to hum an with dosim etric  ad justm ents  and 10 for hum an variability).
Bd W t = body weight; (C ) = capsule; Cardio = cardiovascular; C E L  = can cer effect level; d = day(s); E ndocr = endocrine; (F ) = feed; F = Fem ale; (G ) = gavage; G astro = 
gastro intestinal; Gd = gestation day; (G O ) = g avage  in oil; (G W ) = g avag e  in w ater; H em ato  = hem atological; Im m uno /Lym phoret = im m unological/lym phoreticu lar; L D 50  = lethal 
dose, 5 0 %  kill; LO A E L  = low est-o bserved -adverse -effec t level; M = m ale; min = m inute(s); M e tab  = m etabolic; mo = m onth(s); M usc/skel = m usculoskeletal; N O A E L  = 
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Figure 3-1 Levels of Significant Exposure to RDX - Oral (Continued)
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*Doses represent the lowest dose tested per study that produced a tumorigenic 
















n-Mink Cancer Effect Level-Animals
o-Other LOAEL, More Serious-Animals
LOAEL, Less Serious-Animals 
NOAEL - Animals
Cancer Effect Level-Humans 
LOAEL, More Serious-Humans 
LOAEL, Less Serious-Humans 
NOAEL - Humans
LD50/LC50 






No studies were located regarding respiratory, musculoskeletal, dermal, or ocular effects in humans after 
acute oral exposure to RDX. No studies were located regarding systemic effects in humans after 
intermediate or chronic oral exposure to RDX. The highest NOAEL values and all reliable LOAEL 
values for systemic effects in each species and duration category are recorded in Table 3-1 and plotted in 
Figure 3-1.
Respiratory Effects. Adverse respiratory effects were not observed in animals following acute, 
intermediate, or chronic exposure. An acute-duration study in 3 anesthetized dogs showed no significant 
changes in breathing rate when 15 mg/kg RDX was administered by gavage (von Oettingen et al. 1949). 
No histopathology was seen in the lungs, trachea, or bronchi of rats exposed for 3-13 weeks to 
100 mg/kg/day o f RDX in the diet (Levine et al. 1990), 40 mg/kg/day RDX in the diet for 90 days (U.S. 
Army 1980b), or 15 mg/kg/day via gavage for 90 days (U.S. Army 2006). Similarly, no histopathological 
alterations were observed in the respiratory system o f mice exposed to 100 or 320 mg/kg/day in the diet 
for 3 or 6 months (U.S. Army 1980b, 1984c), dogs exposed to 10 mg/kg/day in the diet for 90 days (U.S. 
Navy 1974a) or 50 mg/kg via capsules 6 days/week for 6 weeks (von Oettingen et al. 1949), or monkeys 
administered 10 mg/kg/day via gavage for 90 days (U.S. Navy 1974b). Chronic-duration studies also 
revealed no histopathology in rats (U.S. Army 1983a; U.S. Navy 1976) or mice (U.S. Army 1984c).
Cardiovascular Effects. Sinusoidal tachycardia was observed in five men who accidentally ingested 
37-250 mg/kg RDX (Kufukardalì et al. 2003).
Few, if  any, changes were observed in cardiovascular parameters measured in animals exposed to RDX. 
An acute-duration study in 3 anesthetized dogs showed no significant changes in heart rate when 
15 mg/kg RDX was administered by gavage (von Oettingen et al. 1949). Intermediate-duration studies 
revealed no histopathology in the heart o f rats exposed to 15-100 mg/kg/day o f RDX (Levine et al. 1981; 
U.S. Army 2006). Slight myocardial degeneration was observed in rats exposed to 40 mg/kg/day and 
mice exposed to 320 mg/kg/day in the diet for 90 days (U.S. Army 1980b). No pathology was seen in the 
hearts o f dogs (U.S. Navy 1974a; von Oettingen et al. 1949) or monkeys (U.S. Navy 1974b) exposed to 
RDX for intermediate periods. Hyaline degeneration of the heart muscles was observed in rats following 
intermediate exposure to 50 mg/kg/day o f RDX (Sunderman 1944). Chronic exposure produced no 
cardiac histopathology in rats (U.S. Army 1983a; U.S. Navy 1976), but it increased relative heart weights 




Gastrointestinal Effects. Humans who accidentally or intentionally consumed unknown levels o f 
RDX for an acute period had nausea, vomiting, and abdominal pain (Kasuske et al. 2009; Ketel and 
Hughes 1972; Küçükardalï et al. 2003). In three of five cases in which men accidentally ingested 37­
250 mg/kg, an endoscopic examination conducted 3 days after exposure revealed erosive gastroduodenitis 
(Küçükardalï et al. 2003).
Vomiting was reported in dogs acutely exposed to 100 and 300 mg/kg/day RDX (Sunderman 1944). 
Vomiting was also observed in five o f six monkeys administered via gavage 10 mg/kg/day for 90 days, 
compared to one of six in the control group (U.S. Navy 1974b). There were 15 episodes o f vomiting 
(excluding vomiting, which occurred during the gavage procedure) in this group compared to 1 episode in 
the control group. In monkeys administered 1 mg/kg/day, two o f six animals (three episodes) vomited; 
one other animal in this group vomited only during the gavage procedure. Following intermediate 
exposure of rats to 50 mg/kg/day RDX, mild congestion o f the intestines was reported (Sunderman 1944). 
No histopathology was seen in the stomachs or intestines o f rats (Levine et al. 1981, 1990; U.S. Army 
1980b, 1983a), mice (U.S. Army 1980b, 1984c), dogs (U.S. Navy 1974a; von Oettingen et al. 1949), or 
monkeys (U.S. Navy 1974b). Chronic exposure also did not produce histopathological alterations in rats 
(U.S. Army 1983a; U.S. Navy 1976) or mice (U.S. Army 1984c).
Hematological Effects. Humans who accidentally consumed unknown levels o f RDX for an acute 
duration generally had normal blood counts (Ketel and Hughes 1972; Woody et al. 1986). Temporary 
decreased hematocrit and leukocytosis were reported in a study o f six men who consumed C-4 containing 
RDX (Stone et al. 1969). Similarly, leukocytosis and methemoglobinemia were noted in a report o f five 
men accidentally ingesting 37-250 mg/kg RDX (Küçükardalï et al. 2003).
Decreased hemoglobin and erythrocyte levels, increased platelet counts, and splenic extramedullary 
hematopoiesis were observed in male rats exposed to 40 mg/kg/day RDX in the diet for 6 months (U.S. 
Army 1983a). However, oral doses of 15 mg/kg/day (administered via gavage) (U.S. Army 2006) or 
40 mg/kg/day (administered via the diet) (U.S. Army 1980b) for 13 weeks did not result in significant 
hematological effects. Similarly, decreased hemoglobin and erythrocyte levels were observed in mice 
exposed to 160 mg/kg/day for 90 days (U.S. Army 1980b). No significant hematological effects were 
found in mice exposed to 100 mg/kg/day for 6 months (U.S. Army 1984c) and dogs exposed to 
50 mg/kg/day for 6 weeks (von Oettingen et al. 1949). Species differences in hematological responses to 
RDX may relate to differences in their activity o f erythrocyte methemoglobin reductase (Rockwood et al.
3. HEALTH EFFECTS
RDX 51
2003; Smith and Beutler 1966). Slight, but statistically significant, increases in the number o f leukocytes 
were observed in rats exposed to >10 mg/kg/day for 13 weeks (Levine et al. 1981). Necrotic and 
degenerative megakaryocytes were observed in the bone marrow o f monkeys given 10 mg/kg/day of 
RDX for 90 days (U.S. Navy 1974b). Chronic administration o f 40 mg/kg/day o f RDX in the diet for 1­
2 years produced decreased hematocrit, hemoglobin, and erythrocytes in rats; the effects were not 
considered biologically significant and there were no compensatory responses (U.S. Army 1983a). 
Significant increases in platelet levels were also observed at 40 mg/kg/day (U.S. Army 1983a). No 
significant hematological effects were observed in mice chronically exposed to 100 mg/kg/day (U.S. 
Army 1984c).
M usculoskeletal Effects. No histopathological alterations were observed in muscle or skeletal tissue 
o f rats (Levine et al. 1981, 1990; U.S. Army 1980b, 1983a), mice (U.S. Army 1980b, 1984c), or dogs 
(U.S. Navy 1974a) exposed for intermediate periods. Muscles and bones were also normal in rats (U.S. 
Army 1983a; U.S. Navy 1976) and mice (U.S. Army 1984c) exposed for chronic periods.
Hepatic Effects. Slightly elevated serum aspartate aminotransferase and/or alanine aminotransferase 
(Küçükardalï et al. 2003; Merrill 1968; Stone et al. 1969) were observed in humans ingesting unknown 
levels o f RDX after using C-4 cooking fuel for an acute duration; other studies reported normal liver 
enzyme levels (Ketel and Hughes 1972). Liver biopsies were normal (Stone et al. 1969).
Minor adverse hepatic effects have been noted in some animal studies. Slight decreases in alanine 
aminotransferase levels were observed in rats exposed to 40 mg/kg/day for 26 weeks (U.S. Army 1983a). 
Decreases in serum triglyceride levels were noted in rats exposed to >10 mg/kg/day RDX for 13 weeks 
(Levine et al. 1981, 1990), decreases in serum cholesterol were observed in male rats administered 
>8 mg/kg/day for 90 days (U.S. Army 2006), and decreases in serum triglycerides and cholesterol were 
observed in rats exposed to 40 mg/kg/day for 6 months to 2 years (U.S. Army 1983a). Increases in serum 
cholesterol were also observed in female mice exposed to 35 or 100 mg/kg/day for 1-2 years (U.S. Army 
1984c). Increases in liver weight have been observed in rats exposed to 30 or 100 mg/kg/day (Levine et 
al. 1981, 1990) and mice exposed to 100 or 320 mg/kg/day (U.S. Army 1980b, 1984c); hepatomegaly was 
observed in rats exposed to 40 mg/kg/day (U.S. Army 1983a). However, most studies did not find 
histological alterations in the livers o f rats (Levine et al. 1981; U.S. Army 1983a), mice (U.S. Army 
1984c), dogs (U.S. Navy 1974a; von Oettingen et al. 1949), white-footed mice (U.S. Army 1999), or 
monkeys (U.S. Navy 1974b). Two studies did find histological effects; hepatocellular vacuolization was 
observed in mice exposed to 320 mg/kg/day for 90 days (U.S. Army 1980b) and fatty degeneration was
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observed in rats exposed to 50 mg/kg/day for 78 days (Sunderman 1944). Although the alterations in 
serum clinical chemistry parameters may be indicative o f minor changes in liver function, the lack of 
histological damage at similar or higher doses suggests that the liver may not be a sensitive target o f RDX 
toxicity and the alterations may not be biologically significant.
Renal Effects. Humans who accidentally consumed unknown levels o f RDX for an acute duration 
showed no (Woody et al. 1986) or only slight (Ketel and Hughes 1972; Stone et al. 1969) changes in renal 
function parameters. Proteinuria and glucosuria were observed in men after accidental ingestion o f RDX 
(Kufukardalì et al. 2003; Merrill 1968).
Few adverse renal effects were reported in animals. No histopathological alterations were observed in the 
kidneys from white-footed mice following 14-day dietary exposure (U.S. Army 1999) or from rats 
following intermediate exposure periods (Levine et al. 1981, 1990; U.S. Army 1980b, 1983a, 2006). 
Normal kidney parameters were also observed in dogs (U.S. Navy 1974a; von Oettingen et al. 1949) and 
monkeys (U.S. Navy 1974b). In contrast, mild tubular nephrosis was reported in mice given high doses 
(320 mg/kg/day) in the food for 13 weeks, but was not seen at lower doses (160 mg/kg/day) (U.S. Army 
1980b). Following chronic exposure to 40 mg/kg/day o f RDX in food, renal papillary necrosis and 
elevated blood urea nitrogen levels were observed in rats (U.S. Army 1983a); these effects were not 
observed at 8 mg/kg/day. Other studies showed normal renal parameters in rats at lower levels 
(10 mg/kg/day) (U.S. Navy 1976). Increased kidney weights, but no other signs o f kidney toxicity, were 
observed in mice chronically exposed to 100 mg/kg/day (U.S. Army 1984c).
Endocrine Effects. No histopathological alterations were observed in the adrenal glands o f rats (U.S. 
Army 1980b, 1983a; U.S. Navy 1976), mice (U.S. Army 1984c), dogs (U.S. Navy 1974a), or monkeys 
(U.S. Navy 1974b) exposed for intermediate periods. One study (U.S. Army 1980b) observed mild focal 
subscapular fibroplasia in the adrenal glands o f female mice exposed to 320 mg/kg/day RDX for 90 days.
Dermal Effects. No significant skin lesions were seen in rats (U.S. Army 1980b, 1983a) exposed for 
intermediate periods to RDX in the food.
Ocular Effects. No significant ophthalmologic alterations were observed in rats administered 
15 mg/kg/day via gavage for 90 days (U.S. Army 2006). Female rats exposed to 40 mg/kg/day o f RDX 
in their food for 2 years had cataracts (U.S. Army 1983a), but this was not seen in the male rats in this
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study, in male or female rats exposed to 40 mg/kg/day in another study (U.S. Army 1980b), or in mice 
exposed to a higher level (100 mg/kg/day) (U.S. Army 1984c).
Body Weight Effects. W eight loss or lack o f weight gain of >10% was seen in rats fed 25­
40 mg/kg/day (Levine et al. 1981, 1990; von Oettingen et al. 1949) and dogs fed 50 mg/kg/day (von 
Oettingen et al. 1949) for an intermediate duration, and in rats receiving 40 mg/kg/day RDX (U.S. Army 
1983a) and mice receiving 100 mg/kg/day (U.S. Army 1984c) for a chronic period.
Metabolic Effects. Hyperglycemia, hypokalemia, and metabolic acidosis with anion gap were 
observed in men accidentally ingesting 37-250 mg/kg RDX (Küçükardalï et al. 2003). In rats exposed to 
40 mg/kg/day RDX in the diet for 13-78 weeks, significant decreases in blood glucose levels were 
observed (U.S. Army 1983a).
3.2.2.3 Immunological and Lymphoreticular Effects
No studies were located regarding immunological effects in humans after oral exposure to RDX.
No studies were located regarding immunological effects in animals after acute oral exposure to RDX. 
Studies of intermediate duration (6-13 weeks) failed to reveal any marked pathological alterations in the 
spleen, thymus, and/or lymph nodes in rats (Levine et al. 1990; U.S. Army 1980b), mice (U.S. Army 
1980b), dogs (U.S. Navy 1974a; von Oettingen et al. 1949), or monkeys (U.S. Navy 1974b). No 
significant alterations in spleen and thymus organ weights or cellularity, or in the proportion o f cell 
surface markers were observed in rats exposed to 15 mg/kg/day for 90 days (U.S. Army 2006). The 
NOAEL value from the U.S. Army (2006) is recorded in Table 3-1 and plotted in Figure 3-1; NOAEL 
values for studies only examining potential histopathological alterations in lymphoreticular organs were 
not listed.
3.2.2.4 Neurological Effects
The available studies have identified the nervous system as a target system in humans following oral 
exposure to RDX. Numerous case reports are available that describe seizures in men (Hollander and 
Colbach 1969; Kasuske et al. 2009; Ketel and Hughes 1972; Küçükardalï et al. 2003; Merrill 1968; Stone 
et al. 1969) and in one child (Woody et al. 1986) after accidental consumption of unknown quantities o f 
RDX for acute periods and in men intentionally chewing on C-4 (Goldberg et al. 1992; Harrell-Bruder 
and Hutchins 1995). The RDX was almost always mixed with other components in the form o f the
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explosive C-4, which is 91% RDX (mixed with polyisobutylene, motor oil, and di-(2-ethylhexyl) 
sebacate). In most o f the cases, RDX intakes were not known; Stone et al. (1969) reported doses (357 and 
2,571 mg/kg) for two cases. In a report o f five cases (Küçükardalï et al. 2003), repetitive tonic-clonic 
convulsions were first observed 4-16 hours after RDX exposure; in one case, convulsions were observed 
for 3 days, although the frequency and duration gradually decreased with time. Most studies reported that 
recovery occurred within a few days or weeks. Accompanying complaints included disorientation, 
nausea, restlessness, muscle twitching, lethargy, and hyperactive deep tendon reflexes. In most cases, no 
other neurological evaluations were performed. Küçükardalï et al. (2003) noted abnormalities in 
electroencephalograms (EEG) in three of the five cases. In the case reported by Harrell-Bruder and 
Hutchins (1995), no EEG abnormalities were found. No intermediate- or chronic-duration exposure data 
have been reported for humans.
Animal studies have also shown that the nervous system is a target system following oral exposure to 
RDX. Seizures were observed in rats receiving a single gavage dose o f >25 mg/kg (U.S. Army 2006; 
Burdette et al. 1988; Meyer et al. 2005; Schneider et al. 1977), deer mice receiving a gavage dose of 
136 mg/kg (Smith et al. 2007), and miniature swine receiving a single gavage dose o f >10 mg/kg 
(JHU/U.S. Army 2006; Schneider et al. 1977). Seizures were also observed in 20% o f rats administered a 
single dose of 12.5 mg/kg/day; however, the incidence was not significantly different from controls 
(Burdette et al. 1988). Following administration o f a single dose o f >25 mg/kg RDX, seizures and 
convulsions typically occur within 3 hours (U.S. Army 2006; Burdette et al. 1988). Convulsions and 
hyperactivity were also noted in “several” surviving rat dams administered 20 mg/kg/day by gavage during 
gestation days 6-15 (U.S. Army 1986d); incidence data were not provided. Hyperactivity was observed in 
approximately 70% o f rat dams administered 20 mg/kg/day RDX via gavage on gestation days 6-19 (U.S. 
Army 1980b). In a 14-day exposure study, tremors and convulsions were observed in rats receiving 
gavage doses of >17 mg/kg/day; no marked neurological effects were noted at 8.5 mg/kg/day (U.S. Army 
2006). In neurobehavioral tests, decreases in motor activity, hindlimb splay, taste aversion to saccharine, 
response rate in scheduled-controlled behavior tests, auditory startle amplitude, and increases in startle 
latency were observed in rats receiving a single gavage dose o f >12.5 mg/kg/day (U.S. Army 1985b).
Seizures and convulsions have also been observed in rats, monkeys, and dogs exposed to RDX for 
intermediate or chronic durations. Seizures and convulsions were observed in rats administered gavage 
doses >8 mg/kg/day for 90 days (U.S. Army 2006), in rats exposed to dietary RDX at doses of 
>25 mg/kg/day (Sunderman 1944; U.S. Army 1983a; von Oettingen et al. 1949), dogs exposed to 
50 mg/kg/day via a capsule (von Oettingen et al. 1949), and monkeys administered 10 mg/kg/day via
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gavage (U.S. Navy 1974b). Few studies have reported the time course o f the convulsions/seizures. In the 
U.S. Army (2006) study, convulsions/seizures were observed at the beginning o f the study in rats 
administered 12 or 15 mg/kg/day and were seen throughout the study; convulsions/seizures were also 
observed at 8 and 10 mg/kg/day, however, the investigators did not note when the convulsions/seizures 
first occurred for these dose levels. In a chronic dietary study, seizures and convulsions were first 
observed after 26 weeks o f exposure to 40 mg/kg/day (U.S. Army 1983a). In monkeys, the effects were 
typically observed after 34-57 doses, although effects were also seen in some monkeys after the 2nd or 
12th dose, and did not occur on a regular basis (U.S. Navy 1974b). Other overt neurological signs 
observed following intermediate or chronic exposure include hyperactivity, hyperreactivity, increased 
arousal, and increased fighting in rats exposed to gavage doses of >10 mg/kg/day (U.S. Army 2006), in 
rats exposed to >25 mg/kg/day in the diet (Levine et al. 1990; U.S. Army et al. 1983a; von Oettingen et 
al. 1949), and dogs administered capsules containing 50 mg/kg/day (von Oettingen et al. 1949). The 
highest NOAELs for overt neurological effects were 4 mg/kg/day in rats receiving gavage doses (U.S. 
Army 2006), 15 mg/kg/day in rats exposed via the diet (von Oettingen et al. 1949), and 1 mg/kg/day in 
monkeys receiving gavage doses (U.S. Navy 1974b). Neurobehavioral performance was assessed in rats 
receiving gavage doses o f RDX for 30 or 90 days. No significant alterations were observed in motor 
activity, flavor aversion, scheduled-controlled behavior, or acoustic startle in rats administered 10 
mg/kg/day for 15 or 30 days (U.S. Army 1985b). No RDX-related alterations in foot splay, front limb 
grip strength, or response to stimuli were found in rats administered 15 mg/kg/day for 90 days (U.S.
Army 2006). No significant histological alterations have been found in the brain (U.S. Army 1983a, 
2006).
The highest NOAEL values and all reliable LOAEL values for neurological effects in each species and 
duration category are recorded in Table 3-1 and plotted in Figure 3-1.
3.2.2.5 Reproductive Effects
No studies were located regarding reproductive effects in humans after oral exposure to RDX.
Toxicity studies lasting 13 weeks showed no pathological changes in the gonads or uteri o f rats (Levine et 
al. 1981, 1990; U.S. Army 1980b, 1983a) or mice (U.S. Army 1980b, 1984c) exposed to RDX. No 
functional tests were performed. One study did report spermatic granulomas in the prostates o f rats 
exposed to 40 mg/kg/day for 6 months (U.S. Army 1983a); this effect was not observed in rats exposed 
after 1 or 2 years o f exposure (U.S. Army 1983a). This study (U.S. Army 1983a) also reported an
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increase in the incidence o f testicular degeneration in rats exposed to 40 mg/kg/day for 6 months (3/10, 
not statistically significant) or 1 year (4/10), but not after 2 years (0/4).
Histological examinations o f rats exposed to >1.5 mg/kg/day in the feed for 2 years revealed suppurative 
inflammation in the prostate (U.S. Army 1983a). The prostate effects were predominantly observed in 
rats dying early and may have been secondary to a bacterial infection o f the urinary tract. Urinary bladder 
distention and cystitis were observed in rats exposed to 40 mg/kg/day for 1 or 2 years. Testicular 
degeneration was observed in rats exposed to 40 mg/kg/day for 1 year (U.S. Army 1983a); a 
nonstatistically significant increase in testicular degeneration was also observed in mice exposed to 
>35 mg/kg/day for 1-2 years (U.S. Army 1984c). No significant histological alterations have been 
observed in the ovaries or uterus o f rats (U.S. Army 1983a) or mice (U.S. Army 1984c) chronically 
exposed to RDX.
Two studies examined reproductive function. In a two-generation study, no significant alterations in 
reproduction were observed in the F0 and Fi rats exposed to 16 mg/kg/day in the diet (U.S. Army 1980b). 
At 50 mg/kg/day, nonstatistically significant decreases in fertility were observed in the F0 generation. In 
a dominant lethality assay (U.S. Army 1980b), decreases in fertility were observed in male rats exposed 
to 50 mg/kg/day for 15 weeks prior to mating with unexposed females; however, the investigators noted 
that this effect may have been secondary to the impaired well-being o f the males. The highest NOAEL 
values and all reliable LOAEL values for reproductive effects in each species and duration category are 
recorded in Table 3-1 and plotted in Figure 3-1.
3.2.2.6 Developmental Effects
No studies were located regarding developmental effects in humans after oral exposure to RDX.
There are two available developmental studies in rats (exposed for 9 or 13 days during gestation) that are 
inconclusive because o f excessive maternal toxicity at the high dose (20 mg/kg/day). In one study, no 
excessive gross, visceral, or skeletal anomalies were found in fetuses when the dams were exposed to 
2 mg/kg/day o f RDX (U.S. Army 1980b). High maternal lethality, decreased maternal body weights, and 
adverse maternal neurological effects precluded judgment regarding fetal toxicity at 20 mg/kg/day. The 
other rat study (U.S. Army 1986d) also showed high maternal toxicity (increased mortality and seizures) 
at 20 mg/kg/day. These investigators also reported a significant decrease in fetal weights and lengths at 
>2 mg/kg/day when data were analyzed on an individual basis rather than a litter basis. However, it
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appears that there was an overlap in the standard deviations for the fetal body weight and length values; 
when analyzed on a litter basis, decreases in fetal weights and lengths were only significant at the 
20 mg/kg/day dose level. In contrast to rats, rabbits (exposed for 22 days during gestation) showed no 
adverse fetal or maternal effects at 20 mg/kg/day (U.S. Army 1980b). In a two-generation reproduction 
study, an increase in the number o f stillbirths, a decrease in the number o f pups per litter at birth, and a 
decrease in the number o f live litters at weeks 7, 14, and 21 were observed in the F1 offspring o f rats 
exposed to 50 mg/kg/day (a dose that also resulted in increased maternal deaths and decreased feed 
consumption) (U.S. Army 1980b). In the F2 generation, a decrease in terminal body weights and an 
increase in renal tubular epithelial-lined cysts were observed at 16 mg/kg/day. Similar cysts were 
observed in F2 pups exposed to 0 or 5 mg/kg/day. The highest NOAEL values and all reliable LOAEL 
values for developmental effects for each species and duration category are recorded in Table 3-1 and 
plotted in Figure 3-1.
3.2.2.7 Cancer
No studies were located regarding cancer in humans after oral exposure to RDX.
RDX was not found to be carcinogenic when fed to F344 rats (U.S. Army 1983a) or Sprague-Dawley rats 
(U.S. Navy 1976) for at least 1 year. Adequate doses, numbers o f animals, and survival rates were 
achieved for both o f these studies. Only female B6C3Fj mice showed an increased incidence of 
combined hepatocellular adenomas and carcinomas when compared to concurrent or historical controls 
(U.S. Army 1984c). However, a re-evaluation o f these data using revised diagnostic criteria resulted in a 
reclassification of several hepatocellular adenomas as foci o f cytoplasmic alterations (Parker et al. 2006). 
As noted in the abstract o f the Parker et al. (2006) paper, the combined incidence of hepatocellular 
adenomas and carcinomas was significantly increased (no information regarding statistical analysis was 
presented in the paper) in the 35 mg/kg/day group, but not in the 100 mg/kg/day group. The investigators 
noted that the combined incidence of hepatocellular adenomas and carcinomas in the 35 mg/kg/day group 
(10/64, 16%) was within the range o f published historical control data (0-21% ) and suggested that the 
study provided equivocal evidence of a carcinogenic effect. The 35 mg/kg/day dose is listed as a cancer 
effect level (CEL) in Table 3-1 and Figure 3-1. The lifetime average doses that would result in risk of 





No studies were located regarding death in humans after dermal exposure to RDX.
Deaths were observed in rabbits receiving repeated dermal applications o f 37.5 mg/kg/day RDX in 
cyclohexanone (1/6 deaths) or 27 mg/kg/day RDX in acetone (2/6) deaths; no gross pathological effects 
were seen (U.S. Army 1974). Because o f the lack o f data presented, it is difficult to determine whether 
RDX alone was responsible for the deaths reported in this study.
3.2.3.2 System ic Effects
No studies were located regarding respiratory, cardiovascular, gastrointestinal, hematological, 
musculoskeletal, hepatic, or renal effects in humans after dermal exposure to RDX. Two older studies of 
dermal and ocular effects were located for humans following dermal exposure to RDX.
One animal study examined the potential systemic toxicity o f RDX following a single dermal application 
(U.S. Army 1974); however, no details were provided regarding the “pathological examination”; thus, 
NOAELs for systemic effects were not presented for this study. The highest NOAEL values and all 
reliable LOAEL values for systemic effects in each species and duration category are recorded in 
Table 3-2.
Respiratory Effects. No alterations were noted in the respiratory rates o f dogs following single or 
multiple dermal exposures to RDX in dimethyl sulfoxide (DMSO) (U.S. Army 1974).
Cardiovascular Effects. No adverse effects were seen on blood pressure, heart rate, or 
electrocardiograms o f dogs dermally exposed to a single application or repeated exposure (5 days/week 
for 4 weeks) o f 289 mg/kg RDX in DMSO (U.S. Army 1974). No lesions were seen in the hearts of 
rabbits exposed to 165 mg/kg RDX in DMSO 5 days/week for 4 weeks (U.S. Army 1974).
Gastrointestinal Effects. Necropsy did not reveal any lesions in the intestines o f rabbits exposed to 
165 mg/kg RDX in DMSO 5 days/week for 4 weeks (U.S. Army 1974).
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Table 3-2 Levels o f S ig n ifica n t E xposure  to  RDX - Dermal
S p e c ie s
(S tra in )
E x p o s u re /
D u ra t io n /
F re q u e n c y
(R o u te )
S y s te m  N O A E L  L e s s  S e rio u s
L O A E L
S e rio u s
R e fe re n c e  
C h e m ic a l F o rm C o m m e n ts
A C U T E  E X P O S U R E
S y s te m ic
Gn Pig 
(N S )
once or 3  tim es
D erm al 5 1 0  1 00 0  (e ry them a)
m g/kg /day  m g/kg/day
U .S . A rm y 1 97 4 R D X  in D M S O
Dog
(N S )
R esp 2 8 9
m g/kg/day
U .S . A rm y 1 97 4 R D X  in D M S O




H em ato 165
m g/kg
U .S . A rm y 1 97 4 R D X  in D M S O  (1 65  
m g/kg), R D X  in 
cyc lohexanone (37  
m g/kg)
D erm al 2 7  (derm atitis) 
m g/kg
N e u ro lo g ic a l
Dog 3  d
(N S ) 1x/day
C ardio 4 8 0
m g/kg/day
U .S . A rm y 1 97 4 R D X  in D M S O
IN TERM ED IATE E X P O S U R E
S y s te m ic
Gn Pig 3  w k  , D erm al
(N S ) 3  d /w k 165
mg













Table 3-2 Levels o f S ig n ifica n t E xposure  to  RDX - Dermal (continued)
S p e c ie s
(S tra in )
E x p o s u re /
D u ra t io n /
F re q u e n c y
(R o u te )
L O A E L
S y s te m N O A E L L e s s  S e rio u s S e rio u s
R e fe re n c e  
C h e m ic a l F o rm C o m m e n ts
Dog 4  w k
(N S ) s  d /w k
R esp 2 8 9
m g/kg/day
U .S . A rm y 1 97 4 R D X  in D M S O
C ardio 2 8 9
m g/kg/day




4  w k  
s  d /w k
R esp 165
m g/kg/day
U .S . A rm y 1 97 4 R D X  in D M S O  (1 65  
m g/kg /day), R D X  in 












D erm al 3 7 .5  1 6 5  (derm atitis)
m g/kg /day  m g/kg/day
Cardio  = cardiovascular; d = day(s); Gastro = gastrointestinal; Gn Pig = gu inea pig; LO A E L  = low est-o bserved -adverse -effec t level; M e tab  = m etabolic; M usc/skel = m usculoskeletal; 










Hematological Effects. Blood samples taken from rabbits after a single exposure to 165 mg/kg RDX 
in DMSO revealed no significant changes in hematological parameters (U.S. Army 1974).
Musculoskeletal Effects. Necropsy did not reveal pathology in the muscle or bone tissue o f rabbits 
exposed to 165 mg/kg RDX in DMSO 5 days/week for 4 weeks (U.S. Army 1974).
Hepatic Effects. No alterations in serum clinical chemistry parameters were found in rabbits after 
acute or intermediate dermal exposure to RDX. Also, no pathological alterations were noted in the liver 
o f rabbits exposed for 4 weeks (U.S. Army 1974).
Renal Effects. No histological alterations were noted in the kidneys o f rabbits exposed to 165 mg/kg 
RDX in DMSO 5 days/week for 4 weeks (U.S. Army 1974).
Dermal Effects. One volunteer had a patch o f skin covered with dry RDX for 2 days. No irritation 
was observed following removal o f the gauze coverings (von Oettingen et al. 1949). An accurate dose 
could not be determined because o f the lack o f information provided in the study. Another study reported 
dermatitis in workers exposed to RDX fumes o f unknown levels and for unknown duration (Sunderman 
1944).
Dermatitis was observed in rabbits exposed once to 27 mg/kg RDX in acetone, 37.5 mg/kg RDX in 
cyclohexanone, or 165 mg/kg RDX in DMSO (U.S. Army 1974); the dermatitis persisted for at least 
30 days and was most pronounced in the rabbits exposed to 165 mg/kg RDX in DMSO. Slight erythema 
was noted in guinea pigs exposed once to 1,000 mg/kg (U.S. Army 1974). Guinea pigs exposed once to 
an unspecified amount o f RDX had exudative dermatitis with edema (Sunderman 1944). The lesions 
healed promptly after the guinea pigs were removed from the source o f exposure.
In rabbits repeatedly exposed to 165 mg/kg RDX in DMSO 5 days/week for 4 weeks, dermatitis was 
observed after 14 and 30 days o f exposure; no dermal effects were observed at 16.5 mg/kg RDX in 
DMSO or in rabbits administered lower RDX doses in cyclohexanone (37.5 mg/kg/day) or acetone 
(27 mg/kg/day) vehicles (U.S. Army 1974).
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Ocular Effects. There are limited human data regarding the ocular toxicity o f RDX. Conjunctivitis 
was reported by workers exposed to RDX fumes (Sunderman 1944); no information was provided 
regarding exposure levels or duration o f exposure.
Cataracts were observed in guinea pigs exposed through cutaneous or intradermal applications of RDX in 
solvents. However, the incidence o f cataracts did not appear to be greater than that found after exposure 
to the solvents alone. This suggests that RDX itself did not contribute to cataract formation (U.S. Army 
1974).
Body Weight Effects. Decreased body weight classified as small and transient (no further details 
were provided) was reported in rabbits after a single dermal application of 2,000 mg/kg o f RDX.
However, by the end o f the observation period, most o f the surviving animals showed weight gain (U.S. 
Army 1984b).
No studies were located regarding the following effects in humans or animals after dermal exposure to 
RDX:






No studies were located regarding genotoxicity o f RDX in humans following inhalation, oral, or dermal 
exposure to the chemical. One in vitro study was located in which human fibroblasts (WI-38 cells) were 
incubated in the presence of RDX and tritiated thymidine (3H-TdR) to measure unscheduled 
deoxyribonucleic acid (DNA) synthesis (U.S. Army 1978b) (see Table 3-3). RDX was tested in 
concentrations o f up to 4,000 ^g/mL both with and without metabolic activation. RDX was not found to 
significantly increase the rate of unscheduled DNA synthesis in the cells o f any exposure group regardless 
o f whether or not metabolic activators were present. Therefore, RDX was not observed to induce DNA 




Table 3-3. Genotoxicity of RDX In Vitro
Results





TA98, TA100, TA1535, TA1537, 
TA1538
Gene mutation U.S. Army 1980b
S. typhimurium
TA98, TA100, TA1535, TA1537, 
TA1538
Gene mutation U.S. Army 1977b
S. typhimurium
TA98, TA100, TA1535, TA1537, 
TA1538
Gene mutation Whong et al. 1980
S. typhimurium 
TA98, TA100
Gene mutation - - Lachance et al. 1999
S. typhimurium 
TA98, TA100
Gene mutation - - George et al. 2001
S. typhimurium 
TA98, TA100
Gene mutation - - Pan et al. 2007
S. typhimurium 
TA97a
Gene mutation ± - Pan et al. 2007
Vibrio fischeri Gene mutation ± ± Arfsten et al. 1994
Eukaryotic organisms:
Fungi:
Saccharomyces cerevisiae Gene mutation - - U.S. Army 1977b
Mammalian cells:
Human fibroblasts DNA damage - - U.S. Army 1978b
Chinese hamster V79 lung cells Gene mutation - - Lachance et al. 1999
Mouse lymphoma L5178Y cells Gene mutation - - Reddy et al. 2005a
—  = negative result; + = positive result; ± = weak or equivocal result; DNA = deoxyribonucleic acid
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Only two in vivo animal studies were located and both provided negative evidence o f mutagenicity. U.S. 
Army (1980b) investigated the effects of oral doses o f RDX on dominant lethal mutations in rats. RDX 
was administered to the rats in the diet in doses o f 0, 5, 16, or 50 mg/kg/day for 15 weeks. The males in 
each exposure group were then allowed to mate with untreated females for 2 weeks. There were no 
significant effects on the number o f corpora lutea, implants, or live or dead embryos (U.S. Army 1980b); 
no dominant lethal mutations were observed. In the other in vivo study, administration o f a single gavage 
dose of up to 250 mg RDX/kg to male mice did not significantly increase the incidence of micronuclei in 
bone marrow cells examined 24 hours after dosing (Reddy et al. 2005a).
The in vitro genotoxicity o f RDX has been investigated in several assays (Table 3-3). Most o f the results 
o f reverse mutation assays with Salmonella typhimurium  conducted by several investigators (George et al. 
2001; Lachance et al. 1999; Pan et al. 2007; U.S. Army 1977b, 1980b; Whong et al. 1980), 
Saccharomyces cerevisiae (U.S. Army 1977b), or Vibrio fischeri (Arfsten et al. 1994) have been negative. 
A weakly positive result was found in one S. typhimurium strain (TA97a) (Pan et al. 2007). In 
mammalian cells, forward mutation assays in mouse lymphoma L5178Y cells (Reddy et al. 2005a) and 
hamster V79 lung cells (Lachance et al. 1999) were negative.
Although the results o f in vitro assays have been negative for RDX, some studies o f environmental 
biotransformation products o f RDX have reported positive results. For example, George et al. (2001) 
reported that hexahydro-1-nitroso-3,5-dinitro-1,3,5-triazine (MNX) and hexahydro-1,3-dinitroso-5-nitro- 
1,3,5,-triazine, were not mutagenic in S. typhimurium TA98 or TA100 with or without metabolic 
activation, but hexahydro-1,3,5-trinitroso-1,3,5-triazine (TNX) was weakly genotoxic in strain TA100 but 
negative in strain TA98. Studies conducted by Pan et al. (2007) showed that in the presence o f metabolic 
activation, both MNX and TNX were mutagenic in S. typhimurium TA97a, weakly mutagenic in strain 
TA102, and not mutagenic in strain TA98; in addition, TNX was weakly mutagenic in strain TA100 in 
the presence o f metabolic activation. Pan et al. (2007) also reported that neither MNX nor TNX were 
mutagenic in S. typhimurium TA97a in the absence o f metabolic activation.
Collectively, the available information suggests that RDX is not a mutagenic substance, but some o f its 
environmental biotransformation products may be o f concern, especially since they have been identified 




Very little is known regarding the toxicokinetics o f RDX in humans, but reports o f adverse effects 
following inhalation and oral exposure and measurements o f RDX in blood from poisoned individuals 
indicate that RDX is absorbed through the lungs and the gastrointestinal tract. No information is 
available regarding the distribution and metabolism o f RDX in humans. A single case study found RDX 
in the cerebrospinal fluid following oral exposure (Woody et al. 1986), suggesting possible distribution to 
the nervous system. RDX was almost completely absorbed in miniature pigs after a single oral dose 
(Major and Reddy 2007). In rats, mixing RDX with soil considerably reduced absorption compared to 
administration o f neat RDX (Crouse et al. 2008). No preferential accumulation o f RDX in specific tissues 
has been reported in animal studies (Schneider et al. 1977, 1978). Several metabolites were identified in 
the urine from miniature pigs dosed orally with RDX (Major and Reddy 2007). The urine was the main 
route o f elimination o f 14C-RDX-derived radioactivity (Schneider et al. 1977).
3.4.1 Absorption
3.4.1.1 Inhalation Exposure
Neurological effects have been observed in humans following inhalation exposure, indicating that RDX 
can be absorbed through the lungs (Kaplan et al. 1965; Testud et al. 1996a). The extent o f absorption 
through the lungs has not been determined. As described in an abstract, approximately 30% of an 
intratracheal dose was excreted in the urine and feces during a 6-day period (Reddy et al. 1989).
3.4.1.2 Oral Exposure
Adverse effects observed in humans following accidental or intentional ingestion o f RDX indicate that it 
is absorbed through the gastrointestinal tract (Davies et al. 2007; Hollander and Colbach 1969; Harrell- 
Bruder and Hutchins 1995; Kaplan et al. 1965; Kasuske et al. 2009; Ketel and Hughes 1972; Merrill 
1968; Stone et al. 1969). Measurements o f RDX in blood provide direct evidence that gastrointestinal 
absorption occurs. A study o f a child who ingested an unknown amount o f RDX reported an apparent 
peak plasma concentration prior to 24 hours postingestion (Woody et al. 1986). At 24 hours (first time 
measurements were made), the serum concentration o f RDX was 10.7 ^g/mL and decreased gradually 
thereafter, but it was detectable in serum over a 120-hour period following the estimated time of 
ingestion. Using an estimated volume o f distribution o f 2.2 L/kg, Woody et al. (1986) estimated an 
ingested dose o f 84.8 mg RDX/kg or 1.23 g for the 14.5 kg child. More recently, Kufukardali et al.
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(2003) reported five cases o f accidental ingestion of RDX with estimated doses between 37 and 
250 mg/kg (how the doses were estimated was not indicated). Three hours after ingestion, the serum 
concentrations o f RDX ranged from 268 to 969 pg/mL. In two o f the patients, blood levels 72 hours after 
ingestion were approximately 2-fold those measured 3 hours after ingestion, suggesting very slow 
absorption.
Administration of a single oral dose o f 14C-RDX in 0.5% carboxymethylcellulose in water to miniature 
pigs resulted in relatively low levels o f radioactivity (6% o f the dose in males and 2% in females) in the 
gastrointestinal contents and feces over a 24-hour period, suggesting nearly complete absorption (Major 
and Reddy 2007). Data shown for a single male pig (two males and two females were used in the study) 
indicate that Peak RDX concentration in plasma in miniature pigs administered single doses o f RDX 
occurred 8-12 hours after dosing, indicating that although absorption may have been complete over a 
24-hour period, it occurred at a relatively slow rate (JHU/U.S. Army 2006; Major and Reddy 2007). In 
contrast, a study in rats administered 3 or 18 mg/kg RDX via capsule reported Peak RDX levels in the 
blood 3.5 hours after exposure (Bannon et al. 2009a).
Crouse et al. (2008) studied the bioavailability o f RDX from soil in rats. Rats were administered capsules 
containing neat RDX or RDX mixed with two types of soils. The results showed that administration of 
RDX mixed with soils resulted in peak blood levels o f RDX 15-25% lower that when administered neat. 
However, the times to reach peak levels (4-6 hours postdosing) did not appear to differ significantly 
between neat doses o f RDX and RDX mixed with soil.
3.4.1.3 Dermal Exposure
A study using excised human skin in flow-through diffusion cells showed poor absorption o f RDX in this 
type o f preparation (Reddy et al. 2008). 14C-RDX was applied in acetone or in two soils differing in their 
carbon content (1.9 vs. 9.5%) to the epidermal surface and receptor fluid was collected for up to 24 hours. 
At this time, the RDX remaining on the skin was washed with soap and water and the radioactivity in the 
washing was counted. Dermal absorption was defined as the amount of radioactivity in the receptor fluid, 
the dermis, and the portion o f the epidermis beneath the stratum corneum. A total o f 2.5% o f the dose 
applied in acetone diffused through the skin into the receptor fluid, whereas 5.7% o f the applied dose was 
found in the combined receptor fluid and skin (stratum corneum, epidermis and dermis). Approximately
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80% of the applied dose was recovered (receptor fluid plus skin plus washings). Application o f RDX in 
soil resulted in even less absorption; 2.6% in the low-carbon soil and 1.4% in the high-carbon soil were 
recovered in the receptor fluid and skin in 24 hours.
A similar study using excised pig skin was conducted earlier by Reifenrath et al. (2002). The results also 
showed relatively poor absorption. Only 4% o f the applied dose o f RDX in acetone was absorbed over a 




No studies were located in humans or animals regarding distribution following inhalation exposure.
3.4.2.2 Oral Exposure
Limited information is available from a study o f child who ingested an unknown amount o f RDX (W oody 
et al. 1986). RDX was found in the cerebrospinal fluid o f the child at a concentration o f 8.94 ^g/mL 
24 hours after ingestion (only time measured).
In rats given RDX by gavage, levels in the plasma and brain reached a steady state for 2-24 hours and 
then disappeared 3 days postexposure, but no other tissues were sampled (U.S. Army 1985b). In another 
single exposure study in rats (Bannon et al. 2009a), blood and brain RDX levels paralleled each other 
during the first 48 hours post-exposure; these data suggest that RDX did not accumulate in the brain. 
Miniature swine showed no preferential distribution o f RDX to the brain, heart, liver, kidneys, or fat 
24 hours following a single gavage dose o f 100 mg RDX/kg (Schneider et al. 1977). Three hours after 
oral administration o f RDX to juvenile miniature pigs, the highest levels o f RDX were found in the 
hippocampus and cortex compared to the heart, kidney, liver, blood, lung, and muscle (JHU/U.S. Army 
2006). Rats given RDX once by gavage showed the highest levels o f RDX in the kidneys, with less in the 
brain and heart, and the least amount in the plasma and liver over a 24-hour observation period (Schneider 
et al. 1977). Tissue/plasma ratios during the first 24 hours varied between 0.15 and 10.46, indicating that 
RDX accumulated to some extent in the tissues examined. In mice administered radiolabelled RDX via 
stomach perfusion, the highest levels o f radioactivity were found in the liver, followed by the kidney, 
muscle, lung, spleen, heart, and brain (Guo et al. 1985). Results from longer-term studies showed no
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preferential distribution o f RDX in rats given the chemical by gavage or in the drinking water for 90 days 
(Schneider et al. 1978). In a recent study o f the effects RDX on gene expression in the brain of rats, 
administration o f 3 or 18 mg RDX/kg in a capsule resulted in peak brain and blood concentrations of 
RDX approximately 3.5 hours after dosing, regardless o f the dose (Bannon et al. 2009a). No RDX could 
be detected in the brain or blood from low-dose rats 24 hours after dosing or in blood or brain from high­
dose rats 48 hours after dosing.
An unpublished study indicates that RDX was found in the brain of rat pups whose mothers were 
administered RDX from gestation day 6 through postnatal day 10 (U.S. Army 2007b). On postnatal days 
0, 3, 5, and 10, dams and pups were tested for RDX in milk and brain, respectively. Significantly higher 
concentrations o f RDX were found in the brain from pups sacrificed immediately after birth than in the 
brain o f pups sacrificed on postnatal day 10. No explanation was offered for this finding by the 
investigators. It is plausible that the gastrointestinal tract o f newborn pups did not absorb RDX, but RDX 
readily crossed the placenta. Alternatively, it could be that newborn pups have the ability to 
metabolize/excrete RDX that is not present in the fetus. In any case, transplacental exposure occurred. 
Since RDX was also found in the dam’s milk, transfer o f RDX to the offspring via the milk can also 
occur.
3.4.2.3 Dermal Exposure
No studies were located in humans or animals regarding distribution following dermal exposure.
3.4.3 Metabolism
There are no studies available regarding RDX metabolism in humans following inhalation, oral, or dermal 
exposure.
RDX was extensively metabolized in rats (Schneider et al. 1977). Administration o f a single gavage dose 
o f 50 mg 14C-RDX/kg resulted in <0.6% o f the dose in the carcass 4 days after dosing and only 3% was 
excreted unchanged, mostly in the urine. The metabolites were not characterized.
A study o f the metabolism o f RDX in miniature pigs showed that RDX is rapidly and extensively 
metabolized by loss o f two nitro groups followed by ring cleavage (Major and Reddy 2007). Pigs were 
administered a single gavage dose (43 mg/kg) o f 14C-RDX combined with carboxymethylcellulose in 
water and blood and excreta were collected for up to 24 hours. Metabolites were characterized by liquid
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chromatography/mass spectrometry (LC/MS) in selected samples of urine, plasma, and liver. Analysis of 
urine revealed two major metabolites, 4-nitro-2,4-diazabutanal and 4-nitro-2,4-diazabutanamide. Using a 
more sensitive method o f analysis, the investigators also identified MNX in both male and female urine 
and DNX in male urine. Analysis o f plasma showed quantifiable amounts o f RDX, and trace levels of 
MNX, DNX, and TNX. Analysis o f liver extracts showed that most o f the radioactivity was in the form 
o f water-soluble, high-molecular-weight compounds rather than as RDX or any identifiable metabolites.
An in vitro study examining RDX metabolism (assessed by measuring loss o f RDX) under low oxygen 
conditions determined that 46.6, 40.1, 34.6, 25.5, and 11.6% of the RDX was metabolized in human, rat, 
monkey, pig, and rabbit liver microsomes, respectively, following a 30-minute incubation period (U.S. 
Army 2008). After a 180-minute incubation period, 51.8, 47.2, 35.7, 33.7, and 18.0% of the RDX was 
metabolized, respectively. Under anaerobic conditions with nitrogen replacing oxygen, RDX was 
metabolized by several human recombinant cytochrome P450 isoforms (CYP1A1, CYP2B6, CYP2C8, 
CYP2C18, CYP2E1, CYP3A5); with the exception o f CYP1A1, the RDX metabolite, MEDINA, was 
produced. In contrast, under aerobic conditions, no loss o f RDX was detected in human liver 
microsomes, S9, hepatocytes, or a number o f human recombinant cytochrome 450 isoforms (U.S. Army
2008).
RDX was metabolized in vitro by rabbit cytochrome CYP2B4 to 4-nitro-2,4-diazabutanal, nitrite, 
formaldehyde, and ammonia (Bhushan et al. 2003). This reaction was observed in a cell-free, isolated 
enzyme system; therefore, it’s relevance to in vivo metabolism is unknown.
3.4.4 Elimination and Excretion
3.4.4.1 Inhalation Exposure
No relevant information was located from studies in humans. In rats receiving a single intratracheal dose 
o f radiolabelled RDX, 23 and 3% of the label was excreted in the urine and feces, respectively, during the 
first 4 days; during the first 6 days, 26 and 5%, respectively, was excreted (Reddy et al. 1989; only 
available as an abstract).
3.4.4.2 Oral Exposure
Only one study is available that provides some data on excretion in humans after oral exposure. In a child 
who ingested an unknown amount o f RDX, apparent peak concentration in urine occurred at
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approximately 48 hours after ingestion and in feces 96 hours after ingestion (Woody et al. 1986). RDX 
could still be detected in feces 144 hours following ingestion.
Rats given a single radiolabeled gavage dose o f RDX eliminated 43% of the radioactivity in exhaled air, 
34% in the urine, and 3% in the feces within 4 days; about 10% remained in the carcass (Schneider et al.
1977). A longer-term study showed similar excretion patterns; during a continuous drinking water study, 
50% was eliminated in the exhaled air, 34% in the urine, and 5% in the feces (Schneider et al. 1978). 
There was no evidence that RDX accumulated in the tissues during longer-term exposure. Following 
administration o f radiolabelled RDX to mice via stomach perfusion, 38.18% of the dose was excreted in 
the urine and 26.64% was excreted in the feces on day 1. On days 2-9, 11.20% o f the dose was excreted 
in the urine. Ten days after dosing, 75.25% of the dose was excreted in the urine and feces (Guo et al.
1985).
Urine was the major route o f elimination of 14C-RDX-derived radioactivity in miniature pigs given a 
single dose of the chemical (Major and Reddy 2007). Over a 24-hour period, 16-17% o f the administered 
dose was recovered in the urine compared to <6% recovered in the gastrointestinal contents and feces.
3.4.4.3 Dermal Exposure
No relevant information was located from studies in humans or animals.
3.4.5 Physiologically Based Pharm acokinetic (PBPK)/Pharmacodynamic (PD) Models
Physiologically based pharmacokinetic (PBPK) models use mathematical descriptions of the uptake and 
disposition o f chemical substances to quantitatively describe the relationships among critical biological 
processes (Krishnan et al. 1994). PBPK models are also called biologically based tissue dosimetry 
models. PBPK models are increasingly used in risk assessments, primarily to predict the concentration of 
potentially toxic moieties o f a chemical that will be delivered to any given target tissue following various 
combinations o f route, dose level, and test species (Clewell and Andersen 1985). Physiologically based 
pharmacodynamic (PBPD) models use mathematical descriptions of the dose-response function to 
quantitatively describe the relationship between target tissue dose and toxic end points.
PBPK/PD models refine our understanding o f complex quantitative dose behaviors by helping to 
delineate and characterize the relationships between: (1) the external/exposure concentration and target 
tissue dose o f the toxic moiety, and (2) the target tissue dose and observed responses (Andersen and
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Krishnan 1994; Andersen et al. 1987). These models are biologically and mechanistically based and can 
be used to extrapolate the pharmacokinetic behavior o f chemical substances from high to low dose, from 
route to route, between species, and between subpopulations within a species. The biological basis o f 
PBPK models results in more meaningful extrapolations than those generated with the more conventional 
use of uncertainty factors.
The PBPK model for a chemical substance is developed in four interconnected steps: (1) model 
representation, (2) model parameterization, (3) model simulation, and (4) model validation (Krishnan and 
Andersen 1994). In the early 1990s, validated PBPK models were developed for a number of 
toxicologically important chemical substances, both volatile and nonvolatile (Krishnan and Andersen 
1994; Leung 1993). PBPK models for a particular substance require estimates o f the chemical substance- 
specific physicochemical parameters, and species-specific physiological and biological parameters. The 
numerical estimates o f these model parameters are incorporated within a set o f differential and algebraic 
equations that describe the pharmacokinetic processes. Solving these differential and algebraic equations 
provides the predictions of tissue dose. Computers then provide process simulations based on these 
solutions.
The structure and mathematical expressions used in PBPK models significantly simplify the true 
complexities o f biological systems. If  the uptake and disposition o f the chemical substance(s) are 
adequately described, however, this simplification is desirable because data are often unavailable for 
many biological processes. A simplified scheme reduces the magnitude o f cumulative uncertainty. The 
adequacy o f the model is, therefore, o f great importance, and model validation is essential to the use of 
PBPK models in risk assessment.
PBPK models improve the pharmacokinetic extrapolations used in risk assessments that identify the 
maximal (i.e., the safe) levels for human exposure to chemical substances (Andersen and Krishnan 1994). 
PBPK models provide a scientifically sound means to predict the target tissue dose o f chemicals in 
humans who are exposed to environmental levels (for example, levels that might occur at hazardous waste 
sites) based on the results o f studies where doses were higher or were administered in different species. 
Figure 3-2 shows a conceptualized representation of a PBPK model.
If PBPK models for RDX exist, the overall results and individual models are discussed in this section in 
terms o f their use in risk assessment, tissue dosimetry, and dose, route, and species extrapolations.
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Figure 3-2. Conceptual Representation of a Physiologically Based 
Pharmacokinetic (PBPK) Model for a Hypothetical 
Chemical Substance
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Note: This is a conceptual representation of a physiologically based pharmacokinetic (PBPK) model for a 
hypothetical chemical substance. The chemical substance is shown to be absorbed via the skin, by inhalation, or by 
ingestion, metabolized in the liver, and excreted in the urine or by exhalation.
Source: adapted from Krishnan and Andersen 1994
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Krishnan Model (Krishnan et al. 2009; U.S. Army 2007a; Sweeney et al. 2012)
Description of the Model. Krishnan et al. (2009; U.S. Army 2007a) developed a PBPK model for 
simulating kinetics o f RDX in rats. The model was subsequently modified and extended to include 
simulations o f human kinetics (Sweeney et al. 2012). The structure o f the model is essentially identical to 
the generic model depicted in Figure 3-2, with the following tissue compartments: brain, fat, liver, richly 
perfused tissues (RPT), and slowly perfused tissues (SPT). Parameters and parameter values reported in 
Sweeney et al. (2012) are presented in Table 3-4.
The model simulates absorption o f RDX from the gastrointestinal tract as first order transfers to liver 
from stomach (KAS, hour-1) and duodenum (KAD, hour-1), with first-order transfer from stomach 
contents to duodenum contents (KT, hour-1). Since no other transfers from the gastrointestinal tract are 
simulated (i.e., transfer to lower gastrointestinal-tract or fecal excretion), 100% o f the oral dose is 
eventually absorbed at infinite time after an oral dose. Distribution of RDX to tissues is simulated as 
flow-limited transfers in which instantaneous partitioning o f RDX between tissue and blood is assumed, 
the tissue-venous blood concentration ratio is given by a tissue-blood partition coefficient, and blood- 
tissue clearance (L/hour) is assumed to be equivalent to tissue blood flow. Elimination o f absorbed RDX 
is assumed to be entirely by metabolism, all o f which is attributed to the liver, and is simulated as a first 
order processes (KfC, kg0'33/hour-1). Metabolites of RDX are not simulated in the model.
Sweeney et al. (2012) derived values for several parameters in the rat model, based on statistical 
optimization o f predicted blood concentration kinetics against observations from rat studies not used for 
parameter estimation by Krishnan et al. (2009). A value for a single absorption rate constant in rats was 
estimated by Krishnan et al. (2009) based on model performance (visual inspection o f fit to observations) 
in simulating blood RDX kinetics in rats that received a single oral dose o f RDX (Schneider et al. 1977). 
Sweeney et al. (2012) derived alternative values for a two-compartment gastrointestinal model (stomach, 
duodenum) by optimization against observed blood RDX kinetics from various rat oral studies (Bannon et 
al. 2009a; Crouse et al. 2008; Krishnan et al. 2009).
Tissue:blood partition coefficients for RDX were estimated by Krishnan et al. (2009) based on a 
measured n-octanol:water partition coefficient for RDX, and reported water and lipid contents o f specific 




Table 3-4. Parameter Values for Sweeney et al.(2012) PBPK Model of RDX in Rats
and Humans
Value
Description Rat Human Source
Body weight (BW, kg) 0.3 70 Observed
Cardiac output (KQC, L/hour/kg074) 15 14 Brown et al. 1997, as cited in Sweeney 
et al. 2012; Krishnan et al. 2009; 
Timchalk et al. 2002
Blood flow (KQ) fraction of cardiac output
Liver (KQL) 0.25 0.175 Brown et al. 1997, as cited in Sweeney
Brain (KQB) 0.03 0.114 et al. 2012; Krishnan et al. 2009;
Fat (KQF) 0.09 0.085 Timchalk et al. 2002
Slowly perfused tissues (KQS) 0.20 0.2449
Rapidly perfused tissues (KQR) 0.43 0.3811 1 -(KQL+KQB+KQF+KQS)
Compartment volumes ( Vi) fraction of body weight
Liver (KVL) 0.04 0.026 Brown et al. 1997, as cited in Sweeney
Brain (KVB) 0.012 0.02 et al. 2012; Krishnan et al. 2009;
Fat (KVF) 0.07 0.21 Timchalk et al. 2002
Rapidly perfused tissues (KVR) 0.04 0.052
Blood (KVV) 0.06 0.079
Slowly perfused tissues (KVS) 0.688 0.523 0.91 -  (KVL+KVB+KVF+KVR+KVV)
Tissue:blood partition coefficients
Liver (PL) 1.2 1.3 Krishnan et al. 2009 (predicted from
Brain (PB) 1.4 1.6 n-octanol:water partition coefficient)
Rapidly perfused tissues (PS) 1.4 1.6
Fat (PF) 5.57 5.57 Optimized— intravenous rat dataa
Slowly perfused tissues (PR) 0.15 0.15
Liver metabolism
Metabolism (KfC, kg033/hour) 2.6 11.2 Optimized— intravenous rat dataa 
Optimized— oral human datab
Gastrointestinal absorption
Optimized— oral human databAbsorption from stomach (KAS, hour-1) 0.033
gavage (rat) 0.83 NA Optimized— oral rat datac
capsule (rat) 0.12 NA
coarse (rat) 0.005 NA
Transfer to duodenum (KT, hour") 0 Optimized— oral human datab
gavage (rat) 1.37 NA Optimized— oral rat datac
capsule (rat) 0 NA
coarse (rat) 0 NA
Optimized— oral human databAbsorption from duodenum (KAD, hour-1) NA
gavage (rat) 0.0258 NA Optimized— oral rat dataa
capsule (rat) NA NA
coarse (rat) NA NA
aKrishnan et al. 2009.
bÖzhan et al. 2003; Woody et al. 1986.
cBannon et al. 2009a; Crouse et al. 2008; Krishnan et al. 2009; Schneider et al. 1977.
Source: adapted from Sweeney et al. 2012
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observed blood RDX kinetics following intravenous dosing o f rats with RDX (Schneider et al. 1977). 
Sweeney et al. (2012) re-evaluated the values for the partition coefficients for adipose and slowly 
perfused tissue, and the metabolism rate constant, and simultaneously optimized all three parameters 
against blood RDX kinetics from a rat intravenous study conducted by Krishnan et al. (2009). The 
simultaneous optimization yielded values o f 5.57 and 0.15 for the partition coefficients for adipose and 
slowly perfused tissue, respectively, whereas Krishnan et al. (2009) estimated values o f 7.55 and 1. The 
optimized value for the metabolism rate constant was 2.6 kg03/hour, whereas Krishnan et al. (2009) 
estimated the value to be 2.6 kg/hour. For a 0.4 kg rat (Krishnan et al. 2009), the corresponding values 
for the metabolism rates constants are 3.4 hours-1, based on the Sweeney et al. (2012) estimate, and
5.5 hours-1, based on the Krishnan et al. (2009) estimate.
Parameter values for the human model were scaled to body weight (e.g., flows scaled to BW074 and 
volumes to BW 1), with the exception o f the metabolism and absorption rate constants. Absorption and 
metabolism rate constants for humans were optimized against observations o f blood RDX kinetics in 
cases o f ingestion exposures in humans (Ozhan et al. 2003; Woody et al. 1986). Because doses in the 
human cases were unknown, dose was also optimized for each case. The estimated parameter values 
based on simulation o f plasma RDX concentrations in a 3-year old child who ingested an unknown 
amount o f RDX (Woody et al. 1986) were: dose 58.9 mg/kg; KAS 0.060/hour; KfC 9.87 kg033/hour. 
Corresponding values based on plasma RDX kinetics in adults were: dose 3.5 mg/kg; KAS 0.033/hour; 
KfC 11.2 kg033/hour. Sweeney et al. (2012) also estimated the value for the first-order metabolism rate 
constant based on scaling o f the rat value against the ratio o f in vitro metabolism rates in rats and humans, 
adjusted for microsomal protein (Lipscomb and Poet 2008, as cited in Sweeney et al. 2012; U.S. Army
2008) as follows:
K fC h =  K fC r  ■ MRR hfT ■ MSPRh/r ■ BWR%™
where KfC is the first-order metabolism rate constant in human or rat (human or rat, respectively), MRR 
is the in vitro metabolism rate ratio (human:rat), MSP is the microsomal protein yield ratio (human:rat), 
and BWR is the body weight ratio (human:rat). The estimated values for the metabolism rate constant in 
humans was 12.4 kg033/hour, which was similar to the value for adults estimated by optimization against 
the Ozhan et al. (2003) data.
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Validation of the Model. Krishnan et al. (2009) estimated the metabolism rate constant based on 
blood RDX kinetics obtained from an intravenous study in rats (Schneider et al. 1977), and then evaluated 
model performance against data obtained from a different intravenous study conducted in rats (Krishnan 
et al. 2009). The same approach was used to evaluate the gastrointestinal absorption rate constant; data 
from a study in which rats received a single gavage dose o f RDX (Krishnan et al. 2009) were used to 
estimate the parameter values, and the resulting model was evaluated against data from a different gavage 
rat study (Schneider et al. 1977). In both evaluations, the studies that were used to evaluate the model 
administered lower doses than the studies used to estimate parameter values.
As previously described, Sweeney et al. (2012) optimized the absorption and metabolism parameter 
values, and tissue:blood partition coefficients for adipose and SPT in the rat using data from intravenous 
and oral dosing studies reported in Krishnan et al. (2009). The results o f optimization o f the intravenous 
studies were compared to an independent data set (Schneider et al. 1977) and the results were summarized 
with the following conclusion: “ ... the agreement between the model and the iv data o f  Schneier eta l. 
(1977) was very good (not shown).” In the oral dosing studies, rats received a gavage dose o f RDX 
dissolved in water. The absorption parameters were re-optimized to simulate blood RDX kinetics in 
studies in which RDX was administered as a granular RDX (coarse) or in a gelatin capsule, or as a 
suspension in water (Bannon et al. 2009a; Crouse et al. 2008; Schneider et al. 1977). One o f the studies 
included measurements of brain RDX concentrations (Bannon et al. 2009a). Since these studies were 
used to calibrate the absorption kinetics parameters to account for the different dosing formulations, they 
do not represent a fully independent validation o f the rat model for simulating oral dosing. However, 
these evaluations do allow validation o f the simulations o f distribution and elimination kinetics derived 
from intravenous studies. Blood RDX kinetics obtained for cases o f human ingestion o f RDX were used 
to estimate values for absorption and metabolism parameters in the human. The human model was not 
evaluated against observations independent o f those used to estimate parameter values.
All o f the model calibration and evaluation studies were conducted with data from single-dose studies. 
Although Sweeney et al. (2012) used a statistical procedure (maximum likelihood) to estimate parameter 
values, statistical comparisons o f goodness o f fit were not reported in Sweeney et al. (2012), and were not 
reported in Krishnan et al. (2009).
Risk A ssessm ent. The RDX model predicts blood and brain levels of RDX that would occur in 
association with oral doses to RDX. These predictions are potentially useful for predicting internal doses 
o f RDX in rats and/or humans (e.g., blood or brain concentrations), and for making extrapolations of
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these internal dose metrics across species. The model has been used to extrapolate dosages in repeated 
oral dosing studies in rats to equivalent oral dosages in humans in a derivation o f human equivalent 
external doses and candidate chronic oral reference doses (Sweeney et al. 2012). Several internal dose 
metrics were explored in the interspecies dosimetry extrapolation. Peak and average brain RDX 
concentrations were used for dosimetry o f neurological end points observed in rats in intermediate gavage 
and chronic dietary studies (U.S. Army 1983a, 2006). The time-weighted average RDX concentration in 
richly perfused tissue and steady-state body weight-adjusted rate o f metabolism were used for dosimetry 
o f prostate inflammation observed in rats in a chronic dietary study (U.S. Army 1984c) and alterations in 
survival time, terminal body weight, and hematocrit and hemoglobin concentrations in rats in a chronic 
dietary study (U.S. Army 1984c). Sweeney et al. (2012) estimated human equivalent external doses 
ranging from 1.6 to 8 mg/kg/day.
Target Tissues. The RDX model was calibrated to predict blood RDX kinetics following oral 
exposures to RDX, although it also predicts concentrations in brain and other tissues. Sweeney et al. 
(2012) presented simulations o f brain RDX concentration in comparison to measurements made in rats 
(Bannon et al. 2009a). The model has been used to predict concentrations of RDX in brain, which has 
been shown to be an important toxicity target tissue for RDX (Sweeney et al. 2012).
Species Extrapolation. Sweeney et al. (2012) scaled the rat model to humans using a combination 
o f allometric scaling and optimization o f selected model parameters (absorption and metabolism rate 
constants). The scaled human model has not been evaluated against independent observations not used to 
estimate model parameter values. The model has been used to extrapolate rat dosages to humans based 
on predicted internal dosimetry (Sweeney et al. 2012).
Interroute Extrapolation. The RDX model as it is currently configured simulates RDX kinetics 
associated with intravenous and oral dosing. Simulation o f other potential routes of exposure (e.g., 
inhalation, dermal) would require development o f models for the absorption o f inhaled RDX, or RDX 
deposited on the skin.
Strengths and Limitations. Strengths o f the model are that it simulates disposition and clearance of 
intravenously injected or ingested RDX in rodents and humans, including predicting levels o f RDX in the 
brain, a target tissue for toxicity. However, limitations include: (1) all model calibration and evaluation 
studies were conducted with data from single-dose studies and confidence in simulating RDX kinetics of 
repeated dosing schedules has not been evaluated; (2) the human model was not evaluated against
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observations independent o f those used to estimate parameter values; and (3) the validity o f predictions of 
brain levels of RDX in humans is based solely on performance o f the model in predicting observed blood 
kinetics in humans who ingested unknown doses of RDX (dose was optimized to the blood RDX data).
3.5 MECHANISMS OF ACTION
3.5.1 Pharm acokinetic Mechanisms
Absorption. The mechanism(s) o f absorption o f RDX is not known. There are no studies that 
calculated rates o f absorption that could have provided some indication o f a possible mechanism of 
absorption. In rats administered RDX in a capsule, peak blood concentrations were achieved 4-6 hours 
after dosing (Crouse et al. 2008). In a male miniature pig given a single gavage dose o f RDX as a 
suspension in 0.5% carboxymethylcellulose in water, peak plasma concentration o f RDX occurred at 
approximately 12 hours after dosing, which would suggest a relatively low rate o f absorption. Studies 
with excised human and pig skin showed that mixing RDX with soil significantly reduced dermal 
absorption relative to RDX neat (Reddy et al. 2008; Reifenrath et al. 2002).
Distribution. No specific mechanism o f distribution was apparent in the available studies. In rats, the 
distribution o f RDX (single doses) seemed unaffected by the route of administration (parenteral vs. oral) 
or by the dose (Schneider et al. 1977). The concentration o f RDX-derived radioactivity in most tissues 
was fairly stable between 2 and 24 hours after dosing except in the liver, where it fluctuated widely. High 
concentrations o f radioactivity occurred in the liver at 2, 12, and 24 hours after dosing, which led 
Schneider et al. (1978) to suggest that there might be diurnal variations in the hepatic metabolism of 
RDX. In 90-day studies, RDX did not accumulate in any o f the tissues examined (Schneider et al. 1978).
Metabolism. The metabolism o f RDX has been studied in some detail in miniature pigs (Major and 
Reddy 2007) and there is some evidence suggesting that a cytochrome orthologue to the rabbit, CYP2B4, 
may be involved (Bhushan et al. 2003). The two major metabolites characterized were 4-nitro-2,4-diaza- 
butanal and 4-nitro-2,4-diazabutanamide. Trace amount o f MNX, DNX, and TNX were also detected. 
Some studies have provided some information regarding the role of metabolism in the toxicity o f RDX.
In rats, administration of RDX intravenously resulted in convulsive activity within seconds after the 
injection, which suggested that the convulsions are produced by the parent compound (Schneider et al.
1977). In a 90-day gavage study in monkeys, convulsive events were associated with higher RDX 
concentrations in plasma (U.S. Navy 1974b), which would also support the idea o f the parent compound 
being responsible for the convulsive activity. More recently, Meyer et al. (2005) reported that MNX and
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RDX were equipotent in inducing convulsions and lethality in female Sprague-Dawley rats in single-dose 
gavage studies o f 14-day duration; both DNX and TNX were less potent. In a study o f age-dependent 
acute toxicity o f RDX in deer mice, Smith et al. (2007) reported that, for all three age brackets tested, 
RDX was significantly more potent than MNX and TNX.
Excretion. The urine and exhaled CO2 were the main routes o f excretion o f 14C-RDX-derived 
radioactivity in rats following acute- or intermediate-duration exposure to RDX (Schneider et al. 1977,
1978). In the acute studies, only 3% o f the administered radioactivity was recovered in the feces over a 
4-day period (Schneider et al. 1977). The urine was also the main excretory route o f radioactivity in 
miniature pigs following a single gavage dose o f RDX (Major and Reddy 2007). No information was 
located regarding how the size o f the dose might affect the distribution o f metabolic products among 
excretory pathways.
3.5.2 M echanisms of Toxicity
The main effect o f high doses o f RDX in humans and animals is the induction o f hyperactivity manifested 
as convulsions or seizures. RDX has also induced other effects; however, because these effects have not 
been well characterized and/or have been seen inconsistently in animal studies, this section will focus 
mainly on the potential mechanisms o f neurological effects. In vitro studies in primary human cells, 
including neurons, astrocytes, and microglia cells, have found minimal evidence of cytotoxicity (U.S. 
Army 2010), suggesting that the observed neurological effects o f RDX are likely to be reversible effects 
on neurotransmission. Hyperactivity can result from a chemical acting centrally and/or on the peripheral 
nervous system. Chemicals such as organophosphorus pesticides or nerve agents, such as sarin and 
soman, act mainly by inhibiting cholinesterase activity in the brain (McDonough and Shih 1997), but 
limited information is available regarding possible effects o f RDX on cholinesterase activity. Based 
purely on the chemical structure of RDX, it seems unlikely that it would possess potent anticholinesterase 
properties. In rats receiving a single intraperitoneal dose o f RDX, small, but significant, decreases in 
brain cholinesterase levels were found 1.5, 3, or 6 hours after dosing. By 24 hours after dosing, the 
cholinesterase levels were similar to controls (Maryland University 1975). However, in rats receiving
2.5 or 6.5 mg/kg/day RDX administered intraperitoneally for 6 or 12 weeks, significant increases in brain 
cholinesterase levels were found. An in vitro study found a 53% decrease in cholinesterase activity in 
brain homogenates incubated with 4.5x10-3 M RDX (Maryland University 1975). In contrast, no 
alterations in frontal lobe or blood acetylcholinesterase activity were observed at the onset o f seizures in 
rats administered a single gavage dose o f 75 mg/kg RDX (Williams et al. 2011). The Maryland
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University study (1975) also found significant increases in monoamine oxidase activity in rats receiving 
intraperitoneal doses of 2.5 or 6.5 mg/kg/day RDX for 6 or 12 weeks or 0.3 mg/kg/day for 12 weeks. 
However, following a single dose, a small, but not statistically significant, decrease in monoamine 
oxidase activity was observed 0.5, 1.5, 3, 6, or 24 hours after dosing. As with cholinesterase activity,
RDX induced a dose-related decrease in monoamine oxidase activity in vitro.
Studies in rats by Burdette et al. (1988) suggested that limbic structures may be a primary target for RDX 
toxicity. The suggestion was based on observations of spontaneous seizure characteristics and an 
accelerated rate o f amygdaloid kindling following administration o f a subconvulsive dose o f RDX.
Recent studies provide evidence o f the involvement o f GABA (y-aminobutyric acid) receptors in RDX- 
induced neurologic dysfunction. Antagonism o f GABAergic neurons within the central nervous system 
leads to generalized nervous system stimulation. Binding o f GABA to its receptor opens chloride- 
selective ion channels leading to influx of chloride into neurons through an electrochemical gradient 
resulting in hyperpolarization o f the membrane and inhibition o f cell firing. A reduced inhibitory drive 
results in uninhibited activity in effector neurons. Williams et al. (2011) found that RDX binds to the 
picrotoxin convulsant site on GABAa receptors, but did not bind to other neurotransmitter receptors that 
are targets o f other known convulsants, including the glutamate family o f receptors, nicotinic and 
muscarinic acetylcholine receptors, the glycine receptors, and the batrachotoxin site o f the sodium 
channel. This finding is supported by 3-D modeling, which found that RDX does not appear to be a 
ligand for the N-methyl-D-aspartate-glutamate receptor in postsynaptic neurons (Ford-Green et al. 2011). 
In vitro, RDX reduced the frequency and amplitude o f spontaneous GABAa receptor-mediated inhibitory 
postsynaptic currents and the amplitude o f GABA-evoked postsynaptic currents in the rat basolateral 
amygdala. Williams et al. (2011) also found a significant negative correlation between the levels o f RDX 
in the brain and the time to seizure onset in rats administered 75 mg/kg RDX via gavage. These findings 
suggest that the convulsions were due to parent compound rather than a metabolite. Similarly, a study of 
Northern bobwhite quail found 20 times higher brain RDX levels in birds with seizures, compared to 
birds exposed to the same dosage but did not develop seizures (Gust et al. 2009).
Some support for the hypothesis o f an RDX-induced imbalance between inhibitory and excitatory 
systems is provided by a recent study o f global gene expression in the brain of rats dosed with either 3 or 
18 mg RDX/kg (Bannon et al. 2009a). Relative to low-dose rats, gene expression in the cerebral cortex of 
high-dose rats was significantly decreased, particularly for processes related to the generation, packaging, 
mobilization, and release of neurotransmitters. Significantly down-regulated was the glutamate signaling 
pathway, which could be a response to excessive excitation resulting from the removal o f the inhibition
3. HEALTH EFFECTS
RDX 81
by GABAergic pathways, caused in turn by RDX. In vitro studies using human neuroblastoma cells 
found an RDX-induced transient increase in calcium levels (released from intracellular calcium stores) 
(Ehrich et al. 2009); this increase in calcium may mediate the release o f glutamate. Genomic results from 
a study o f Northern bobwhite quail found significant alterations in the differential expression of 
transcripts involved the electrophysiology and signal transduction o f neurons (Gust et al. 2009). The 
investigators suggested that these alterations may result in an inhibition of neuronal cell repolarization 
postaction potential leading to heightened neuronal excitability and seizures. Zhang and Pan (2009) 
found significant alterations in the number o f microRNAs (miRNAs) expressed and expression levels in 
the brains o f mice exposed to low levels o f RDX in the diet for 28 days. The most affected miRNA was 
MiR-206, which was significantly up-regulated in the brain. The brain-derived neurotrophic factors 
(BDNF) gene is a potential miRNA target. Zhang and Pan (2009) speculated that miR-206 may 
contribute to the neurological effects associated with RDX exposure through its reduction o f BDNF gene 
expression. The results o f this study should be interpreted cautiously; additional research is needed to 
evaluate the role o f altered miRNA expression in RDX toxicity. Bannon et al. (2009b) noted that the 
significance o f miRNA as a predictor of toxic insult or disease has not been demonstrated.
3.5.3 Animal-to-Human Extrapolations
Virtually all o f the information regarding the effects o f RDX is derived from cases o f acute exposure to 
doses o f RDX that induced frank effects. In both humans and animals, high doses o f RDX affect 
primarily the nervous system. However, which experimental animal is the best model for human 
exposure is unknown, although the basic mechanism for seizure induction is probably the same in humans 
and animals. Studies in animals have provided enough information to establish approximate blood levels 
o f RDX that are associated with convulsive activity (Burdette et al. 1988; Schneider et al. 1977, 1978;
U.S. Navy 1974b). That information is lacking in humans. Only two o f the numerous case reports 
available measured RDX in the blood o f the patients, Woody et al. (1986) and Kufukardali et al. (2003). 
Blood levels o f RDX reported by Woody et al. (1986) appear to be consistent with what has been 
measured in animal studies administered doses similar to those estimated for the patient in Woody et al. 
(1986). However, blood levels o f RDX reported by Kufukardali et al. (2003) were at least 3 orders o f 
magnitude lower, even though the doses that the investigators estimated the patients had consumed (37­
250 mg RDX/kg) were in the range o f that estimated by Woody et al. (1986) (84.8 mg RDX/kg). No 
explanation was offered by Kufukardali et al. (2003) for this discrepancy. Although there are limited data 
on the toxicokinetics o f RDX in humans, the Krishnan PBPK model (Krishnan et al. 2009; Sweeney et al. 
2012; U.S. Army 2007a) allows for extrapolation o f the results o f animal studies to humans.
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3.6 TOXICITIES MEDIATED THROUGH THE NEUROENDOCRINE AXIS
Recently, attention has focused on the potential hazardous effects o f certain chemicals on the endocrine 
system because o f the ability o f these chemicals to mimic or block endogenous hormones. Chemicals 
with this type of activity are most commonly referred to as endocrine disruptors. However, appropriate 
terminology to describe such effects remains controversial. The terminology endocrine disruptors, 
initially used by Thomas and Colborn (1992), was also used in 1996 when Congress mandated the EPA to 
develop a screening program for “ ...certain substances [which] may have an effect produced by a 
naturally occurring estrogen, or other such endocrine effect[s]...” . To meet this mandate, EPA convened a 
panel called the Endocrine Disruptors Screening and Testing Advisory Committee (EDSTAC), and in 
1998, the EDSTAC completed its deliberations and made recommendations to EPA concerning endocrine 
disruptors. In 1999, the National Academy o f Sciences released a report that referred to these same types 
o f chemicals as hormonally active agents. The terminology endocrine modulators has also been used to 
convey the fact that effects caused by such chemicals may not necessarily be adverse. Many scientists 
agree that chemicals with the ability to disrupt or modulate the endocrine system are a potential threat to 
the health of humans, aquatic animals, and wildlife. However, others think that endocrine-active 
chemicals do not pose a significant health risk, particularly in view of the fact that hormone mimics exist 
in the natural environment. Examples o f natural hormone mimics are the isoflavinoid phytoestrogens 
(Adlercreutz 1995; Livingston 1978; Mayr et al. 1992). These chemicals are derived from plants and are 
similar in structure and action to endogenous estrogen. Although the public health significance and 
descriptive terminology o f substances capable o f affecting the endocrine system remains controversial, 
scientists agree that these chemicals may affect the synthesis, secretion, transport, binding, action, or 
elimination o f natural hormones in the body responsible for maintaining homeostasis, reproduction, 
development, and/or behavior (EPA 1997). Stated differently, such compounds may cause toxicities that 
are mediated through the neuroendocrine axis. As a result, these chemicals may play a role in altering, 
for example, metabolic, sexual, immune, and neurobehavioral function. Such chemicals are also thought 
to be involved in inducing breast, testicular, and prostate cancers, as well as endometriosis (Berger 1994; 
Giwercman et al. 1993; Hoel et al. 1992).
There is no evidence suggesting that the reproductive and developmental effects reported in animals 
summarized in Sections 3.2.2.5 and 3.2.2.6, respectively, involve actions o f RDX on the neuroendocrine 




This section discusses potential health effects from exposures during the period from conception to 
maturity at 18 years o f age in humans, when all biological systems will have fully developed. Potential 
effects on offspring resulting from exposures o f parental germ cells are considered, as well as any indirect 
effects on the fetus and neonate resulting from maternal exposure during gestation and lactation.
Relevant animal and in vitro models are also discussed.
Children are not small adults. They differ from adults in their exposures and may differ in their 
susceptibility to hazardous chemicals. Children’s unique physiology and behavior can influence the 
extent o f their exposure. Exposures o f children are discussed in Section 6.6, Exposures o f Children.
Children sometimes differ from adults in their susceptibility to hazardous chemicals, but whether there is 
a difference depends on the chemical (Guzelian et al. 1992; NRC 1993). Children may be more or less 
susceptible than adults to health effects, and the relationship may change with developmental age 
(Guzelian et al. 1992; NRC 1993). Vulnerability often depends on developmental stage. There are 
critical periods o f structural and functional development during both prenatal and postnatal life, and a 
particular structure or function will be most sensitive to disruption during its critical period(s). Damage 
may not be evident until a later stage o f development. There are often differences in pharmacokinetics 
and metabolism between children and adults. For example, absorption may be different in neonates 
because o f the immaturity o f their gastrointestinal tract and their larger skin surface area in proportion to 
body weight (Morselli et al. 1980; NRC 1993); the gastrointestinal absorption o f lead is greatest in infants 
and young children (Ziegler et al. 1978). Distribution o f xenobiotics may be different; for example, 
infants have a larger proportion o f their bodies as extracellular water, and their brains and livers are 
proportionately larger (Altman and Dittmer 1974; Fomon 1966; Fomon et al. 1982; Owen and Brozek 
1966; Widdowson and Dickerson 1964). The infant also has an immature blood-brain barrier (Adinolfi 
1985; Johanson 1980) and probably an immature blood-testis barrier (Setchell and Waites 1975). Many 
xenobiotic metabolizing enzymes have distinctive developmental patterns. At various stages o f growth 
and development, levels o f particular enzymes may be higher or lower than those o f adults, and 
sometimes unique enzymes may exist at particular developmental stages (Komori et al. 1990; Leeder and 
Kearns 1997; NRC 1993; Vieira et al. 1996). W hether differences in xenobiotic metabolism make the 
child more or less susceptible also depends on whether the relevant enzymes are involved in activation of 
the parent compound to its toxic form or in detoxification. There may also be differences in excretion, 
particularly in newborns who all have a low glomerular filtration rate and have not developed efficient
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tubular secretion and resorption capacities (Altman and Dittmer 1974; NRC 1993; W est et al. 1948). 
Children and adults may differ in their capacity to repair damage from chemical insults. Children also 
have a longer remaining lifetime in which to express damage from chemicals; this potential is particularly 
relevant to cancer.
Certain characteristics of the developing human may increase exposure or susceptibility, whereas others 
may decrease susceptibility to the same chemical. For example, although infants breathe more air per 
kilogram o f body weight than adults breathe, this difference might be somewhat counterbalanced by their 
alveoli being less developed, which results in a disproportionately smaller surface area for alveolar 
absorption (NRC 1993).
There are limited data on the toxicity and toxicokinetic properties o f RDX in children. Clonic-tonic 
convulsions were reported in a 3-year-old child ingesting RDX (Woody et al. 1986). As described in the 
case-report, the observed effects are similar to those observed in adults (Goldberg et al. 1992; Harrell- 
Bruder and Hutchins 1995; Hollander and Colbach 1969; Kasuske et al. 2009; Ketel and Hughes 1972; 
Kufukardali et al. 2003; Merrill 1968; Stone et al. 1969). The lack o f adequate exposure data in most o f 
these cases precludes evaluating whether children are more susceptible to RDX toxicity. Age-specific 
differences in LD50 values were found in deer mice; 21-day-old mice were the most sensitive followed by 
200- and 50-day-old animals (Smith et al. 2007). The LD50 in the 50-day-old mice was approximately 
twice as great as the value in 200-day-old mice. It is not known if  similar differences would occur for 
other toxic effects.
As discussed in greater detail in Section 3.2.2.6, developmental effects (decreases in growth and survival) 
have been observed in the offspring o f rats orally exposed to RDX (U.S. Army 1980b, 1986d). These 
effects were typically observed at doses associated with RDX-induced seizures in the dams and may not 
have been a direct effect on the fetus/pup. No developmental effects have been observed in rabbits (U.S. 
Army 1980b).
3.8 BIOMARKERS OF EXPOSURE AND EFFECT
Biomarkers are broadly defined as indicators signaling events in biologic systems or samples. They have 




A biomarker o f exposure is a xenobiotic substance or its metabolite(s) or the product o f an interaction 
between a xenobiotic agent and some target molecule(s) or cell(s) that is measured within a compartment 
o f an organism (NAS/NRC 1989). The preferred biomarkers of exposure are generally the substance 
itself, substance-specific metabolites in readily obtainable body fluid(s), or excreta. However, several 
factors can confound the use and interpretation o f biomarkers o f exposure. The body burden of a 
substance may be the result o f exposures from more than one source. The substance being measured may 
be a metabolite o f another xenobiotic substance (e.g., high urinary levels o f phenol can result from 
exposure to several different aromatic compounds). Depending on the properties o f the substance (e.g., 
biologic half-life) and environmental conditions (e.g., duration and route o f exposure), the substance and 
all o f its metabolites may have left the body by the time samples can be taken. It may be difficult to 
identify individuals exposed to hazardous substances that are commonly found in body tissues and fluids 
(e.g., essential mineral nutrients such as copper, zinc, and selenium). Biomarkers o f exposure to RDX are 
discussed in Section 3.8.1.
Biomarkers o f effect are defined as any measurable biochemical, physiologic, or other alteration within an 
organism that, depending on magnitude, can be recognized as an established or potential health 
impairment or disease (NAS/NRC 1989). This definition encompasses biochemical or cellular signals of 
tissue dysfunction (e.g., increased liver enzyme activity or pathologic changes in female genital epithelial 
cells), as well as physiologic signs of dysfunction such as increased blood pressure or decreased lung 
capacity. Note that these markers are not often substance specific. They also may not be directly 
adverse, but can indicate potential health impairment (e.g., DNA adducts). Biomarkers o f effects caused 
by RDX are discussed in Section 3.8.2.
A biomarker o f susceptibility is an indicator o f an inherent or acquired limitation o f an organism's ability 
to respond to the challenge o f exposure to a specific xenobiotic substance. It can be an intrinsic genetic or 
other characteristic or a preexisting disease that results in an increase in absorbed dose, a decrease in the 
biologically effective dose, or a target tissue response. If biomarkers o f susceptibility exist, they are 
discussed in Section 3.10, Populations That Are Unusually Susceptible.
3.8.1 Biomarkers Used to Identify or Quantify Exposure to RDX
RDX was detected in the serum, urine, and feces o f a child who consumed unknown levels of RDX in the 
form o f C-4 (91% RDX). RDX was measured in the serum for 120 hours and in the feces for 144 hours 
after the presumed time o f ingestion (Woody et al. 1986). RDX was also measured in plasma from five
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male cases described by Küçükardalï et al. (2003). Therefore, the chemical itself is a specific biomarker 
o f exposure. Since the metabolism o f RDX in humans has not been studied, it is not known whether 
single measurements o f RDX in blood or urine could be used only as a biomarker o f recent exposure or 
also as a biomarker o f low-level prolonged exposure.
3.8.2 Biomarkers Used to Characterize Effects Caused by RDX
High oral doses o f RDX are known to produce seizures in humans (Davies et al. 2007; Harrell-Bruder and 
Hutchins 1995; Hollander and Colbach 1969; Kaplan et al. 1965; Kasuske et al. 2009; Ketel and Hughes 
1972; Küçükardalï et al. 2003; Merrill 1968; Stone et al. 1969; Testud et al. 1996a; Woody et al. 1986) 
and animals (Burdette et al. 1988; Schneider et al. 1977; U.S. Army 1983a; U.S. Navy 1974b; von 
Oettingen et al. 1949), but this effect is not specific to RDX. Thus, there are no known specific 
biomarkers to characterize effects caused by inhalation, oral, or dermal exposure to RDX.
3.9 INTERACTIONS WITH OTHER CHEMICALS
Many o f the human studies on the accidental inhalation or ingestion o f RDX involved composition C-4, 
which was used for demolition by the U.S. Armed Forces during the Vietnam War. Composition C-4 was 
91% RDX, with the other components consisting o f polyisobutylene, motor oil, and 2-ethylhexyl 
sebacate. Minimal information is available on the toxicological properties o f these components o f C-4, 
and it is not known whether they may contribute to the effects seen from exposure to C-4. However, 
since RDX is the primary component o f C-4, the assumption has been made that the major effects noted 
from C-4 are due to RDX. In addition, the human and animal reports o f ingested RDX usually are not 
limited to pure RDX, but are almost always reports o f RDX contaminated with octahydro- 
1,3,5,7-tetranitro-1,3,5,7-tetrazocine (HMX) or other substances. There are no studies regarding the 
interactions o f these substances. However, there are several studies in which the oral toxicity o f 
trinitrotoluene (TNT) and RDX were investigated. In one study (Levine et al. 1990), TNT and RDX were 
co-administered in the feed o f rats for 13 weeks. This co-administration potentiated the decrease in body 
weight gain as compared to RDX alone. TNT antagonized the lethal effects and the hypotriglyceridemia 
induced by RDX. RDX antagonized the hypercholesterolemia, splenomegaly, testicular atrophy, 




3.10 POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE
A susceptible population will exhibit a different or enhanced response to RDX than will most persons 
exposed to the same level o f RDX in the environment. Reasons may include genetic makeup, age, health 
and nutritional status, and exposure to other toxic substances (e.g., cigarette smoke). These parameters 
result in reduced detoxification or excretion o f RDX, or compromised function o f organs affected by 
RDX. Populations who are at greater risk due to their unusually high exposure to RDX are discussed in 
Section 6.7, Populations with Potentially High Exposures.
There are no known populations that would be unusually susceptible to RDX toxicity because o f their 
genetic make-up, developmental stage, health status, nutritional status, or chemical exposure history.
3.11 METHODS FOR REDUCING TOXIC EFFECTS
This section will describe clinical practice and research concerning methods for reducing toxic effects o f 
exposure to RDX. However, because some o f the treatments discussed may be experimental and 
unproven, this section should not be used as a guide for treatment o f exposures to RDX. When specific 
exposures have occurred, poison control centers and medical toxicologists should be consulted for 
medical advice.
3.11.1 Reducing Peak Absorption Following Exposure
A general recommendation for reducing absorption after inhalation exposure to RDX is to move the 
patient to fresh air (HSDB 2009). Emesis is not recommended following oral exposure because o f the 
probability o f developing seizures (HSDB 2009). Charcoal may be administered to reduce absorption 
following oral exposure. The only information located for reducing absorption following dermal 
exposure specifically o f RDX is a study by Twibell et al. (1984) which reported that washing the hands 
immediately after handling RDX can remove approximately 90% of the residue. Information summarized 
by HSDB (2009) suggests removing contaminated clothing and washing the exposed area thoroughly 
with soap and water. In case o f eye contact, irrigation o f the exposed eyes with copious amounts o f room 
temperature water for at least 15 minutes is recommended.
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3.11.2 Reducing Body Burden
No information was located on specific methods for reducing the body burden of RDX. However, 
Küçükardalï et al. (2003) reported that hemodialysis was unsuccessful in reducing the serum levels of 
RDX in three cases o f oral intoxication with the chemical when performed approximately 3 hours after 
ingestion.
3.11.3 Interfering with the Mechanism of Action for Toxic Effects
The primary adverse effect o f RDX is the induction o f convulsive activity and seizures for which standard 
treatments are available. Intravenous administration of a benzodiazepine such as diazepam or lorazepam 
is recommended (HSDB 2009). If  seizures recur after diazepam, phenobarbital or propofol should be 
considered (30 mg for adults or 10 mg for children older than 5 years).
3.12 ADEQUACY OF THE DATABASE
Section 104(I)(5) o f CERCLA, as amended, directs the Administrator o f ATSDR (in consultation with the 
Administrator o f EPA and agencies and programs o f the Public Health Service) to assess whether 
adequate information on the health effects of RDX is available. Where adequate information is not 
available, ATSDR, in conjunction with the National Toxicology Program (NTP), is required to assure the 
initiation of a program o f research designed to determine the health effects (and techniques for developing 
methods to determine such health effects) o f RDX.
The following categories o f possible data needs have been identified by a joint team o f scientists from 
ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if  met would 
reduce the uncertainties o f human health assessment. This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled. In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed.
3.12.1 Existing Information on Health Effects of RDX
The existing data on health effects o f inhalation, oral, and dermal exposure of humans and animals to 
RDX are summarized in Figure 3-3. The purpose o f this figure is to illustrate the existing information 
concerning the health effects o f RDX. Each dot in the figure indicates that one or more studies provide
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information associated with that particular effect. The dot does not necessarily imply anything about the 
quality o f the study or studies, nor should missing information in this figure be interpreted as a “data 
need” . A data need, as defined in ATSDR’s Decision Guide fo r  Identifying Substance-Specific Data 
Needs Related to Toxicological Profiles (Agency for Toxic Substances and Disease Registry 1989d), is 
substance-specific information necessary to conduct comprehensive public health assessments.
Generally, ATSDR defines a data gap more broadly as any substance-specific information missing from 
the scientific literature.
Case studies are available regarding systemic effects in humans following acute exposures to RDX via all 
three routes. One study in the workplace provides information on immunological and neurological effects 
following inhalation exposure for chronic periods (Hathaway and Buck 1977). Neurological effects have 
also been described following acute oral exposures to RDX (Hollander and Colbach 1969; Kasuske et al. 
2009; Ketel and Hughes 1972; Küçükardalï et al. 2003; Merrill 1968; Stone et al. 1969; Woody et al.
1986).
Animal data on inhalation exposure is limited to one study. Oral animal data are available for all 
exposure durations and for all end points. Dermal data on death and systemic effects are available for 
animals exposed to RDX for acute and intermediate exposure periods.
3.12.2 Identification of Data Needs
Acute-Duration Exposure . The nervous system is one o f the main targets for RDX toxicity in 
humans exposed by the inhalation (Hollander and Colbach 1969; Testud et al. 1996a) or oral (Goldberg et 
al. 1992; Harrell-Bruder and Hutchins 1995; Hollander and Colbach 1969; Kasuske et al. 2009; Ketel and 
Hughes 1972; Küçükardalï et al. 2003; Merrill 1968; Stone et al. 1969; Woody et al. 1986) routes, and 
animal studies involving oral exposure support this finding (Burdette et al. 1988; Meyer et al. 2005; 
Schneider et al. 1977; U.S. Army 1985b, 2006). There is a small number of acute-duration animal studies 
and no studies that adequately examined potential systemic effects. Increases in occurrence of 
convulsions, tremors, and/or seizures were consistently observed in the available studies (Burdette et al. 
1988; U.S. Army 1980b, 1985b, 1986d, 2006). In addition, decreases in growth were observed in the 
fetuses o f rats exposed to lethal doses o f RDX (U.S. Army 1986d). One animal study suggests that the 
skin is a target organ for RDX following dermal exposure (U.S. Army 1974). However, the use of 
solvents confounded the results. No acute inhalation MRLs could be derived because o f the lack of 
human and animal studies with accurate exposure estimates. The available acute exposure data for
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animals was adequate for the derivation o f an MRL based on an increased incidence of 
convulsions/seizures/tremors (U.S. Army 2006). Further acute inhalation and oral studies on the 
developmental and neurological effects o f RDX would be useful in determining levels that may cause 
harm to humans living near hazardous waste sites; these studies should also evaluate potential systemic 
effects.
Intermediate-Duration Exposure . No studies examining the toxicity in humans following 
intermediate-duration exposure to RDX were identified. No animal studies were identified examining 
RDX toxicity following inhalation exposure; thus, an intermediate-duration inhalation MRL could not be 
derived. Inhalation studies are needed to identify potential targets o f toxicity and establish dose-response 
relationships; these studies would be useful in determining levels that may cause harm to humans who 
live near hazardous waste sites. The nervous system is the target organ for RDX toxicity in animals 
exposed by the oral route for intermediate periods (Levine et al. 1981, 1990; U.S. Army 1983a, 1985b, 
2006; U.S. Navy 1974b; von Oettingen et al. 1949). The most consistently observed effect was 
convulsions, seizures, and tremors. Systemic effects (hematological and serum chemistry alterations), 
reproductive effects (testicular degeneration, possible decrease in male fertility), and developmental 
effects (decreases in growth and decreased viability) have also been observed. However, these effects 
have not been consistently observed across studies. Difference in the exposure route (dietary versus 
gavage) and RDX formulation (finely ground versus coarsely ground) may explain possible differences in 
the results; however, this has not been adequately assessed and additional oral exposure studies are 
needed to evaluate apparent study differences. An intermediate oral MRL based on an increased 
incidence of convulsions in rats was derived (U.S. Army 2006). Studies involving intermediate dermal 
exposure to RDX did not identify a target organ (U.S. Army 1974).
Chronic-Duration Exposure and Cancer. Only one human study was located for chronic- 
inhalation exposure. This study revealed no adverse health effects following chronic exposures to 
unknown levels o f RDX in the air (Hathaway and Buck 1977). No animal studies concerning chronic 
inhalation exposure were located. No chronic inhalation MRLs could be derived because o f the lack of 
human and animal studies with accurate exposure estimates. Therefore, further inhalation studies would 
be useful to identify target organs and define the potential for human health risks.
No human studies concerning chronic oral exposure were located. The most sensitive target organ for 
adverse effects in animals following chronic oral exposure is the nervous system; an increased occurrence 
o f convulsions and seizures were observed in rats (U.S. Army 1983a). Mild adverse systemic effects
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have also been observed in rats (U.S. Army 1983a) and mice (U.S. Army 1984c). A second chronic- 
duration study in rats (U.S. Navy 1976) did not find any adverse effects. An increased incidence of 
prostate gland inflammation was observed in rats exposed to RDX for 2 years (U.S. Army 1983a). The 
inflammation was observed at the lowest adverse effect level; it may have been secondary to a bacterial 
infection. Because the second rat study (U.S. Navy 1976) did not examine the prostate, the prostate effect 
could not be confirmed. Additional studies are needed to further evaluate the prostate as a potential target 
o f RDX toxicity. These studies should include end points addressing immunotoxicity o f chronic exposure 
to RDX. A chronic-duration oral MRL was derived for RDX based on the neurological effects observed 
in the U.S. Army (1983a) study. Only one human study was located for chronic dermal exposure 
(Sunderman 1944). This study reported dermatitis in workers exposed to RDX, but no dose levels were 
reported. No animal studies concerning chronic dermal exposure were located. Additional chronic oral 
and dermal studies would be useful to better define dose levels that may cause a risk to humans.
No studies are available regarding cancer in humans following any route o f exposure. Increased 
incidences of combined hepatocellular adenomas and carcinomas were found in female mice orally 
exposed to RDX (U.S. Army 1984c). A re-evaluation o f the histopathology slides from this study 
resulted in a re-classification o f several o f the tumors as nonneoplastic alterations (Parker et al. 2006). No 
increases in neoplastic lesions were observed in rat oral exposure studies (U.S. Army 1983a; U.S. Navy 
1976). The risk o f developing cancer by the inhalation or dermal routes has not been investigated.
Further inhalation, oral, or dermal carcinogenicity studies would be useful to determine whether RDX 
poses a risk o f cancer for humans.
Genotoxicity. Data from microbial mutagenicity studies using S. typhimurium and S. cerevisiae have 
consistently produced negative results (George et al. 2001; Lachance et al. 1999; Pan et al. 2007; U.S. 
Army 1977b, 1980b; Whong et al. 1980). Therefore, at this time, additional studies with RDX would 
probably not provide any new key information. Studies involving humans and mammalian species are 
few. The three mammalian studies available were negative for DNA damage in human fibroblasts (U.S. 
Army 1978b), dominant lethal mutations in rats (U.S. Army 1980b), and induction o f micronuclei in bone 
marrow cells from mice (Reddy et al. 2005a). Additional studies o f N-nitroso metabolites o f RDX, such 
as MNX and TNX, would be valuable since N-nitroso compounds often yield genotoxicity. Research 
employing toxicogenomics or a combination of genetics, molecular biology, and bioinformatics may be 
able to uncover the molecular targets o f RDX.
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Reproductive Toxicity. No data are available on the reproductive toxicity o f RDX in humans via 
inhalation, oral, or dermal routes o f exposure. No inhalation or dermal studies are available for animals. 
An oral study in mice (U.S. Army 1984c) and one in rats (U.S. Navy 1976) revealed no histopathology in 
the ovaries, testes, or uterus. One oral study (U.S. Army 1983a) did reveal spermatic granulomas in the 
prostate of rats after 6 months o f exposure and testicular degeneration in rats exposed for 1 year. This 
study also reported an increased incidence o f suppurative inflammation o f the prostate in rats exposed for 
2 years; however, the inflammation was primarily observed in rats dying early and there is concern that 
the inflammation may be secondary to a bacterial infection rather than a primary effect o f RDX. No 
pharmacokinetic data are available that can be used to determine whether the reproductive system is 
likely to be a target for RDX toxicity. Therefore, further studies to determine whether the prostate is 
indeed the most sensitive organ are important. A two-generation reproductive study in rats (U.S. Army 
1980b) reported nonsignificant decreases in F0 male fertility when the exposed males were mated with 
unexposed females or exposed females; additional studies are needed to confirm this effect.
Developmental Toxicity. No human studies on developmental effects are available for exposure to 
RDX via inhalation, oral, or dermal routes. No inhalation or dermal studies are available for animals.
Two acute duration oral studies examined the potential developmental toxicity o f RDX. Maternal deaths 
were observed in both studies at the highest dose tested (U.S. Army 1980b, 1986d). No increases in the 
occurrence o f fetal malformations were observed (U.S. Army 1980b). One study reported a decrease in 
fetal weight and length at the dose level associated with maternal deaths and neurotoxicity. In a two- 
generation study, increases in the occurrence o f stillbirths and decreases in pup survival were observed in 
the Fj offspring o f dams exposed to lethal doses; a decrease in pup body weights and increase in the 
incidence of renal cysts were observed in the F2 pups (U.S. Army 1980b). The one available oral study in 
rabbits revealed no fetotoxicity (U.S. Army 1980b). No pharmacokinetic data are available that can be 
used to determine whether the developmental system is likely to be a target organ. Further developmental 
studies via the oral route are important to determine whether humans exposed to RDX at or near 
hazardous waste sites are at risk o f experiencing adverse developmental effects.
Immunotoxicity. The only available immunological study in humans reveals no changes in the 
antinuclear antibodies o f workers exposed to RDX in the air (Hathaway and Buck 1977). No other 
functional tests were performed. No histopathological alterations were found in the spleen, thymus, or 
lymph nodes of rats (Levine et al. 1990; U.S. Army 1980b, 2006) or mice (U.S. Army 1980b), or in the 
spleens of dogs (U.S. Navy 1974a; von Oettingen et al. 1949) or monkeys (U.S. Navy 1974b), after 
intermediate exposure via the oral route. In addition, no alterations in the proportion o f cell surface
3. HEALTH EFFECTS
RDX 94
markers were observed in rats (U.S. Army 2006). A study by Levine et al. (1981) demonstrated mild 
leukocytosis. Further oral studies examining immune function would be useful to determine whether 
RDX adversely affects the immune system. In addition, inhalation and dermal studies would help 
determine whether exposure to RDX at or near hazardous waste sites would affect the human immune 
system.
Neurotoxicity. The nervous system is a major target organ for RDX toxicity. Seizures have been 
reported in humans exposed for acute periods by inhalation (Kaplan et al. 1965; Testud et al. 1996a), 
ingestion (Goldberg et al. 1992; Harrell-Bruder and Hutchins 1995; Kasuske et al. 2009; Kufukardali et 
al. 2003; Merrill 1968; Stone et al. 1969; Woody et al. 1986), or a combination of the inhalation and oral 
routes (Hollander and Colbach 1969; Ketel and Hughes 1972). Oral studies in animals have supported 
this finding for acute (Burdette et al. 1988; Meyer et al. 2005; Schneider et al. 1977; U.S. Army 1980b, 
1986d, 2006), intermediate (Sunderman 1944; U.S. Army 1983a, 2006; U.S. Navy 1974b; von Oettingen 
et al. 1949), and chronic (U.S. Army 1983a) exposure durations. Neurobehavioral alterations were 
observed in rats receiving a single gavage dose o f RDX (U.S. Army 1985b), but not after repeated 
intermediate-duration exposure (U.S. Army 1985b, 2006). The conflicting results may be a reflection of 
when the behavioral tests were conducted, in relation to gavage dosing rather than a duration-related 
difference. Additional neurobehavioral function tests are needed to confirm the results observed in the 
acute study. More sensitive neurological tests in animals via inhalation, oral, or dermal routes would be 
helpful in establishing definite less serious LOAELs.
Epidemiological and Human Dosimetry Studies. There is one human study that tested blood 
chemistry and hematology in 70 workers exposed to an average o f 0.28 mg/m3 o f RDX in the air 
(Hathaway and Buck 1977). All o f the other human studies are case reports o f individuals ingesting RDX 
(Goldberg et al. 1992; Harrell-Bruder and Hutchins 1995; Hollander and Colbach 1969; Ketel and 
Hughes 1972; Kufukardali et al. 2003; Merrill 1968; Stone et al. 1969; Woody et al. 1986) or exposed to 
RDX dust (Kaplan et al. 1965; Testud et al. 1996a). No epidemiology studies are available for exposure 
in drinking water. If populations with appropriate exposures could be identified, it would be useful to 
conduct epidemiologic and human dosimetry studies to establish cause-and-effect relationships and to 
plan future monitoring o f individuals living near hazardous waste sites.
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Exposure. Thus far, RDX in urine or blood is the only known biomarker o f exposure to RDX. RDX has 
been measured in these media in cases o f accidental ingestion o f the chemical (Küçükardalï et al. 2003; 
Woody et al. 1986). There is no information regarding the metabolism o f RDX in humans; therefore, 
monitoring o f the blood and/or urine o f RDX workers could help identify RDX-derived products that can 
be used as biomarkers in studies o f populations living near sites where RDX has been found.
Effect. There is no known sensitive biomarker for the effects o f RDX. The most prominent effects are 
seizures in humans (Davies et al. 2007; Harrell-Bruder and Hutchins 1995; Hollander and Colbach 1969; 
Kaplan et al. 1965; Ketel and Hughes 1972; Küçükardalï et al. 2003; Merrill 1968; Stone et al. 1969; 
Testud et al. 1996a; Woody et al. 1986) or animals (Burdette et al. 1988; Schneider et al. 1977; U.S.
Army 1983a; U.S. Navy 1974b; von Oettingen et al. 1949), but seizures can be evoked by a large number 
o f substances and disease states. As mentioned previously, two studies o f accidental poisoning with RDX 
measured levels o f RDX in blood from the patients. However, additional studies are necessary to 
establish: (1) levels of RDX in blood that are associated with adverse neurological effects and (2) levels 
o f exposure that are associated with specific levels o f RDX in blood.
Absorption, Distribution, Metabolism, and Excretion. No studies are available regarding the 
toxicokinetics o f RDX in humans. However, pulmonary and gastrointestinal absorption of RDX in 
humans can be inferred from reports o f adverse health effects following exposure by these routes 
(Harrell-Bruder and Hutchins 1995; Hollander and Colbach 1969; Kaplan et al. 1965; Ketel and Hughes 
1972; Küçükardalï et al. 2003; Merrill 1968; Stone et al. 1969; Testud et al. 1996a; Woody et al. 1986) 
and from measurements o f RDX in blood and urine after exposure in some studies (i.e., Küçükardalï et al. 
2003; Woody et al. 1986). Relatively poor dermal absorption of RDX was reported in a study with 
excised human skin (Reddy et al. 2008); similar findings were reported in a study with excised pig skin 
(Reifenrath et al. 2002). No studies were located regarding the metabolism o f RDX in humans. Analysis 
o f blood and excreta from workers exposed to RDX could provide valuable information regarding the 
metabolism o f RDX in humans. No inhalation toxicokinetic data were located in animals. Oral studies in 
rats indicate that mixing RDX with soil considerably reduces its bioavailability (Crouse et al. 2008). A 
recent study in miniature pigs showed that oral administration of RDX in carboxymethylcellulose and 
water results in almost complete absorption (Major and Reddy 2007). Earlier studies in rats provided 
information on some parameters of oral absorption, distribution, and elimination (Schneider et al. 1977,
1978). These studies did not show any preferential accumulation o f RDX in tissues. RDX was found in
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the brain o f rat pups born to dams exposed to RDX during gestation (U.S. Army 2007b). Additional 
studies o f the perinatal transfer o f RDX in animals are needed, particularly to determine the relative 
contribution o f gestational vs. lactational exposure. The metabolism o f RDX has been studied in 
miniature pigs and the major metabolites have been characterized (Major and Reddy 2007). Since the 
main target for RDX appears to be the nervous system, additional studies of distribution o f RDX and 
metabolites to different brain areas would be valuable. These studies should try to determine possible 
temporal correlations between the presence o f RDX and/or metabolites in specific brain areas and the 
manifestation of clinical signs such as convulsive activity and seizures.
Comparative Toxicokinetics. The only comparative toxicokinetics data available are the results o f 
dermal absorption studies in excised human and pig skin, which showed relatively poor absorption in 
both preparations (Reddy et al. 2008; Reifenrath et al. 2002). This suggests that pigs would probably be a 
good animal model for dermal absorption studies. As mentioned previously, analyses o f blood and urine 
from subjects exposed to RDX during its manufacture or use or from individuals accidentally or 
intentionally exposed to high amounts o f RDX could provide information on the metabolism o f RDX in 
humans that can be compared with data collected from animals studies to establish which animal species 
serves as the best model for extrapolating results to humans. A PBPK model was developed that 
simulates disposition o f RDX in the rat, swine, and humans (Krishnan et al. 2009; Sweeney et al. 2012; 
U.S. Army 2007a); this model was considered suitable for risk assessment.
Methods for Reducing Toxic Effects. There are no known mitigation measures specifically for 
RDX-induced toxicity, other than standard anticonvulsant therapy. Since gastrointestinal absorption of 
RDX seems to be quite slow (Kufukardali et al. 2003), studies should focus on developing methods to 
accelerate its removal from the gastrointestinal tract to prevent RDX-induced adverse neurological 
effects. Washing the skin was reported to be effective in removing the chemical from the skin (Twibell et 
al. 1984). No data are available regarding adverse health effects o f low-level, long-term exposure of 
humans to RDX; therefore, no specific mitigation studies can be proposed at this time for that exposure 
scenario.
Children’s  Susceptibility. Data needs relating to both prenatal and childhood exposures, and 
developmental effects expressed either prenatally or during childhood, are discussed in detail in the 
Developmental Toxicity subsection above.
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There are limited data on potential age-related differences in the toxicity and toxicokinetics o f RDX. 
Neurological effects, similar to those observed in adults, have been observed in a child accidentally 
ingesting RDX (Woody et al. 1986). However, the lack o f dose information precludes determining 
whether children are more susceptible than adults. A study in deer mice found age-related differences in 
lethality (Smith et al. 2007). Additional animal studies are needed to evaluate whether there are potential 
differences in RDX toxicity between adults and children. These studies should include a wide-range of 
ages from birth through old age to assess whether there are differences in susceptibility as the nervous 
system matures.
Child health data needs relating to exposure are discussed in Section 6.8.1, Identification o f Data Needs: 
Exposures o f Children.
3.12.3 Ongoing Studies
The U.S. Army is concurrently developing a swine PBPK model, which can be extrapolated to humans.
No ongoing studies pertaining to RDX were identified in the Federal Research in Progress database 
(FEDRIP 2009).
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4. CHEMICAL AND PHYSICAL INFORMATION
4.1 CHEMICAL IDENTITY
RDX is a nitramine produced mainly for use in explosives (HSDB 2009). Information regarding the 
chemical identity o f RDX is located in Table 4-1.
4.2 PHYSICAL AND CHEMICAL PROPERTIES
RDX is a white crystalline solid. Information regarding the physical and chemical properties o f RDX is 
located in Table 4-2. Pure RDX is a highly explosive compound that can be initiated by impact, 
temperature, and friction (Akhavan 2004; Boileau et al. 2009; HSDB 2009). RDX is toxic by inhalation 
and dermal routes (Lewis 2007). Acrid fumes o f nitrogen oxides may be released when heated to 
decomposition (HSDB 2009; Lewis 2000).
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Table 4-1. Chemical Identity of RDX
Characteristic Information Reference
Chemical name RDX HSDB 2009
Synonym(s) Cyclonite; hexogen; cyclotrimethylenetrinitramine; 
hexogen 5W;T4; hexahydro-1,S,5-trinitro-
1.5.5-triazine; 1 ,S,5-triaza-1 ,S,5,-trinitrocyclohexane;
1.5.5-trinitrohexahydro-1,S,5-triazine; cyclotri- 
methylenenitramine; hexolite; S-triazine, hexahydro-
1.5.5-trinitro-; 1,S,5-triazine, hexahydro-1,S,5-trinitro-;
1.5.5-triazine, perhydro, 1,S,5-trinitro-; trimethylene- 
trinitramine; sym-trimethylene trinitramine; 1,S,5-tri- 
nitrohexahydro-S-triazine; 1,S,5-trinitroperhydro-
1.5.5-triazine; 1 ,S,5-trinitro-1,S,5-triazacyclohexane; 
trinitrotrimethylenetriamine
HSDB 2009
Registered trade name(s) No data
Chemical formula CSH6N6O6 HSDB 2009
Chemical structure n o 2
Nn
O2N '  'NO2
O'Neil et al. 2006
Identification numbers:
CAS registry 121-82-4 HSDB 2009
RTECS XY9450000 RTECS 2009
EPA hazardous waste No data
OHM/TADS No data




HSDB 2079 HSDB 2009
NCI No data
CAS = Chemical Abstracts Service; DOT/UN/NA/IMDG = Department of Transportation/United Nations/North 
America/International Maritime Dangerous Goods Code; EPA = Environmental Protection Agency;
HSDB = Hazardous Substances Data Bank; NCI = National Cancer Institute; OHM/TADS = Oil and Hazardous 
Materials/Technical Assistance Data System; RTECS = Registry of Toxic Effects of Chemical Substances
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Table 4-2. Physical and Chemical Properties of RDX
Property Information Reference
Molecular weight 222.26 Merck 1989
Color White Akhavan 2004
Physical state Crystalline solid Akhavan 2004
Melting point 204-206 °C Boileau et al. 2009; Merck 1989
Boiling point Decomposes U.S. Army 1991
Decomposition temperature: 213 °C Akhavan 2004






Water at 20 °C 38.4-38.9 mg/L; 60 mg/L U.S. Army 1983b, 1991
Organic solvents Slightly soluble in methanol, ether, ethyl Merck 1989 
acetate, glacial acetic acid
Partition coefficients:
Log Kow 0.87 HSDB 2009; PHYSPROP 2009
Log Koc 1.80a U.S. Army 1987a
Vapor pressure
At 20 °C 1x10-9 mm Hg (Torr) U.S. Army 1987a
At unidentified temperature 0.05 Pa (3.8x10-4 mm Hg) Boileau et al. 2009
Henry's law constant at 25 °C 2.0x10-11 atm-m3/molb PHYSPROP 2009
Autoignition temperature No data
Flashpoint No data
Flammability limits No data
Explosive limits Explosion may be prompted by sudden 
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5. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
5.1 PRODUCTION
No information is available in the Toxic Release Inventory (TRI) database on facilities that manufacture 
or process RDX because this chemical is not required to be reported under Section 313 o f the Emergency 
Planning and Community Right-to-Know Act (Title III o f the Superfund Amendments and 
Reauthorization Act o f 1986) (EPA 2010).
RDX is produced by nitrolysis o f hexamine with nitric acid (HSDB 2009; Lewis 2007). In the Bachmann 
process, used in the United States, hexamine is reacted with nitric acid, ammonium nitrate, glacial acetic 
acid, and acetic anhydride (Boileau et al. 2009; Budavari and O'Neil 1989; HSDB 2009; U.S. Army 
1978c, 1986e). The crude product is filtered and recrystallized to form RDX (U.S. Army 1986a). The 
Woolrich process, typically used in the United Kingdom and France, does not use acetic anhydride. The 
raw materials consist o f hexamine and 98-99%  nitric acid; however, this complex exothermic reaction is 
not completely understood (Boileau et al. 2009).
Another process that has been used to manufacture RDX by the direct nitration of HMX has not yielded a 
percentage o f RDX as high as that produced in the Bachmann process (Budavari and O'Neil 1989; U.S. 
Army 1978c).
Production o f RDX peaked in the 1960s when it was ranked third in explosive production by volume in 
the United States (U.S. Army 1986e). The average volume o f RDX produced from 1969 to 1971 was 
15 million pounds per month. However, production o f RDX decreased to a yearly total o f 16 million 
pounds for 1984.
RDX is not produced commercially in the United States (HSDB 2009). Current production in the United 
States is limited to military use at the Holston Army Ammunition Plant in Kingsport, Tennessee (SRI
2009). In the past, several Army ammunition plants, such as Louisiana (Shreveport, Louisiana), Lone 
Star (Texarkana, Texas), Iowa (Middletown, Iowa), and Milan (Milan, Tennessee), may have also 
handled and packaged RDX (U.S. Army 1986e). In 1980, RDX was produced at five facilities in the 
United States, including Borden (Fayetteville, North Carolina), Hooker (North Tonawanda, New York), 
Plastics Engineering (Sheboygan, Wisconsin), Tenneco (Fords, New Jersey), and Wright Chemical
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(Riegelwood, North Carolina). U.S. capacity in 1980 was 119 million pounds per year (CMR 1980). In 
2006, 6.9 million pounds were produced at Holston Army Ammunition Plant (EPA 2006c).
5.2 IMPORT/EXPORT
No information is available regarding the import or export o f RDX.
5.3 USE
RDX is a nitramine explosive compound (Turley and Brewster 1987) that can be utilized as a propellant, 
gunpowder, or high explosive depending on the initiation type (Boileau et al. 2009). RDX has both 
military and civilian applications. As a military explosive, RDX can be used alone as a base charge for 
detonators or mixed with another explosive such as TNT to form cyclotols, which produce a bursting 
charge for aerial bombs, mines, and torpedoes (HSDB 2009; Lewis 2000; Sax and Lewis 1989; Stokinger 
1982). As an explosive, RDX is one and a half times more powerful than TNT and is easily initiated with 
mercury fulminate (Lewis 2007). Common military uses o f RDX have been as an ingredient in plastic 
bonded explosives or plastic explosives, which have been used as explosive fill in almost all types of 
munition compounds (Gibbs and Popolato 1980; HSDB 2009). The plasticized form o f RDX, 
composition C-4, contains 91% RDX, 2.1% polyisobutylene, 1.6% motor oil, and 5.3% 2-ethylhexyl 
sebacate (Turley and Brewster 1987). Combinations o f RDX and HMX, another explosive, have been the 
chief ingredients in approximately 75 products (U.S. Army 1978c).
5.4 DISPOSAL
Waste water treatment sludges resulting from the manufacture o f RDX are classified as hazardous wastes 
and are subject to EPA regulations (EPA 1990a). For more information on regulations that apply to 
RDX, see Chapter 8.
Propellants and explosives have been disposed o f through burning, decomposition, re-use, and recovery 
(Bohn et al. 1997). Byproducts o f military explosives such as RDX have also been openly burned in 
many Army ammunition plants in the past. There are indications that, in recent years, as much as 80% of 
waste munitions and propellants have been disposed o f by incineration (U.S. Army 1986a). Wastes 
containing RDX have been incinerated by grinding the explosive wastes with a flying knife cutter and 
spraying the ground material with water to form a slurry. The types o f incineration used to dispose of 
waste munitions containing RDX include rotary kiln incineration, fluidized bed incineration, and
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pyrolytic incineration (U.S. Army 1986a). The primary disadvantage o f open burning or incineration is 
that explosive contaminants are often released into the air, water, and soils (U.S. Army 1986c).
Munitions such as RDX have also been disposed o f in the past by dumping into deep seawater 
(Hoffsommer and Rosen 1972).
RDX wastes found in soils and sediments have been degraded in composts using substances such as hay, 
horse feed, sewage sludge, wood shavings or sawdust, animal manure, and fruit and vegetable wastes 
(Greist et al. 1993; Gunderson et al. 1997; U.S. Army 1986b; Williams et al. 1992). In a mechanically 
stirred amended compost, the concentration o f RDX in soil was reduced from <800 to 39 mg/kg after 
44 days (Griest et al. 1993). RDX in contaminated soil from a dry explosives washout lagoon decreased 
from 884 to <2.9 mg/kg after 6 months using a 70% organic compost (Gunderson et al. 1997). RDX has 
been removed from munitions waste waters and contaminated groundwater by activated carbon columns 
(Bricka and Sharp 1992; U.S. Army 1987c; Wujcik et al. 1992). No RDX was detected when 
contaminated groundwater containing 487 ^g/L o f RDX was passed through granular activated carbon 
(GAC) columns at a loading rate o f 7.11 gpm/ft, a flow rate o f 0.7 gpm, and an empty-bed contact time of 
4.2 minutes (Wujcik et al. 1992). Once carbon columns were saturated with explosive, they were 
traditionally destroyed by open burning. Since this practice is no longer allowed in many areas, other 
disposal alternatives for spent carbons, such as thermal reactivation for reuse, oxidative incineration with 
ash burial, and thermal deactivation with carbon burial, have been investigated (U.S. Army 1987c). In a 
feasibility study, ultraviolet irradiation was found to provide effective treatment o f RDX-contaminated 
groundwater (Bricka and Sharp 1992).
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6. POTENTIAL FOR HUMAN EXPOSURE
6.1 OVERVIEW
RDX has been identified at 31 out o f the 1,699 hazardous waste sites that have been proposed for 
inclusion on the EPA National Priorities List (NPL) (HazDat 2007). However, the number o f sites 
evaluated for RDX is not known. The frequency o f these sites can be seen in Figure 6-1.
RDX is a military explosive produced by the nitrolysis o f hexamine with nitric acid (Boileau et al. 2009). 
It is a synthetic compound and is not known to exist in nature. Effluents and emissions from ammunition 
plants are responsible for the release o f RDX into the environment (Pennington and Brannon 2002; U.S. 
Army 1984a). RDX is expected to exist as a particulate in the atmosphere. When released to water, RDX 
is subject to photolysis (half-life of 9-13 hours). Photoproducts include formaldehyde and nitrosamines 
(U.S. Army 1980a). Alkaline hydrolysis can also occur (Balakrishnan et al. 2003; Heilmann et al. 1996). 
RDX undergoes biodegradation in water and soil under anaerobic conditions (Funk et al. 1993; 
Pennington and Brannon 2002; U.S. Army 1984f). Its biodegradation products include MNX; DNX; 
TNX; hydrazine; 1,1-dimethyl-hydrazine, 1,2-dimethyl-hydrazine; formaldehyde; and methanol 
(McCormick et al. 1981). RDX is mobile in soil, and can leach into groundwater (U.S. Army 1980c), and 
can be transported from soils or water to terrestrial and aquatic plants (Best et al. 1999; Harvey et al.
1991, 1997; Pennington and Brannon 2002; Simini and Checkai 1996).
RDX has been identified in environmental samples, primarily near army munition depots (Bishop et al. 
1988; Dacre 1994). Indoor air samples collected at ammunition plants were found to contain RDX in 
concentrations ranging from 0.032 to 60 mg/m3 (Bishop et al. 1988; U.S. Army 1975). In water, RDX 
has been identified in a variety o f groundwater samples from ammunition plants in the United States (<1­
14,100 ^g/L) and Germany (21-3,800 ^g/L) (Bart et al. 1997; Best et al. 1999; Godejohann et al. 1998; 
Steuckart et al. 1994; U.S. Army 1988). Sediment samples from Army depots have been found to contain 
RDX in concentrations ranging from <0.1 to 3,574 mg/kg (Simini et al. 1995; Sunahara et al. 1999; U.S. 
Army 1988) and in composts prepared from contaminated sediments (>2.9-896 mg/kg) (Griest et al.
1995; Gunderson et al. 1997). Additionally, RDX was indentified in plant species irrigated with or grown 
in contaminated water (<20-3,196 ^g/L) (Best et al. 1999; Pennington and Brannon 2002).
For the general population, exposure to RDX is primarily limited to areas around ammunition plants and 
military installations where it is manufactured, converted to munitions, packed, loaded, or released
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through the demilitarization o f antiquated munitions (Hundal et al. 1997; Pennington and Brannon 2002; 
U.S. Army 1980a, 1984a, 1984f). The most likely route o f exposure is ingestion o f contaminated 
drinking water or agricultural crops irrigated with contaminated water (Harvey et al. 1991, 1997; Simini 
and Checkai 1996). Dermal contact with soil containing RDX or inhalation exposure o f contaminated 
particulate matter produced during incineration of RDX-containing waste material are also possible routes 
o f exposure. Occupational exposure to RDX can occur when workers handle RDX at Army ammunition 
plants (Hathaway and Buck 1977; Kaplan et al. 1965). According to the National Occupational Exposure 
Survey (NOES) o f 1981-1983 conducted by NIOSH, the estimated number o f workers potentially 
exposed to RDX in the United States was 488 (NIOSH 1990).
Since RDX releases are not required to be reported under SARA Section 313, there are no data on RDX 
in the Toxics Release Inventory (TRI 1993).
6.2 RELEASES TO THE ENVIRONMENT
6.2.1 Air
There is no information on releases o f RDX to the atmosphere from manufacturing and processing 
facilities because these releases are not required to be reported (EPA 1997). However, all emissions are 
evaluated under Title V o f the 1990 federal Clean Air Act Amendments within each state’s Title V 
programs. RDX emissions from the manufacturing process are considered insignificant under the Title V 
air pollution control permits for facilities because they are contained systems. Thus, emission quantities 
are such that dispersion from the facilities is unlikely to be detectable by ambient monitoring.
RDX can enter the air through the release of contaminated particulate matter formed during the 
incineration o f RDX-containing mixtures (U.S. Army 1984a). RDX can also enter the air through 
evaporation from aquatic effluent streams or waste storage lagoons (U.S. Army 1984a).
6.2.2 Water
There is no information on releases o f RDX to the water from manufacturing and processing facilities 
because these releases are not required to be reported (EPA 1997). W ater discharges from RDX 
manufacturing and processing facilities are regulated by the National Pollutant Discharge Elimination 
System (NPDES) permit managed by each state’s NPDES program. The monitoring methodology may 
vary from state to state.
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RDX can be released to water in waste discharge effluents from ammunition production, formulation, 
manufacturing, loading, assembly, and packing, and through the demilitarization and disposal of 
antiquated munitions (Hundal et al. 1997; Pennington and Brannon 2002; U.S. Army 1980a, 1984a, 
1984f).
6.2.3 Soil
There is no information on releases o f RDX to the soil from manufacturing and processing facilities 
because these releases are not required to be reported (EPA 1997). Releases to soil are generally confined 
to manufacturing facilities and points o f use such as firing ranges. These sites are monitored by the 
Department o f the Army as well as state and federal environmental regulatory authorities under several 
environmental programs such as CERCLA, RCRA, Emergency Planning and Community Right-to-Know 
Act (EPCRA). Response activities include monitoring, cleanup, and land use controls as determined 
approporiate.
Manufacturing, packing, and use o f RDX have often resulted in contamination o f soil. RDX can enter 
soil by leaching from waste lagoons and from improper disposal o f contaminated sludge (U.S. Army 
1984a). RDX can also enter the soil from spills during manufacture, transportation, and storage.
Releases can also occur from the settling o f airborne particulates from manufacturing and demilitarization 
practices such as incineration onto soil surfaces (Hundal et al. 1997; Pennington and Brannon 2002; U.S. 
Army 1984a).
6.3 ENVIRONMENTAL FATE
6.3.1 Transport and Partitioning
RDX is expected to exist in the particulate phase in the atmosphere. The solubility o f RDX in water is 
low to negligible (Budavari and O'Neil 1989). The following water solubility values have been reported: 
21.8-21.9 mg/L at 10 °C, 38.4-38.9 mg/L at 20 °C, 59.7 mg/L at 25 °C, and 66.7-67 mg/L at 30 °C (U.S. 
Army 1983b; Yalkowsky and He 2003). RDX is slightly soluble in methanol, ether, ethyl acetate, and 
glacial acetic acid (Budavari and O'Neil 1989). The Henry's law constant for RDX is approximately 
2x10-11 atm-m3/mol (PHYSPROP 2009), indicating that volatilization from water or moist soil surfaces is 
expected to be a slow process.
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The soil adsorption coefficients normalized to organic carbon content (Koc) for RDX range from 42 to 
167 (U.S. Army 1980c). These Koc values are indicative o f moderate-to-high mobility in soil (Swann et 
al. 1983); therefore, RDX can be expected to leach into groundwater. Experimental data have shown that 
RDX is not readily bound or retained in soil as evidenced by its early breakthrough in column leachates 
(U.S. Army 1985a). A lysimeter study o f the migration o f RDX in soil showed that RDX was found in 
leachate from the soil columns (U.S. Navy 1982). Based on these Koc values and the experimental data, 
adsorption to sediment and particulate matter in the aquatic environment should not be significant (U.S. 
Army 1980a). Although RDX does not significantly adsorb to sediment, greater adsorption occurs with 
an increase in organic matter or clay content (U.S. Army 1980a). However, the clay content seems to be 
more important than organic matter content in influencing the amount o f RDX adsorbed (U.S. Army 
1980a). In a study sponsored by the U.S. Army Medical Research and Development Command 
(USAMRDC), the adsorption rate constant o f RDX in soil was found to be low (Kd o f <1 mg/g). The 
adsorption constant was linearly correlated with a combination o f soil properties, such organic carbon and 
clay content, pH, and cation exchange capacity (U.S. Army 1993a). Adsorption to soil was measured 
using samples from the Louisiana Army Ammunition Plant. RDX was retained on a bentonite/sand 
column with a 90% recovery after 11 pore volumes. Retardation o f RDX by fine-silty soils was limited 
(Selim et al. 1995). It appears that sorption o f RDX in soils is not solely the result o f hydrophobic 
partitioning o f RDX to the organic carbon phase of the soils.
The logarithm o f the octanol/water partition coefficient (log Kow) is a useful preliminary indicator of 
potential bioaccumulation o f a compound. The log Kow for RDX was estimated to be 0.87 (PHYSPROP
2009), indicating that RDX is not very lipid soluble and therefore has a low potential for bioaccumulation 
in aquatic species. Experimental bioconcentration factors in edible tissue for bluegill (Lepomis 
macrochirus), channel catfish (Ictalurus punctatus), and fathead minnow (Pimephales promelas) were 
1.9-6.4, 1.2-5.5, and 1.4-5.9, respectively (U.S. Army 1984a). These factors indicate that 
bioaccumulation in aquatic organisms is not an important fate process.
Data indicate that RDX can be taken up by both terrestrial and aquatic plants (Best et al. 1999; Harvey et 
al. 1991, 1997; Pennington and Brannon 2002; Simini and Checkai 1996; U.S. Army 1990a). Studies o f 
bean plants grown in 10 ppm RDX hydroponic solutions and exposed for 1 or 7 days indicated that 
uptake o f RDX readily occurred. Following uptake, translocation o f the compounds to the aerial tissue 
occurred, resulting in foliar concentrations o f 20 and 97 ppm for the 1- and 7-day exposures, respectively. 
Metabolism o f RDX to polar metabolites was observed in plants exposed for 7 days (Harvey et al. 1991). 
Additional studies o f hydroponic plant-culture systems indicated that RDX (1-10 ppm) was also absorbed
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by the roots of blando brome and wheat and that plant absorption was concentration-dependent (U.S. 
Army 1990a). In a simulation o f field conditions, uptake o f RDX to lettuce leaves, corn stover, and 
alfalfa shoots correlated to levels o f RDX (2, 18, and 90 ppb) in the irrigation water (Simini and Checkai 
1996). Submerged aquatic plants, including Elodea, pondweed, and water star-grass, grown using 
sediment and contaminated groundwater containing 1,529 ^g/L from the Milan Ammunition Plant in 
Milan, Tennessee had RDX concentrations o f 976, 42, and 1,496 ^g/L, respectively, after 13 days. The 
emergent plant species, parrot-feather, sweet-flag, reed canary grass, and wool-grass contained RDX at
3,196, 1,156, 704, and <20 ^g/L, respectively (Best et al. 1999). When grown in soil contaminated with 
58 mg/kg RDX, lettuce was found to contain 1,200 mg/kg o f RDX, while nutsedge, tomato fruit, corn 
kernels, and corn stover contained RDX at concentrations o f 62, 7, 6, and 56 mg/kg, respectively 
(Pennington and Brannon 2002). For plants grown in soils containing 10 ppm RDX over a period of 
60 days, the extent o f plant uptake was found to be dependent both on soil type and plant species (Cataldo 
et al. 1993). RDX was transported unchanged from soils to plants and the plant uptake increased as the 
organic matter content o f soil decreased. In bush bean plants, RDX was mostly concentrated in leaves 
and seed, with less found in roots, stems, and pods. In the case o f wheat and blando brome, RDX mostly 
concentrated in leaves and roots, with very little or none in seeds (Cataldo et al. 1993). After plant 
uptake, RDX in storage tissues o f plants (i.e., roots and stems) mostly metabolized to unidentified polar 
metabolites or nonextractable products, while RDX remained mostly unchanged (>50%) in leaves and 
seed tissues (Cataldo et al. 1993).
6.3.2 Transformation and Degradation 
6.3.2.1 Air
RDX is expected to exist in the particulate form in the atmosphere, and may be subject to removal from 
air by dry deposition. No data were located on photolysis o f RDX in the atmosphere. However, it is 
expected that photolysis o f RDX is an important fate process in the atmosphere since RDX absorbs 
ultraviolet wavelengths between 240 and 350 nm (U.S. Army 1986e) and it undergoes rapid photolysis in 
water (U.S. Army 1980a).
6.3.2.2 Water
In a hydrolysis study o f RDX in seawater (pH 8.1) at 25 °C, 11.6% of initial RDX hydrolyzed in 112 days 
(Hoffsommer and Rosen 1973). Other data found that RDX was stable to hydrolysis in an aqueous 
solution at a pH range normally found in natural waters (U.S. Army 1980a). Therefore, hydrolysis is not
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expected to significantly influence the environmental fate of RDX. Hydrolysis can occur, however, under 
alkaline conditions. RDX underwent alkaline hydrolysis (pH 10) in the presence o f water over 17 days. 
The approximate half-life for this reaction was about 7 days and was accompanied by the formation o f the 
ring cleavage product 4-nitro-2,4-diazabutanal, as well as NO2-, N 2O, formaldehyde, and formic acid 
(Balakrishnan et al. 2003). Aqueous alkaline hydrolysis is thought to be a possible method of 
remediating RDX contaminated waste water (Heilmann et al. 1996).
The primary physical mechanism that degrades RDX in aqueous solutions is photolysis (U.S. Army 
1986e). The range o f ultraviolet wavelengths that produce photolytic reactions with RDX is generally 
between 240 and 350 nm (U.S. Army 1986e). RDX in waste water (23.9 mg/L) exposed to ultraviolet 
radiation decomposed with a half-life o f 3.7 minutes (Burrows et al. 1984). Photolysis o f an aqueous 
solution o f RDX in natural sunlight is fairly rapid with an experimental half-life of 9-13 hours. 
Consequently, RDX is not expected to persist for a long period o f time in clear, sunlit surface waters 
(U.S. Army 1980a). Formaldehyde and nitrosamines were identified as photoproducts. Nitrosamines 
may be o f environmental importance because of their potential mutagenicity/carcinogenicity. Conversion 
to this product, however, occurs only to a limited extent since the product itself is photoreactive (U.S. 
Army 1980a). The rate o f photodegradation under different environmental conditions is also dependent 
upon the nature o f the water body itself. RDX was shown to degrade very slowly in dark, tea-colored 
lagoon waters at a Louisiana Army Ammunition Plant during a field study at this site (U.S. Army 1983b). 
The half-life for RDX was approximately 2,100 days in winter and 456 days in summer for a lagoon 
50 cm deep (U.S. Army 1983b). The slow rate o f degradation was attributed to the rapid attenuation of 
sunlight in the top layers o f the water column, thereby preventing photons o f radiation from reaching 
RDX, which was reported to be well mixed throughout the water column (U.S. Army 1983b).
The biodegradation o f RDX has been studied under aerobic and anaerobic conditions. RDX did not 
undergo aerobic biodegradation using a variety o f inocula and nutrients (Osmon and Klausmeier 1973). 
However, microbial degradation studies were carried out using water and sediment samples collected 
from the Holston River and the waste-water effluents from the Holston Army Ammunition Plant showed 
some degradation (U.S. Army 1980a). Only the addition o f river sediments appeared to stimulate the 
aerobic biodegradation o f RDX in samples of river water containing either 5.5 or 11.5 ppm o f RDX. The 
half-life for the disappearance o f RDX in water samples supplemented with sediment was approximately 
7 days. A lag period of 2-3 weeks was observed before a noticeable degradation o f RDX occurred. The 
results showed that biodegradation o f RDX leads to mineralization o f the molecule (U.S. Army 1980a). 
No degradation o f RDX was observed during a 90-day aerobic experiment with RDX in the lagoon water
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alone, with added yeast extract, or with 1% o f bottom sediment (U.S. Army 1983b). Concentrations of 
RDX remained unchanged when cultures were inoculated with aerobic activated sludge and incubated 
aerobically. No RDX disappeared in uninoculated controls (McCormick et al. 1981).
Data are available indicating that biodegradation o f RDX occurs under anaerobic conditions (U.S. Army 
1984f; Crocker et al. 2006; Funk et al. 1993; Hawari et al. 2000; McCormick et al. 1981; Pennington and 
Brannon 2002; W alker and Kaplan 1992). RDX (50 or 100 ^g/mL) disappeared rapidly from nutrient 
broth cultures inoculated with anaerobic sewage sludge and incubated anaerobically. Biodegradation of 
RDX was complete after 4 days (McCormick et al. 1981). The disappearance o f RDX was accompanied 
by the appearance o f several products identified as the mono-, di-, and trinitroso derivatives o f RDX 
formed by sequential reductions o f the nitro groups to nitroso groups (Crocker et al. 2006; Hawari et al. 
2000; McCormick et al. 1981; W alker and Kaplan 1992). Anaerobic biodegradation products included 
MNX; DNX; TNX; hydrazine; 1,1-dimethyl-hydrazine; 1,2-dimethyl-hydrazine; formaldehyde; and 
methanol. The nitroso intermediates are known to be hazardous. Both 1,1- and 1,2-dimethylhydrazine, as 
well as hydrazine, are known mutagens and/or carcinogens (McCormick et al. 1981), but may be found 
naturally in the environment (e.g., certain mushrooms).
After an incubation period o f 5 days, 97% o f RDX was anaerobically degraded by a mixed population of 
purple photosynthetic bacteria o f the genera Chromatium, Rhodospirillum, and Rhodopseudomonas, and 
possibly others (U.S. Navy 1973). Sixty percent o f RDX was anaerobically degraded by Chromatium 
alone (U.S. Navy 1973). These photosynthetically active cultures, which do not release oxygen, were 
supplemented with sodium acetate and ammonium chloride. It was hypothesized that RDX was not 
actually metabolized, but rather was being reduced and modified as a result o f the active electron transfer 
brought about by the anaerobic photosynthetic activity o f the organisms. Data indicate that hydrogen can 
be the sole electron donor in the anaerobic degradation o f RDX (Beller 2002). A proposed pathway for 
the degradation o f RDX involves reductions leading to destabilization, ring cleavage, and mineralization. 
Degradation intermediates are much more susceptible to degradation under anaerobic conditions than 
under aerobic conditions (Pennington and Brannon 2002).
RDX (13 ppm) in lagoon waste water at the Louisiana Army Ammunition Plant did not undergo 
anaerobic degradation for approximately 90 days with yeast extract repeatedly added as a nutrient (U.S. 
Army 1983b). The RDX concentration fell to 2.9 ppm at day 90 and to 1.4 ppm at day 92. The authors 
reported that the repeated addition o f yeast extract acclimated RDX-utilizing organisms. The RDX-
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acclimated organisms then degraded 9.1 ppm o f RDX 93% after 5 days o f anaerobic incubation (U.S. 
Army 1983b).
6.3.2.3 Sediment and Soil
Three soils containing 0.5-7.2%  organic matter were amended with 60 ppm (mg/kg) RDX and incubated 
for 60 days under aerobic conditions (Cataldo et al. 1993). After 60 days, >95% were extractable and 
remained unchanged as parent RDX; only <2% remained nonextractable in the soils. No significant 
transformation products o f RDX were observed in the soils. RDX was not biodegraded after 56 days 
following addition to three soil samples (Grant et al. 1995). RDX, present at 30 ppm in soil cultures 
containing added potato starch as an additional carbon source, was not degraded after 24 days (Funk et al.
1993). These results indicate that RDX may not be easily amenable to aerobic biodegradation in soils.
Significant biotransformation, however, may occur under certain conditions. The degradation o f pink 
water compounds in soil was studied (U.S. Army 1985a). Pink water is a generic term used for colored 
waters that may contain some explosive compounds, including RDX. A simulated pink water containing 
RDX (30 mg/L) was continuously applied to a series o f soil columns at different flow rates, with and 
without carbon supplementation. The columns were inoculated with combined samples o f micro­
organisms from activated sludge, anaerobic sludge digest, and garden soil. Concentrations o f RDX and 
biotransformation products were monitored on a weekly basis. There appeared to be a significant 
decrease in RDX recovery in the leachate o f the column with slow and fast flow with carbon supplement, 
indicating microbial activity. The mononitroso derivative, MNX, and the dinitroso derivatives o f RDX 
were identified in the leachate of the column with fast flow (100 mL/day) and carbon supplement (2.0 g/L 
glucose). MNX was also identified in the leachates from the columns with slow flow (40 mL/day) with 
and without carbon supplement (U.S. Army 1985a). Since the nitroso derivatives are intermediates in the 
anaerobic biodegradation of RDX in aqueous systems (Walker and Kaplan 1992), it is likely that the 
observed products resulted from anaerobic biodegradation o f RDX. The authors reported that land 
treatment or land farming o f pink water should not be considered as a treatment option for pink water. 
Hazardous biotransformation intermediates and unchanged concentrations o f some o f the pink water 
compounds would contaminate groundwater and soil. RDX, present at 30 ppm in anaerobic soil cultures 
containing added potato starch as an additional carbon source, were totally degraded after 24 days (Funk 
et al. 1993).
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Douglas et al. (2009) added 20 mL o f a solution containing 2.3 mg/L RDX to aqueous slurries containing 
pristine soils and soils fractured to simulate the effects o f detonation. After 92 days, the measured 
concentration was approximately 1.3-2.2 mg/L in the slurries containing the fractured soils and virtually 
unchanged in the slurries containing the pristine soil. The authors suggested that the observed decrease in 
aqueous concentration in the fractured soil could be caused by enhanced adsorption to fractured soil 
particle surfaces or enhanced transformation in the presence o f the fractured soil particles or a 
combination of both.
6.4 LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT
Reliable evaluation o f the potential for human exposure to RDX depends in part on the reliability o f 
supporting analytical data from environmental samples and biological specimens. Concentrations of 
RDX in unpolluted atmospheres and in pristine surface waters are often so low as to be near the limits of 
current analytical methods. In reviewing data on RDX levels monitored or estimated in the environment, 
it should also be noted that the amount o f chemical identified analytically is not necessarily equivalent to 
the amount that is bioavailable. The analytical methods available for monitoring RDX in a variety of 
environmental media are detailed in Chapter 7.
6.4.1 Air
No data are available regarding levels o f RDX in outdoor air. However, indoor air samples collected at 
Holston Army Ammunition Plant in Kingsport, Tennessee in 1974 contained RDX levels ranging from 
not detected (<0.5 mg/m3 [4.5 ppm]) to 60 mg/m3 (546 ppm) (U.S. Army 1975). A more recent study 
found that RDX was detected in only one o f eight indoor air samples taken from the incorporation area of 
Holston Army Ammunition Plant in 1986; the concentration in this sample was 0.032 mg/m3 (0.29 ppm) 
in the particulate fraction (Bishop et al. 1988).
6.4.2 Water
Seawater samples taken in 1971 from a munitions dumping area 85 miles west o f Cape Flattery, 
Washington, and similar samples taken 172 miles south-southeast o f Charleston, South Carolina, were 
analyzed for RDX (U.S. Navy 1972). No RDX was found in any o f the samples examined (detection 
limit o f 5 ppt). RDX was found on-site at the Savanna Army Depot in Illinois in surface water samples at 
a maximum reported concentration of 36.9 ppm (Agency for Toxic Substances and Disease Registry
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1989c). The Savanna Army Depot is on the NPL. It was an Army munitions plant engaged in munitions 
renovation, loading, demolition, and burning, which was closed in 2000.
Onsite groundwater sampling at the Milan Army Ammunition Plant near Milan, Tennessee identified 
RDX at concentrations ranging from not detected to 11.24 ppm (detection limit not reported) (Agency for 
Toxic Substances and Disease Registry 1989b). Filtered groundwater samples from the Milan Army 
Ammunition Plant contained RDX at a concentration o f 1,443 ppb. Filtration reduced RDX 
concentration in the water samples by 27% (Best et al. 1999). U.S. Army (2011) listed a range of 
detectable concentrations of 50-18,000 ppb in groundwater samples and 80-120 ppb in surface water 
samples taken from Milan Army Ammunition Plant. Groundwater samples from the Umatilla Army 
Depot Activity, a munitions storage and handling depot in Hermiston, Oregon and the Naval Submarine 
Base Bangor in Bangor, Washington contained RDX in concentrations ranging from <20 to 8,160 ppb 
(Bart et al. 1997).
Groundwater samples from monitoring and extraction wells at the Naval Base Kitsap at Bangor NPL site 
in Kitsap County, Washington, were collected from May 1994 to August 2004. Concentrations of RDX 
in the samples from a 12-acre Bangor Ordnance Disposal site (Site A) ranged from 0.19 to 1,000 ppb in 
perched zone monitoring wells, from 0.19 to 550 ppb in shallow aquifer monitoring wells, and from 0.4 to 
660 ^g/L in extraction wells (shallow aquifer). RDX concentrations at the site o f a former waste water 
lagoon and overflow ditch (Site F) in groundwater from a shallow aquifer ranged from 0.95 to 3,800 ppb 
(U.S. Navy 2005).
RDX was identified in environmental samples at Cornhusker Army Ammunition Plant and Louisiana 
Army Ammunition Plant army bases (Dacre 1994). Maximum concentrations of RDX detected in water 
at the Cornhusker Army Ammunition Plant (Nebraska) were 307 and 371 ppb from on- and off-site wells, 
respectively (Agency for Toxic Substances and Disease Registry 1989a). A plume o f RDX-contaminated 
groundwater, which stretched 6.5 km, was found near the Cornhusker Army Ammunition Plant. The 
concentrations ranged from 9 to >100 ppb (Spalding and Fulton 1988). A maximum concentration of 
95 ppb in groundwater was reported by U.S. Army (2011) for the Cornhusker Army Ammunition Plant 
The Louisiana Army Ammunition Plant is a shell manufacturing and explosives load, assembly, and pack 
facility (U.S. Army 1988). From 1951 to 1980, waste waters were trucked to and discharged into a series 
o f artificial leaching pits, which resulted in contamination o f soil, sediments, and groundwater. Levels o f 
RDX measured in groundwater at the Louisiana Army Ammunition Plant ranged from 1.3 to 14,100 ppb 
(U.S. Army 1988). U.S. Army (2011) reported a maximum groundwater concentration o f 13,200 ppb at
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this facility. U.S. Army (2011) also reported ranges o f groundwater concentrations o f 0.0087-86.4 ppb at 
Aberdeen Proving Ground and 3.3-13,000 ppb at Iowa Army Ammunition Plant. The surface water 
concentrations ranged from 0.73 to 7.6 ppb at Aberdeen Proving Ground and 4.4 to 249 ppb at Iowa 
Army Ammunition Plant.
RDX was identified in a water sample obtained from a military training site in Germany at 21 ppb 
(Godejohann et al. 1998). Two contaminated water samples from the area o f a former explosive 
production plant at Elsnig in Saxony, Germany contained RDX at concentrations o f 2,380-3,800 and 
310-400 ppb, with the exact concentrations dependent upon the method o f detection (Steuckart et al.
1994).
6.4.3 Sediment and Soil
Ocean floor sediment samples taken in 1971 from a munitions dumping area 85 miles west o f Cape 
Flattery, Washington, and similar samples taken 172 miles south-southeast o f Charleston, South Carolina, 
were analyzed for RDX (U.S. Navy 1972). No RDX was found in any o f the sediment samples analyzed. 
RDX was found onsite at the Savanna Army Depot in Illinois in soil samples at a maximum concentration 
o f 12.3 ppm (Agency for Toxic Substances and Disease Registry 1989c). RDX was found at the 
Louisiana Army Ammunition Plant in soil and drainage sediments at concentrations ranging from <5 to 
602 mg/kg (U.S. Army 1988). RDX was identified in a composite soil sample at a concentration of
130.5 mg/kg. The sample was composed o f topsoil samples from the site o f an explosives factory 
(Sunahara et al. 1999). Soils collected from the Joliet Army Ammunition Plant in Joliet, Illinois 
contained RDX in concentrations ranging from <0.1 to 3,574 mg/kg (Simini et al. 1995). RDX was 
identified in environmental samples at Cornhusker Army Ammunition Plant and Louisiana Army 
Ammunition Plant (Dacre 1994).
RDX was identified in compost at 884 mg/kg. The compost was prepared using contaminated sediments 
from the Umatilla Army Depot Activity in Hermiston, Oregon (Gunderson et al. 1997). Griest et al. 
(1995) identified RDX in dry compost prepared using soils from Umatilla in concentrations ranging from 
>2.9 to 896 mg/kg.
U.S. Army (2011) reported range o f detectable soil concentrations o f 5.45-890 mg/kg at Cornhusker 
Army Ammunition Plant, 0.587-3,300 mg/kg at Milan Army Ammunition Plant, 980 mg/kg at Aberdeen
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Proving Ground, and 2.5-75,000 mg/kg at Iowa Army Ammunition Plant; sediment samples from Iowa 
Army Ammunition Plant contained 0.363-14,100 mg/kg RDX.
6.4.4 Other Environmental Media
Ocean floor fauna samples (rat tail fish and sea cucumbers) taken in 1971 from munitions dumping areas 
in the Atlantic and Pacific Oceans contained no apparent RDX residues (detection limit o f 0.123 ^g/kg) 
(U.S. Navy 1972).
Agricultural crops irrigated with contaminated water have been found to contain RDX. In a laboratory 
study simulating field conditions, uptake o f RDX to lettuce leaves, corn stover, and alfalfa shoots 
correlated to levels o f RDX in the irrigation water (2, 18, and 90 ppb). RDX did not significantly 
concentrate in tomatoes, bush bean seeds and pods, radish roots, and soybean seeds (Simini and Checkai 
1996). Submerged aquatic plants, including Elodea, pondweed, and water star-grass, grown using 
sediment and contaminated groundwater containing 1,529 ^g/L from the Milan Ammunition Plant in 
Milan, Tennessee had RDX concentrations o f 976, 42, and 1,496 ^g/L, respectively, after 13 days. The 
emergent plant species, parrot-feather, sweet-flag, reed canary grass, and wool-grass contained RDX at
3,196, 1,156, 704, and <20 ^g/L, respectively (Best et al. 1999). When grown in soil contaminated with 
58 mg/kg RDX, lettuce was found to contain 1,200 mg/kg o f RDX, while nutsedge, tomato fruit, corn 
kernels, and corn stover contained RDX at concentrations o f 62, 7, 6, and 56 mg/kg, respectively 
(Pennington and Brannon 2002).
6.5 GENERAL POPULATION AND OCCUPATIONAL EXPOSURE
For the general population, exposure to RDX is most likely limited to areas around Army ammunition 
plants where RDX is manufactured, converted to munitions, or released through the demilitarization of 
antiquated munitions (Hundal et al. 1997; Pennington and Brannon 2002; U.S. Army 1980a, 1984a, 
1984f). Two surveys o f public places, including taxis, trains, and airplanes, hotels, and private homes, 
rarely detected RDX (Crowson et al. 1996; Cullum et al. 2004). The most likely route o f exposure for 
populations living in the vicinity o f Army ammunition plants is ingestion o f contaminated drinking water 
or agricultural crops that have been irrigated with contaminated water (Harvey et al. 1991, 1997; Simini 
and Checkai 1996). Dermal contact with soil containing RDX and inhalation o f contaminated particulate 
matter produced during incineration o f RDX-containing waste material are also possible routes of 
exposure. However, since no monitoring data were located regarding levels o f RDX in outdoor air, the 
extent o f exposure by this route is not known. Dermal contact with contaminated soil is also a possible
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route o f exposure. However, since no absorption data following dermal exposure to RDX were located, 
the extent o f exposure by this route is also not known.
Occupational exposure to RDX can occur when workers handle RDX in explosive plants (Hathaway and 
Buck 1977; Kaplan et al. 1965; Testud et al. 1996b). Inhalation exposure o f workers to RDX has 
occurred as a result o f release o f dust into the workroom air, principally during dumping o f dried RDX 
powder, screening and blending, and clean-up o f spilled material (Kaplan et al. 1965; Testud et al.
1996b). Exposure to RDX can also occur through dermal contact during manufacture, handling, and 
clean-up o f RDX (Kaplan et al. 1965). RDX was detected at a concentration o f 0.052 mg/m3 (0.47 ppm) 
in the particulate fraction o f one indoor air sample taken from the incorporation area o f Holston Army 
Ammunition Plants in Tennessee in 1986 (Bishop et al. 1988). Based on the observed concentration, the 
potential for exposure to RDX is considered to be very low.
According to the NOES (1981-1983), the estimated number o f workers potentially exposed to RDX in 
the United States was 488 (NIOSH 1990).
6.6 EXPOSURES OF CHILDREN
This section focuses on exposures from conception to maturity at 18 years in humans. Differences from 
adults in susceptibility to hazardous substances are discussed in Section 3.7, Children’s Susceptibility.
Children are not small adults. A child’s exposure may differ from an adult’s exposure in many ways. 
Children drink more fluids, eat more food, breathe more air per kilogram o f body weight, and have a 
larger skin surface in proportion to their body volume. A child’s diet often differs from that o f adults.
The developing human’s source o f nutrition changes with age: from placental nourishment to breast milk 
or formula to the diet o f older children who eat more o f certain types o f foods than adults. A child’s 
behavior and lifestyle also influence exposure. Children crawl on the floor, put things in their mouths, 
sometimes eat inappropriate things (such as dirt or paint chips), and spend more time outdoors. Children 
also are closer to the ground, and they do not use the judgment o f adults to avoid hazards (NRC 1993).
Children can be exposed to RDX by inhalation, oral, or dermal contact with the chemical or by any 
combination o f these routes. Children residing in areas around Army ammunition plants where RDX is 
manufactured, converted to munitions, or released through the demilitarization o f antiquated munitions 
may be exposed to RDX (Hundal et al. 1997; Pennington and Brannon 2002; U.S. Army 1980a, 1984a,
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1984f). The primary route o f exposure is ingestion o f contaminated drinking water. Inhalation exposure 
may result from breathing contaminated particulate matter produced during incineration of 
RDX-containing waste material. Dermal contact with contaminated soil is also a possible route o f 
exposure. Children playing in contaminated water or soil may also be exposed via ingestion.
6.7 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES
Exposure o f workers can occur via the inhalation, oral, or dermal routes, or by any combination o f these 
routes. Workers involved in the production and use o f RDX at Army ammunition plants constitute a 
group at risk because o f the potential for occupational exposure. Persons living near Army ammunition 
plants or hazardous waste sites may have a higher risk o f exposure to RDX resulting from inhalation of 
dusts or fumes, ingestion o f contaminated drinking water, or contact with contaminated soil (Hundal et al. 
1997; Pennington and Brannon 2002; Testud et al. 1996b). Military personnel may also be exposed to 
high levels from the use of explosives that contain RDX. Individuals employed in demilitarization of 
nuclear, biological, and chemical weapons as per international treaty agreements may be exposed to high 
levels o f RDX, as disassembly o f these missiles involves disassembly o f RDX-containing bursters and 
detonators.
6.8 ADEQUACY OF THE DATABASE
Section 104(i)(5) of CERCLA, as amended, directs the Administrator o f ATSDR (in consultation with the 
Administrator o f EPA and agencies and programs o f the Public Health Service) to assess whether 
adequate information on the health effects of RDX is available. Where adequate information is not 
available, ATSDR, in conjunction with NTP, is required to ensure the initiation of a program o f research 
designed to determine the health effects (and techniques for developing methods to determine such health 
effects) o f RDX.
The following categories o f possible data needs have been identified by a joint team o f scientists from 
ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if  met would 
reduce the uncertainties o f human health assessment. This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled. In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed.
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Physical and Chemical Properties . The physical and chemical properties o f RDX are sufficiently 
characterized to permit estimation o f its environmental fate (Akhavan 2004; Budavari and O'Neil 1989; 
McKone and Layton 1986; U.S. Army 1986e, 1987a).
Production, Import/Export, Use, Release, and Disposal. According to the Emergency 
Planning and Community Right-to-Know Act o f 1986, 42 U.S.C. Section 11023, industries are required 
to submit substance release and off-site transfer information to the EPA. The TRI, which contains this 
information for 2006, became available in February o f 2008. This database is updated yearly and should 
provide a list o f industrial production facilities and emissions.
RDX is not produced commercially in the United States. Production in the United States is limited to 
Holston Army Ammunition Plants in Kingsport, Tennessee (SRI 2009),. Current import/export data for 
RDX are not available. RDX is primarily used as a high explosive (Boileau et al. 2009; HSDB 2009; 
Lewis 2007; Budavari and O'Neil 1989; Turley and Brewster 1987). RDX is primarily found in water, 
groundwater, and soil around Army ammunition plants (Agency for Toxic Substances and Disease 
Registry 1989a, 1989b, 1989c; Bart et al. 1997; Bishop et al. 1988; Dacre 1994; Simini et al. 1995; 
Spalding and Fulton 1988; U.S. Army 1988). Data on the most commonly used disposal methods are 
sufficient (Hoffsommer and Rosen 1972; U.S. Army 1986a, 1986c); however, additional data on the 
amounts o f RDX being disposed of and on alternative disposal methods would be useful. RDX wastes 
produced in manufacturing and processing are classified as hazardous wastes and are subject to EPA 
regulations (EPA 1990a).
Environmental Fate . RDX released to the environment partitions into air, water, and soil (Eisenreich 
et al. 1981; Lyman et al. 1982; U.S. Army 1980a, 1983b, 1987a). RDX is transported in soil, surface 
water, and groundwater (Swann et al. 1983; U.S. Army 1980c, 1983b, 1985a, 1986e, 1987a). 
Volatilization is expected to be a slow transport process (Lyman et al. 1982). RDX is expected to exist as 
a particulate in the atmosphere. No data were located in the literature regarding atmospheric transport of 
RDX. Experimental data are needed regarding photolysis o f RDX in the atmosphere. Photolysis is the 
primary mechanism o f RDX degradation in water (half-life o f 9-13 hours) (U.S. Army 1980a, 1986e). 
Biodegradation of RDX occurs in water and soil, principally under anaerobic conditions (Funk et al.
1993; McCormick et al. 1981; Osmon and Klausmeier 1973; Pennington and Brannon 2002; U.S. Army 
1984f, 1985a). Biodegradation half-life data for RDX and its breakdown products in water and soil are
6.8.1 Identification of Data Needs
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needed. This information will be helpful in better identifying the most important pathways o f human 
exposure to RDX.
Bioavailability from Environmental Media. Absorption data regarding dermal exposure in 
humans are not available. Very limited data indicate that RDX is absorbed following inhalation exposure 
(Kaplan et al. 1965; Testud et al. 1996b). RDX is absorbed through the gastrointestinal system following 
ingestion o f the compound (Hollander and Colbach 1969; Ketel and Hughes 1972; Merrill 1968; Stone et 
al. 1969). The oral and dermal routes o f exposure may be o f concern to humans because o f the potential 
for RDX to contaminate drinking water and soil. More information regarding all absorption routes, 
particularly on the absorption o f RDX following ingestion o f contaminated drinking water and soil or 
plants grown in contaminated environments, is needed to better characterize the bioavailability o f RDX.
Food Chain Bioaccumulation . Based on a low log Kow and low experimental BCF values of 1.2­
5.9, RDX has a low bioconcentration potential in aquatic organisms (PHYSPROP 2009; U.S. Army 
1984a). No data were located regarding bioconcentration potential in animals. Data are needed regarding 
bioconcentration/biomagnification potential in terrestrial food chains.
Exposure Levels in Environmental Media. Reliable monitoring data for the levels of RDX in 
contaminated media at hazardous waste sites are needed so that the information obtained on levels of 
RDX in the environment can be used in combination with data on potential pathways o f exposure and the 
known body burden o f RDX to assess the potential risk o f adverse health effects in populations living in 
the vicinity o f hazardous waste sites.
RDX has been detected in surface water, groundwater, and soil at Army ammunition plants and current 
and former military installations (Agency for Toxic Substances and Disease Registry 1989a, 1989b, 
1989c; Bart et al. 1997; Simini et al. 1995; Spalding and Fulton 1988). Data are needed regarding levels 
o f RDX in ambient air and occupational air. No data were located regarding human intake estimates for 
each media. Reliable monitoring data are needed for levels o f RDX in contaminated media at hazardous 
waste sites. The information on RDX levels in the environment and the resulting body burden of RDX 
can be used to assess the potential risk o f adverse health effects in populations living in the vicinity o f 
hazardous waste sites.
Exposure Levels in Humans. RDX has been detected in surface water, groundwater, and soil at 
Army ammunition plants (Agency for Toxic Substances and Disease Registry 1989a, 1989b, 1989c; Bart
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et al. 1997; Simini et al. 1995; Spalding and Fulton 1988). Data are needed regarding levels o f RDX in 
ambient air and occupational air. No data were located regarding human intake estimates for each media. 
Reliable monitoring data are needed for levels o f RDX in contaminated media at hazardous waste sites. 
The information on RDX levels in the environment and the resulting body burden o f RDX can be used to 
assess the potential risk o f adverse health effects in populations living in the vicinity o f hazardous waste 
sites.
This information is necessary for assessing the need to conduct health studies on these populations.
Exposures of Children. RDX has been detected in surface water, groundwater, and soil at Army 
ammunition plants (Agency for Toxic Substances and Disease Registry 1989a, 1989b, 1989c; Bart et al. 
1997; Simini et al. 1995; Spalding and Fulton 1988). Data are needed regarding levels o f RDX in 
ambient air. No data were located regarding human intake estimates for each media. Reliable monitoring 
data are needed for levels of RDX in contaminated media at hazardous waste sites as well as potential 
uptake by children through ingestion of drinking water and contaminated crops, and accidental ingestion 
o f contaminated soils. Dermal contact is also a concern for children playing in or near contaminated 
areas. The information on RDX levels in the environment and the resulting body burden o f RDX can be 
used to assess the potential risk o f adverse health effects in populations living in the vicinity o f hazardous 
waste sites.
Child health data needs relating to susceptibility are discussed in Section 3.12.2, Identification o f Data 
Needs: Children’s Susceptibility.
Exposure Registries. No exposure registries for RDX were located. This substance is not currently 
one o f the compounds for which a sub-registry has been established in the National Exposure Registry. 
The substance will be considered in the future when chemical selection is made for sub-registries to be 
established. The information that is amassed in the National Exposure Registry facilitates the 
epidemiological research needed to assess adverse health outcomes that may be related to exposure to this 
substance.
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6.8.2 Ongoing Studies
The Federal Research in Progress (FEDRIP 2009) database provides additional information obtainable 
from a few ongoing studies that may fill in some o f the data needs identified in Section 6.8.1. These 
studies are summarized in Table 6-1.
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Molecular probing and identification of active 
RDX-utilizing microorganisms
NSF
Schnoor, JL University of Iowa Involvement of an endosymbiotic
Methylobacterium sp. in the biodegradation of 
explosive RDX and HMX inside poplar tree 
(Populus deltoids x Populus nigra)
NSF




The purpose o f this chapter is to describe the analytical methods that are available for detecting, 
measuring, and/or monitoring RDX, its metabolites, and other biomarkers o f exposure and effect to RDX. 
The intent is not to provide an exhaustive list o f analytical methods. Rather, the intention is to identify 
well-established methods that are used as the standard methods o f analysis. Many o f the analytical 
methods used for environmental samples are the methods approved by federal agencies and organizations 
such as EPA and the National Institute for Occupational Safety and Health (NIOSH). Other methods 
presented in this chapter are those that are approved by groups such as the Association o f Official 
Analytical Chemists (AOAC) and the American Public Health Association (APHA). Additionally, 
analytical methods are included that modify previously used methods to obtain lower detection limits 
and/or to improve accuracy (or trueness) and precision.
The most common procedures for the analytical separation o f RDX in biological and environmental 
materials are high-performance liquid chromatography (HPLC) and gas chromatography (GC). These 
methods have been paired with several types of detectors, including thermal energy analyzer (TEA), 
electrochemical detector (ED), electron capture detector (ECD), and ultraviolet (UV). The TEA is very 
selective for nitroso compounds and when paired with either HPLC or GC, gives excellent selectivity, 
recovery, and precision and high sensitivity (Fine et al. 1984; Lafleur and Morriseau 1980). The limited 
reports o f analysis o f materials using HPLC and ED indicate detection limits in the low ppb range and 
good reliability (Krull et al. 1984; Lloyd 1983). GC coupled with ECD appears to have good sensitivity 
(low ppb), accuracy, and precision (Bishop et al. 1981, 1988). UV detection has also been used with 
HPLC separation, but few data are available for comparison with other methods (Burrows and 
Brueggemann 1985; Strobel and Tontarski 1983). The data suggest that this method has very good 
accuracy and precision; however, the selectivity may not be as good as that obtained with other detectors. 
Methods based on mass spectrometry (MS) with sensitivity in the sub-ppb range have been described, but 
specific information on their reliability is limited (St. John et al. 1975; Tanner et al. 1983). MS is 
generally accepted to be highly selective. Sample preparation for RDX analytical methods is relatively 
simple, consisting o f collection o f the sample from air, water, soil, tissue, fluid, residue, or waste followed 
by homogenization if  necessary, one or two extraction/clean-up steps, and concentration of the sample.
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Analytical methods specifically used for the determination o f RDX in biological fluids and tissues are 
limited. Methods were located that discussed the analysis o f RDX in blood, tissues, urine, and hand 
swabs. The separation methods employed included high-performance liquid chromatography (HPLC) or 
gas chromatography (GC). These were combined with detection by thermal energy analyzer (TEA), 
ultraviolet (UV), electrochemical detector (ED), or electron capture detector (ECD). Both HPLC and 
high-resolution gas chromatography (HRGC) can rapidly separate RDX from other explosives, but HPLC 
has the advantage o f being run at ambient temperature, which helps prevent breakdown o f the analyte. 
Pertinent data on these methods are presented in Table 7-1.
Detection of RDX in human and animal plasma as well as human urine and cerebrospinal fluid has been 
accomplished by HPLC/TEA and HPLC/UV (U.S. Army 1981a; Fine et al. 1984; Turley and Brewster 
1987). While both methods provide relatively rapid sample turn-around times, HPLC/TEA is the most 
sensitive and selective o f the two, and requires little sample preparation (Fine et al. 1984). The older 
HPLC/UV method (U.S. Army 1981a) had the problem o f coelution o f a plasma component with the 
RDX peak. This was eradicated by clean-up on a C18 bonded-phase extraction column (Turley and 
Brewster 1987; Woody et al. 1986), but the sensitivity o f HPLC/UV was still several orders o f magnitude 
less (limit o f detection in low ppb) than that o f HPLC/TEA (limit o f detection in low ppt). Reported 
recoveries ranged from 87.7 to 101% (Turley and Brewster 1987; U.S. Army 1981a; Woody et al. 1986). 
Precision was comparable and ranged from 0.65 to 10% coefficient o f variation (CV).
A method o f analyzing feces for RDX was located (Woody et al. 1986). This method used HPLC/UV 
and required extraction o f the sample with acetonitrile and sonication. The limit o f detection was not 
reported, although based on the data presented, it was assumed to be in the low ppb range.
One method was located for analysis o f tissue samples. The method used HPLC/UV to analyze bovine 
kidney, muscle/fat, and liver samples for RDX, but it could be used to analyze human tissues (U.S. Army 
1981a). Optimal sample preparation methods varied slightly for the different tissues, as did detection 
limits and precision. In general, the detection limit was in the low ppb and recovery was high (in the 
range o f 87.7-102.9). Precision ranged from 7 to 16% CV. The primary issue with analysis of tissue 
using this method is the variation in selectivity. Minor differences in sample extraction and 
contamination from unknown sources can create interferences that drastically affect interpretation of 





Table 7-1. Analytical Methods for Determining RDX in Biological Materials












Extract with methylene 
chloride and pentane; filter; 
concentrate
HPLC/TEA 100 ng/L No data
Add NaCl/acetic acid solution HPLC/UV 
to sample; extract with 
toluene; add water; evaporate 
organic phase; combine 




Serum and urine Mix sample with internal HPLC/UV 
standard; clean up on 
C18-bonded-phase extraction 
column, eluting with 
methanol; concentrate
Add NaCl/acetic acid solution HPLC/UV 
to sample; extract with 
toluene; add water; evaporate 
organic phase; combine 
aqueous phase with 
acetonitrile-containing internal 
standard; filter
Homogenize sample; extract HPLC/UV 
with acetonitrile; concentrate; 
add internal standard and 
purified water; filter
Homogenize sample; add HPLC/UV 
NaCl/acetic acid solution; 
evaporate; redissolve in 
acetonitrile-containing internal 
standard; filter
Wipe hand with swab soaked HPLC/TEA; 






















































Table 7-1. Analytical Methods for Determining RDX in Biological Materials
Sample
Analytical detection Percent
Sample matrix Preparation method method limit recovery Reference
Hand swabs Wipe hand with swab soaked 
in ether; extract with ether; 
centrifuge to remove debris; 
decant supernatant and 
evaporate; redissolve in 
pentane; clean up on 
Amberlite XAD-7 beads, 
eluting with ethyl acetate; 
evaporate; redissolve in 













Hand swabs, Wipe hand with dry swab; HPLC/PMDE 8 pg/inj No data Lloyd 1983
standards extract with methanol/ 
potassium phosphate; directly 
inject standards
(standards)
CV = coefficient of variation; ECD = electron capture detection; GC = gas chromatography; HPLC = high­
performance liquid chromatography; HRGC = high-resolution gas chromatography; inj = injection; PMDE = pendant 
mercury drop electrode; TEA = thermal energy analyzer; TLC = thin layer chromatography; UV = ultraviolet
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The only other methods for biological matrices located were for analysis of hand swabs. These are of 
primary importance in forensics, but they could also be used to determine if  dermal exposure of workers 
has occurred. Methods that have been used for the determination o f trace amounts o f RDX on hands 
include HPLC with TEA or electrochemical detection and HRGC with TEA or ECD (Douse 1982; Fine et 
al. 1984; Lloyd 1983). Thin-layer chromatography has also been tested, but because o f the large amounts 
o f sample that are required for the analysis, it is useful only as a screening test for high concentration 
samples (Douse 1982). Separation o f the sample by HPLC and HRGC are comparable, but reported 
recovery for HRGC is low (Douse 1982). This is likely because o f decomposition o f the sample, but the 
data are not available to adequately compare the recovery o f the two methods. The nature o f the detector 
seems to be the most important factor in determining which of the reported methods is most useful for the 
analysis o f RDX in hand-swab extracts. ECD appears to be less sensitive (ng amounts) than either 
electrochemical detection using the pendant mercury drop electrode (PMDE) or TEA (pg amounts). In 
addition, in the method reported, clean-up was required to prevent matrix interference (Douse 1982). For 
both the PMDE and TEA methods, clean-up o f the sample was not required, and both methods were 
rapid, selective, and of high precision (Fine et al. 1984; Lloyd 1983).
7.2 ENVIRONMENTAL SAMPLES
A large variety o f methods have been described for the detection of RDX in environmental samples.
These primarily include HRGC combined with ECD, TEA, mass spectrometry (MS), or flame ionization 
detection (FID); HPLC combined with UV, TEA, MS, photoconductivity (PD), or electrochemical 
detection; automated multiple development high performance thin-layer chromatography (HPTLC- 
AMD); liquid chromatography (LC) with thermospray (TSP) and MS; and several stand-alone MS 
techniques. Other methods have also been proposed, including fluorescent quenching; supercritical fluid 
chromatography (SFC) with UV. Table 7-2 is a summary o f several representative methods for 
determining RDX in various environmental media.
Several methods for determining RDX in air have been investigated. Based on the limited data available, 
the two most common methods are GC/ECD and MS. The data reported are not sufficient to make 
comparisons o f sensitivity and reliability between the methods. GC/ECD, however, appears to have good 
sensitivity (low ppb), accuracy, and precision (Bishop et al. 1981, 1988). An alternate method based on 
spectrophotometry also provided similar results for accuracy and precision (±12.4% CV) and had a 



























Collect sample on 
Tenax-plus-filter tubes; 
desorb with acetonitrile
Collect sample on 
Tenax-GC; desorb with 
acetonitrile
Collect sample on 
glass-fiber filter; extract 
with ethyl acetate
Collect sample in 
sampling tube of glass- 
microfibers and silica 
gel; transfer to H2SO4 
solution and react with 
dihydroxynapthalene- 
disulfonic acid and 
water; dilute with water
Incorporate sample into IDMS 
bulb containing 
isotopically-labeled 
RDX; extract with 
benzene; transfer to 
capillary tube and 
evaporate
Inject sample directly 
into instrument
HRGC/ECD 17 |jg/m3 No data
Add internal standard 
to sample; elute from 
reverse-phase column 
with methanol/water
Dilute sample with 
methanol/acetonitrile; 






Bishop et al. 1988
No data 93-102; 98±4.4 Bishop et al. 1981
average (6­
120 pg test level)
0.5 mg/m No data (precision U.S. Army 1975 
±15%)
40 jg/m 3 95.7-97.3
Sub-ppb No data
APCI/MS/MS Sub-ppb No data
100-102 
(measured at 







St. John et al. 
1975
Tanner et al. 1983
U.S. Army 1983c
Jenkins et al. 




Table 7-2. Analytical Methods for Determining RDX in Environmental Samples
Sample Analytical




Groundwater Collect sample on 
Hayesep R solid 




dilute with methanol/ 
water





Add internal standard 




redissolve in acetone; 
filter; concentrate
Inject sample directly 
into instrument






5-7.5 |jg/L 104-121 U.S. Army 1989a
HPLC/ED =1 jg/L 57-63
well water Porapak resin; rinse 
sorbent with distilled 





Water Collect sample on





Groundwater, Extract sample with 
drinking water isoamyl acetate
HRGC/ECD
HPTLC-AMD 10 ng 





Maskarinec et al. 
1984
<0.1 pg/L 97±5 (spike level Richard and Junk 
4 Mg/L) 1986
No data (RSD Steuckart et al.
1.6-5.9% for 20- 1994 
130 ng in solution)
56-84 (spike level Hable et al. 1991 
0.15-3.0 |jg/L;
RSD 9.3-19)
70±10 (at 103- Hoffsommer and
1,400 ng/L)
HRGC/ECD 60 ng/L 85
40 mg/L No data 
=10 mg/L No data
Rosen 1972
Haas et al. 1990
Yinon and 
Laschever1982






















Air-dry, grind, and 
sieve sample; extract 
with acetonitrile in 
ultrasonic bath; add 
CaCl2; filter; elute from 
reverse-phase column 
with water/methanol
Adjust sample moisture HPLC/UV 
to 20-30%;
homogenize and sieve; 
extract with acetonitrile 
and sonication; 
centrifuge and filter; 
elute from reverse­
phase column with 
methanol/water
HPLC/UV 0.74 |jg/g 84-112
(multilaboratory
determination)
0.6 jg/g 103.7 (spike level 
0.5-200 |jg/g;
CV 0.098)
Bauer et al. 1990; 
Jenkins and Grant 
1987; Jenkins et 




Bongiovanni et al. 
1984
Air-dry sample; extract 
with acetonitrile; filter; 
evaporate; redissolve 





extract with acetone; 
filter
Homogenize sample; 
extract with acetone; 
evaporate; react with 
diphenylamine/H2SO4
Grind sample; extract 
with acetone in ultra­
sonic bath, centrifuge, 
add toluene, and dry; 
remove humic 
substances with 
calcium chloride or 
elution with ethyl 
acetate/petroleum 
ether over biobeads
Extract of soil sample 
and enzyme conjugate 
reagent added to 
immobilized RDX 
antibody; D TECHTM 
RDX test kit required
HPLC/UV 0.005 jg/g No data Lyter 1983
HRGC/ECD 75 ng/g 95






for 20-130 ng in 
solution)
Haas et al. 1990
Haas et al. 1990
Steuckart et al. 
1994


















Soil Soil samples extracted Colorimetric
with acetone; extract screening
passed through ion using spectro-
exchange resin; extract photometry
acidified and mixed 
with zinc dust, color 
developed using a 
NitriVer 3 powder pillow
Agricultural Acid hydrolysis; extract HPLC






Acid hydrolysis; extract HPLC 
with diethyl ether









Acid hydrolysis; extract HPLC 
with diethyl ether
Acid hydrolysis; extract HPLC 
with diethyl ether
Acid hydrolysis; extract HPLC 
with diethyl ether
Agricultural Acid hydrolysis; extract HPLC 









Acid hydrolysis; extract HPLC 
with diethyl ether
Acid hydrolysis; extract HPLC 
with diethyl ether
Acid hydrolysis; extract HPLC 
with diethyl ether







































90±4 (laboratory- Harvey et al. 1997 
grown; spike level 
5 pg/g dry mass)
70±3 (spike level Harvey et al. 1997 
5 pg/g dry mass)
75±18 (laboratory- Harvey et al. 1997 
grown; spike level 
5 pg/g dry mass)
68±11 (spike level Harvey et al. 1997 
5 jg/g dry mass)
103±38 (spike Harvey et al. 1997
level 5 jg/g dry
mass)
76±3 (spike level Harvey et al. 1997 
5 jg/g dry mass)
71 ±9 (spike level Harvey et al. 1997 




Harvey et al. 1997
Harvey et al. 1997
Harvey et al. 1997
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Agricultural Acid hydrolysis; extract 




No data Harvey et al. 1997
Explosive
preparations
Elute from HPLC 
column with isooctane/ 
ethanol





Dissolve sample in 




Low pg No data Fine et al. 1984
Explosives Extract sample with 
acetone; elute from 





8 pg/g No data (CV 0.8% Lloyd 1983 
of 1 ng replicates)
Explosion
debris
Extract sample in 
acetone; clean up on 
cyclohexyl column; 
eluting with methylene 
chloride/hexane; clean 
up on cyanopropyl 
column; elute with 
acetonitrile/water




Dissolve sample in 
acetonitrile; add water; 
elute from reverse­
phase column with 
methanol/water
HPLC/UV No data No data Burrows and
Brueggemann
1985
Explosives Extract with acetone; 
evaporate; redissolve 
in dichloroethane; elute 
from HPLC column with 
dichloroethane/hexane




Dissolve in acetone or 
methanol; elute from 





Low pg No data Berberich et al. 
1988
AMD = automated multiple development; APCI = atmospheric pressure chemical ionization; AOAC = Association of 
Official Analytical Chemists; CaCh = calcium chloride; CI = chemical ionization; CV = coefficient of variation;
EC = electrochemical detection; ECD = electron capture detection; ED = electrochemical detection; FID = flame 
ionization detection; GC = gas chromatography; HPLC = high-performance liquid chromatography; HPTLC = high 
performance thin-layer chromatography; HRGC = high-resolution gas chromatography; H2 SO4  = sulfuric acid;
IDMS = isotope dilution mass spectrometry; MS = mass spectrometry; PD = photoconductivity detection;
PMDE = pendant mercury drop electrode; RSD = relative standard deviation; SD = standard deviation;
TEA = thermal energy analyzer; TSP = thermospray; UV = ultraviolet detection
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1984). MS methods with sensitivity in the sub-ppb range have been described, but specific information 
on their reliability is limited. MS is generally accepted to be highly selective. O f the two MS methods 
described, isotope dilution MS (IDMS) (St. John et al. 1975) and MS/MS with atmospheric pressure 
chemical ionization (APCI) (Tanner et al. 1983), the latter (APCI/MS/MS) is the most rapid and simple to 
perform because the sample o f air containing RDX vapors is directly injected into the instrument. The 
high sensitivity and selectivity o f MS/MS allow the air sample to be injected without prior treatment or 
concentration. However, the method as presented appears to be primarily useful as a screening technique 
to determine if  more rigorous quantitative analysis is required. IDMS requires some sample preparation 
in order to incorporate the known amount o f labeled analyte in the sample containing the unknown 
amount o f RDX. IDMS has been used to measure the vapor pressure o f RDX, which is in the sub-ppb 
range.
The primary analytical methods for determining RDX in water are HPLC/UV and GC/ECD. These 
methods have been used to determine the chemical in waste-water effluents, groundwater, well water, 
drinking water, and seawater. The critical step in the analysis o f RDX by HPLC/UV is separation of the 
sample on a reverse-phase column, which provides good selectivity without risk o f thermal breakdown of 
the analyte (Jenkins et al. 1986; U.S. Army 1983c, 1985c). The method is simple, quick, and 
reproducible. Sensitivity is in the low- to mid-ppb range, with good recovery and excellent precision (2­
7.6% CV). The use of HPLC in combination with photodiode-array detection improves the reliability of 
peak identification (Emmrich et al. 1993). The HPLC-photodiode-array detection method can provide a 
detection limit o f 0.09 ppb for RDX in aqueous samples concentrated 1,000-fold by liquid-liquid 
extraction or by solid phase extraction (C-18) (Levsen et al. 1993). The extraction efficiency o f RDX 
from water to acetonitrile can be improved by using salting out agents (U.S. Army 1991). The sensitivity 
and selectivity o f RDX detection was improved by combining a solid sorbent cartridge to concentrate 
RDX from water and HPLC-tandem ultraviolet and photoconductivity detection (HPLC/UV/PD) (U.S. 
Army 1989a). The system consisted o f a UV absorbance detector set to 254 nm and a photoconductivity 
detector equipped with a zinc photoionization source. The serial use o f the two detectors effectively 
differentiated RDX from other explosives and from contaminants in the solid sorbent cartridge. In 
addition, the sensitivity was improved by a factor of about 3. To prevent negative baseline drift and 
random spikes in the PD, only highly purified water must be used, and the effluent must be exhaustively 
degassed (U.S. Army 1989a). Automated multiple development high performance thin-layer 
chromatography (HPTLC-AMD) has also been used to analyze water samples. Liquid-liquid extraction 
using dichloromethane was used to prepare the samples. A detection limit o f 10 ng was obtained 
(Steuckart et al. 1994).
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For analysis by GC/ECD, water samples may be solvent-extracted (Belkin et al. 1985; Haas et al. 1990; 
Hable et al. 1991; Hoffsommer and Rosen 1972) or collected on a solid sorbent (Richard and Junk 1986). 
Solvent extraction is most commonly used, but solid sorbent collection has the advantages o f being faster 
and cheaper than solvent extraction (Richard and Junk 1986). Sensitivity for the GC/ECD methods 
ranges from low to mid ppt, and the recovery and precision are acceptable. Use o f the solid sorbent 
improved recovery and precision compared to solvent-extraction methods (Richard and Junk 1986). 
Substitution of ED, using a gold-mercury electrode, improved selectivity compared to ECD detection. 
Sensitivity was not as good, but it remained within an order o f magnitude o f that found with GC/ECD 
(Maskarinec et al. 1984). Recovery and precision were comparable. A more recent study indicated that 
GC/ECD is not useful in the determination o f RDX in water samples, as RDX may undergo thermal 
degradation (Steuckart et al. 1994).
Other methods that have been used to determine RDX in water are MS, fluorescence quenching, COD, 
and total organic carbon (TOC) (Jian and Seitz 1990; Roth and Murphy 1978; Yinon and Laschever 
1982). COD and TOC (Roth and Murphy 1978) are well-established standard methods for determining 
organic pollution in water, but they are not selective for RDX. MS with chemical ionization (CI) permits 
direct injection o f the water sample into the analytical instrument, but the sensitivity is substantially less 
than with the HPLC/UV and GC/ECD methods (Yinon and Laschever 1982). Fluorescence quenching 
also lacks sensitivity, and the method is still under development. However, it does permit in situ 
measurement o f samples, and further improvements in the technology may make it a desirable field 
method (Jian and Seitz 1990). Continuous flow immunosensor (CFI) has been found to produce results 
comparable to HPLC in detecting RDX in groundwater samples (Bart et al. 1997). CFI utilizes a small 
column o f plastic beads containing immobilized antibodies with the explosive and a fluorescent dye- 
labeled explosive analog. When the explosive present in the sample displaces the dye-labeled analog in 
the column, the explosive is detected with a detection limit o f approximately 20 ppb (Bart et al. 1997).
The methods that were located for detection o f RDX in soil are based primarily on HPLC/UV analysis 
(Bauer et al. 1990; Bongiovanni et al. 1984; Jenkins and Grant 1987; Jenkins et al. 1989; Lyter 1983; U.S. 
Army 1987b). All o f the methods involve extraction of the sample with acetonitrile, separation using a 
reverse-phase column, and in most cases, elution with acetonitrile/water. Sensitivity for these methods is 
in the sub- to low-ppm range with good recovery (84-112%) and precision (2.3-24%  CV). A variation of 
the method involves the soil sample being extracted with acetonitrile in an ultrasonic bath (Jenkins et al. 
1989; Steuckart et al. 1994). Soil samples can be ground into mortar and extracted with acetone in an
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ultrasonic bath maintained at ambient temperature, centrifuged, added to toluene, and dried over 
anhydrous sodium sulfate. Steuckart et al. (1994) removed humic substances with either a calcium 
chloride solution or elution with ethyl acetate/petroleum ether over biobeads. The samples were analyzed 
by HPTLC-AMD with a detection limit o f 10 ng (Steuckart et al. 1994).
Other analytical methods are based on GC/ECD and spectrophotometry (Haas et al. 1990). In both of 
these methods, the samples were extracted with acetone. The detection limit for spectrophotometric 
determination of RDX in soil was in the low-ppm range, while the detection limit for GC/ECD was in the 
mid-ppb range. No information on accuracy and precision were given for the spectrophotometric method; 
however, the accuracy o f GC/ECD was comparable to HPLC/UV.
Methods are available for identification o f RDX in agricultural crops. Harvey et al. (1997) utilized HPLC 
to determine RDX concentrations. The samples underwent acid hydrolysis with hydrochloric acid and 
extraction with diethyl ether prior to analysis by HPLC. The detection limits and percent recoveries for a 
variety o f crops are listed in Table 7-2 (Harvey et al. 1997). Larson et al. (1999b) used an 18-hour cooled 
sonication extraction technique using acetonitrile to extract RDX from plant tissues that had been exposed 
to contaminated irritation water. The samples were then analyzed with HPLC/UV.
Several methods have been used to detect and measure RDX in explosive materials and debris from 
explosions. The most common separation procedure is HPLC, but HRGC has also been used. These 
methods have been paired with several types of detectors, including TEA, MS, electrochemical detection, 
and UV. The TEA is very selective for nitroso compounds and when paired with either HPLC or HRGC, 
gives excellent selectivity, recovery, and precision and high sensitivity (Fine et al. 1984; Lafleur and 
Morriseau 1980). GC/MS has been used for confirmation o f RDX in samples o f explosive materials 
(Burrows and Brueggemann 1985), and HPLC/MS and MS/MS have been investigated as screening 
methods for explosives (McLucky et al. 1985; Vouros et al. 1977). A sophisticated method linking 
HPLC, thermospray (TSP), and MS or MS/MS (with both positive and negative chemical ionization) has 
also been proposed as an extremely sensitive (low pg range) and selective method for detecting RDX in 
explosive residues (Berberich et al. 1988; Verweij et al. 1993). However, there is no evidence that any 
MS-based method is currently used to quantitatively measure RDX in explosives or explosion debris. A 
relatively new method being investigated uses supercritical fluid extraction chromatography (SFC) to 
separate RDX from other analytes and contaminants followed by detection by UV/FID (Griest et al.
1989). The method is slower but more selective than HPLC/UV. The precision for standard solutions
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was excellent. However, more work is needed to improve the mobile phase and column packing material 
before samples in complex matrices can be analyzed.
7.3 ADEQUACY OF THE DATABASE
Section 104(i)(5) of CERCLA, as amended, directs the Administrator o f ATSDR (in consultation with the 
Administrator o f EPA and agencies and programs o f the Public Health Service) to assess whether 
adequate information on the health effects of RDX is available. Where adequate information is not 
available, ATSDR, in conjunction with NTP, is required to ensure the initiation of a program o f research 
designed to determine the health effects (and techniques for developing methods to determine such health 
effects) o f RDX.
The following categories o f possible data needs have been identified by a joint team o f scientists from 
ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if  met would 
reduce the uncertainties o f human health assessment. This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled. In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed.
7.3.1 Identification of Data Needs
Methods for Determining Biomarkers of Exposure and Effect.
Exposure. Few methods exist for monitoring exposure to RDX. Methods have been reported for 
detection o f the analyte in plasma (Fine et al. 1984; Turley and Brewster 1987; U.S. Army 1981a; Woody 
et al. 1986), urine (Turley and Brewster 1987; Woody et al. 1986), cerebrospinal fluid (Woody et al. 
1986), feces (Woody et al. 1986), and tissues (U.S. Army 1981a), as well as on hands (Douse 1982; Fine 
et al. 1984; Lloyd 1983). The available methods can detect levels in urine and plasma from exposure to 
concentrations below those that would be encountered in most manufacturing situations. In general, these 
methods are reliable and accurate; however, the development o f the LC-MS methodology could be useful 
as a definitive method to validate the specificity o f the HPLC methods. The data are insufficient to 
permit correlation o f RDX levels in the urine or blood with exposure levels.
Effect. There are no known sensitive biomarkers of effect for RDX. Therefore, no methods 
recommendations can be made for this chemical.
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Methods for Determining Parent Compounds and Degradation Products in Environmental 
Media. Methods exist to detect and quantify RDX in air (Bishop et al. 1988; Eminger and Vejrostova 
1984; St. John et al. 1975; Tanner et al. 1983; U.S. Army 1974), water (Haas et al. 1990; Hable et al.
1991; Jian and Seitz 1990; Maskarinec et al. 1984; Richard and Junk 1986; Steuckart et al. 1994; U.S. 
Army 1983c, 1985c, 1989a; Yinon and Laschever 1982), soil (Bongiovanni et al. 1984; Haas et al. 1990; 
Steuckart et al. 1994; U.S. Army 1987b), agricultural crops (Harvey et al. 1997; Larson et al. 1999b), 
explosive materials (Burrows and Brueggemann 1985; Fine et al. 1984; Lafleur and Morriseau 1980; 
Lloyd 1983), and debris from explosions (Fine et al. 1984; Strobel and Tontarski 1983). These methods 
are relatively sensitive and reliable and can be used to detect levels o f the compound in the environment 
that cause known adverse health effects. There are some problems involving reduced sensitivity and 
selectivity with all o f the commonly used methods. Several proposed improvements in current methods, 
such as combining various analytical methods to increase selectivity, sensitivity, reliability, and/or 
accuracy (Berberich et al. 1988; Krull et al. 1984; U.S. Army 1989a), and investigations o f new methods 
(Griest et al. 1989; Jian and Seitz 1990) will be useful in forensics and in monitoring environmental 
contamination from manufacture and disposal o f RDX.
7.3.2 Ongoing Studies





Table 7-3. Ongoing Studies on RDX
Investigator Affiliation Research description Sponsor
Ram, M Triton Systems, 
Inc. Auburn 
University
In situ near real-time detection of RDX in soil U.S. Army
Li, J University of 
Florida
Enhanced quadrupole resonance technology 
for explosive detection
NSF
Indacochea, JE University of 
Illinois at Chicago
Development of a nanostructured-based 





Ultrasensitive, real-time explosives sensor NSF
NSF = National Science Foundation 
Sources: DOD 2009; EPA 2008b; FEDRIP 2009
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8. REGULATIONS, ADVISORIES, AND GUIDELINES
MRLs are substance specific estimates, which are intended to serve as screening levels, are used by 
ATSDR health assessors and other responders to identify contaminants and potential health effects that 
may be o f concern at hazardous waste sites.
The international and national regulations, advisories, and guidelines regarding RDX in air, water, and 
other media are summarized in Table 8-1.
ATSDR has derived an acute-duration oral MRL o f 0.2 mg/kg/day based on a NOAEL o f 8.5 mg/kg/day 
for neurotoxicity in rats administered RDX via gavage 7 days/week for 14 days (U.S. Army 2006b).
Using a PBPK model, an internal dose metric (peak brain concentration) was simulated and a HED of 
6.4547 mg/kg/day was estimated. An uncertainty factor o f 30 (3 for animal to human extrapolation with 
dosimetric adjustment and 10 for human variability) was applied to the NOAELH ED .
ATSDR has derived an intermediate-duration oral MRL o f 0.1 mg/kg/day based on a BMDL10 for 
neurological effects in rats administered RDX via gavage 7 days/week for 90 days (U.S. Army 2006b). 
The BMDL10 was estimated using an internal dose metric to simulate peak brain concentration; a HED of 
the BMDL10 was estimated using a PBPK model. The BMDLHed o f 4.1308 mg/kg/day was divided by an 
uncertainty factor of 30 (3 for animal to human extrapolation with dosimetric adjustments and 10 for 
human variability).
ATSDR has derived a chronic-duration oral MRL o f 0.1 mg/kg/day based on a NOAEL o f 8 mg/kg/day 
for neurotoxicity in rats exposed to dietary RDX for 2 years (U.S. Army 1983a). Using a PBPK model, 
an internal dose metric (peak brain concentration) was simulated and a HED o f 4.223 mg/kg/day was 
estimated. An uncertainty factor o f 30 (3 for animal to human extrapolation with dosimetric adjustment 
and 10 for human variability) was applied to the NOAELH ED .
EPA (IRIS 2009) has derived an oral reference dose (RfD) o f 0.003 mg/kg/day based on a NOAEL
0.3 mg/kg/day and LOAEL o f 1.5 mg/kg/day for inflammation o f the prostate in rats exposed to RDX in 
the diet for 2 years (U.S. Army 1983a). An uncertainty factor o f 100 (10 for extrapolation from animals 
to humans and 10 to protect against unusually susceptible individuals) was applied to the NOAEL.
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Table 8-1. Regulations and Guidelines Applicable to RDX



















Air quality guidelines 




TLV (8-hour TWA)a 
STEL (15-minute TWA) 








PEL (8-hour TWA) for general industry Vacatedb
Drinking water standards and health 
advisories
1-day health advisory for a 10-kg 0.1 mg/L
child




10-4 Cancer risk 0.03 mg/L
National primary drinking water No
standards
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Table 8-1. Regulations and Guidelines Applicable to RDX
Agency Description Information Reference
NATIONAL (cont.)
d. Other














Designated CERCLA hazardous 
substance
No EPA 2009c 
40 CFR 302.4
Effective date of toxic chemical 
release reporting
No EPA 2009d 
40 CFR 372.65











NTP Carcinogenicity classification No NTP 2005
aSkin: refers to the potential significant contribution to the overall exposure by the cutaneous route. 
bOn January 19, 1989, OSHA published its final rule on Air Contaminants, which amended 29 CFR 1910.1000 by 
lowering 212 of OSHA's existing PELs for toxic substances and setting PELs for 164 toxic substances that had been 
previously unregulated. A PEL value of 1.5 mg/m3 was adopted for RDX in March 1989. However, on July 7, 1992, 
the Eleventh Circuit Court of Appeals issued a decision in AFL-CIO vs. OSHA that vacated these revised standards. 
cThe EAFUS list of substances contains ingredients added directly to food that FDA has either approved as food 
additives or listed or affirmed as GRAS. 
dA4: not classifiable as a human carcinogen.
eGroup C: possible human carcinogen, based on hepatocellular adenomas and carcinomas in female B6C3F1 mice.
ACGIH = American Conference of Governmental Industrial Hygienists; AEGL = acute exposure guideline levels; 
AIHA = American Industrial Hygiene Association; CERCLA = Comprehensive Environmental Response, 
Compensation, and Liability Act; CFR = Code of Federal Regulations; DWEL = drinking water equivalent level; 
EAFUS = Everything Added to Food in the United States; EPA = Environmental Protection Agency;
ERPG = emergency response planning guidelines; FDA = Food and Drug Administration; GRAS = Generally 
Recognized As Safe; IARC = International Agency for Research on Cancer; IDLH = immediately dangerous to life or 
health; IRIS = Integrated Risk Information System; NIOSH = National Institute for Occupational Safety and Health; 
NTP = National Toxicology Program; OSHA = Occupational Safety and Health Administration; PEL = permissible 
exposure limit; REL = recommended exposure limit; RfC = inhalation reference concentration; RfD = oral reference 
dose; STEL = short-term expsoure limit; TLV = threshold limit values; TSCA = Toxic Substances Control Act;
TWA = time-weighted average; USC = United States Code; WHO = World Health Organization
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Absorption— The taking up o f liquids by solids, or o f gases by solids or liquids.
Acute Exposure— Exposure to a chemical for a duration o f 14 days or less, as specified in the 
Toxicological Profiles.
Adsorption— The adhesion in an extremely thin layer o f molecules (as o f gases, solutes, or liquids) to the 
surfaces o f solid bodies or liquids with which they are in contact.
Adsorption Coefficient (Koc)— The ratio o f the amount o f a chemical adsorbed per unit weight of 
organic carbon in the soil or sediment to the concentration of the chemical in solution at equilibrium.
Adsorption Ratio (Kd)— The amount o f a chemical adsorbed by sediment or soil (i.e., the solid phase) 
divided by the amount o f chemical in the solution phase, which is in equilibrium with the solid phase, at a 
fixed solid/solution ratio. It is generally expressed in micrograms o f chemical sorbed per gram o f soil or 
sediment.
Benchmark Dose (BMD)— Usually defined as the lower confidence limit on the dose that produces a 
specified magnitude of changes in a specified adverse response. For example, a BMD10 would be the 
dose at the 95% lower confidence limit on a 10% response, and the benchmark response (BMR) would be 
10%. The BMD is determined by modeling the dose response curve in the region o f the dose response 
relationship where biologically observable data are feasible.
Benchmark Dose Model— A statistical dose-response model applied to either experimental toxicological 
or epidemiological data to calculate a BMD.
Bioconcentration F actor (BCF)— The quotient o f the concentration o f a chemical in aquatic organisms 
at a specific time or during a discrete time period of exposure divided by the concentration in the 
surrounding water at the same time or during the same period.
Biomarkers— Broadly defined as indicators signaling events in biologic systems or samples. They have 
been classified as markers o f exposure, markers o f effect, and markers o f susceptibility.
Cancer Effect Level (CEL)— The lowest dose o f chemical in a study, or group o f studies, that produces 
significant increases in the incidence o f cancer (or tumors) between the exposed population and its 
appropriate control.
Carcinogen— A chemical capable o f inducing cancer.
Case-Control Study—A type o f epidemiological study that examines the relationship between a 
particular outcome (disease or condition) and a variety o f potential causative agents (such as toxic 
chemicals). In a case-controlled study, a group o f people with a specified and well-defined outcome is 
identified and compared to a similar group of people without outcome.
Case Report— Describes a single individual with a particular disease or exposure. These may suggest 
some potential topics for scientific research, but are not actual research studies.
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Case Series— Describes the experience o f a small number o f individuals with the same disease or 
exposure. These may suggest potential topics for scientific research, but are not actual research studies.
Ceiling Value— A concentration o f a substance that should not be exceeded, even instantaneously.
Chronic Exposure— Exposure to a chemical for 365 days or more, as specified in the Toxicological 
Profiles.
Cohort Study— A type o f epidemiological study o f a specific group or groups o f people who have had a 
common insult (e.g., exposure to an agent suspected o f causing disease or a common disease) and are 
followed forward from exposure to outcome. At least one exposed group is compared to one unexposed 
group.
Cross-sectional Study— A type o f epidemiological study o f a group or groups o f people that examines 
the relationship between exposure and outcome to a chemical or to chemicals at one point in time.
Data Needs— Substance-specific informational needs that if  met would reduce the uncertainties o f human 
health assessment.
Developmental Toxicity— The occurrence o f adverse effects on the developing organism that may result 
from exposure to a chemical prior to conception (either parent), during prenatal development, or 
postnatally to the time o f sexual maturation. Adverse developmental effects may be detected at any point 
in the life span o f the organism.
Dose-Response Relationship— The quantitative relationship between the amount o f exposure to a 
toxicant and the incidence o f the adverse effects.
Embryotoxicity and Fetotoxicity—Any toxic effect on the conceptus as a result o f prenatal exposure to 
a chemical; the distinguishing feature between the two terms is the stage o f development during which the 
insult occurs. The terms, as used here, include malformations and variations, altered growth, and in utero 
death.
Environmental Protection Agency (EPA) Health Advisory— An estimate o f acceptable drinking water 
levels for a chemical substance based on health effects information. A health advisory is not a legally 
enforceable federal standard, but serves as technical guidance to assist federal, state, and local officials.
Epidemiology— Refers to the investigation o f factors that determine the frequency and distribution of 
disease or other health-related conditions within a defined human population during a specified period.
Genotoxicity— A specific adverse effect on the genome o f living cells that, upon the duplication of 
affected cells, can be expressed as a mutagenic, clastogenic, or carcinogenic event because o f specific 
alteration o f the molecular structure o f the genome.
Half-life— A measure of rate for the time required to eliminate one half o f a quantity o f a chemical from 
the body or environmental media.
Immediately Dangerous to Life or Health (IDLH)— The maximum environmental concentration o f a 




Immunologic Toxicity— The occurrence o f adverse effects on the immune system that may result from 
exposure to environmental agents such as chemicals.
Immunological Effects— Functional changes in the immune response.
Incidence— The ratio o f individuals in a population who develop a specified condition to the total 
number o f individuals in that population who could have developed that condition in a specified time 
period.
Intermediate Exposure— Exposure to a chemical for a duration o f 15-364 days, as specified in the 
Toxicological Profiles.
In  Vitro— Isolated from the living organism and artificially maintained, as in a test tube.
In  Vivo— Occurring within the living organism.
Lethal Concentration^ )  (LClo)— The lowest concentration o f a chemical in air that has been reported 
to have caused death in humans or animals.
Lethal Concentration^ )  (LC50)— A calculated concentration of a chemical in air to which exposure for 
a specific length o f time is expected to cause death in 50% o f a defined experimental animal population.
Lethal Dose(LO) (LDLo)— The lowest dose o f a chemical introduced by a route other than inhalation that 
has been reported to have caused death in humans or animals.
Lethal Dose(50) (LD50)— The dose o f a chemical that has been calculated to cause death in 50% o f a 
defined experimental animal population.
Lethal Time(50) (LT50)— A calculated period o f time within which a specific concentration o f a chemical 
is expected to cause death in 50% of a defined experimental animal population.
Lowest-Observed-Adverse-Effect Level (LOAEL)— The lowest exposure level o f chemical in a study, 
or group of studies, that produces statistically or biologically significant increases in frequency or severity 
o f adverse effects between the exposed population and its appropriate control.
Lymphoreticular Effects— Represent morphological effects involving lymphatic tissues such as the 
lymph nodes, spleen, and thymus.
Malformations— Permanent structural changes that may adversely affect survival, development, or 
function.
Minimal Risk Level (MRL)— An estimate o f daily human exposure to a hazardous substance that is 
likely to be without an appreciable risk o f adverse noncancer health effects over a specified route and 
duration o f exposure.
Modifying F actor (MF)— A value (greater than zero) that is applied to the derivation o f a Minimal Risk 
Level (MRL) to reflect additional concerns about the database that are not covered by the uncertainty 
factors. The default value for a MF is 1.





Mortality— Death; mortality rate is a measure o f the number o f deaths in a population during a specified 
interval o f time.
Mutagen— A substance that causes mutations. A mutation is a change in the DNA sequence o f a cell’s 
DNA. Mutations can lead to birth defects, miscarriages, or cancer.
Necropsy— The gross examination of the organs and tissues o f a dead body to determine the cause of 
death or pathological conditions.
Neurotoxicity— The occurrence o f adverse effects on the nervous system following exposure to a 
chemical.
No-Observed-Adverse-Effect Level (NOAEL)— The dose o f a chemical at which there were no 
statistically or biologically significant increases in frequency or severity o f adverse effects seen between 
the exposed population and its appropriate control. Effects may be produced at this dose, but they are not 
considered to be adverse.
Octanol-Water Partition Coefficient (Kow)— The equilibrium ratio o f the concentrations o f a chemical 
in «-octanol and water, in dilute solution.
Odds Ratio (OR)—A means o f measuring the association between an exposure (such as toxic substances 
and a disease or condition) that represents the best estimate o f relative risk (risk as a ratio o f the incidence 
among subjects exposed to a particular risk factor divided by the incidence among subjects who were not 
exposed to the risk factor). An OR o f >1 is considered to indicate greater risk o f disease in the exposed 
group compared to the unexposed group.
Organophosphate or Organophosphorus Compound—A phosphorus-containing organic compound 
and especially a pesticide that acts by inhibiting cholinesterase.
Permissible Exposure Limit (PEL)— An Occupational Safety and Health Administration (OSHA) 
allowable exposure level in workplace air averaged over an 8-hour shift o f a 40-hour workweek.
Pesticide— General classification of chemicals specifically developed and produced for use in the control 
o f agricultural and public health pests.
Pharmacokinetics— The dynamic behavior o f a material in the body, used to predict the fate 
(disposition) o f an exogenous substance in an organism. Utilizing computational techniques, it provides 
the means of studying the absorption, distribution, metabolism, and excretion o f chemicals by the body.
Pharmacokinetic Model— A set o f equations that can be used to describe the time course o f a parent 
chemical or metabolite in an animal system. There are two types o f pharmacokinetic models: data-based 
and physiologically-based. A data-based model divides the animal system into a series of compartments, 
which, in general, do not represent real, identifiable anatomic regions o f the body, whereas the 
physiologically-based model compartments represent real anatomic regions o f the body.
Physiologically Based Pharmacodynamic (PBPD) Model— A type o f physiologically based dose- 
response model that quantitatively describes the relationship between target tissue dose and toxic end 
points. These models advance the importance o f physiologically based models in that they clearly 




Physiologically Based Pharmacokinetic (PBPK) Model— Comprised o f a series o f compartments 
representing organs or tissue groups with realistic weights and blood flows. These models require a 
variety o f physiological information: tissue volumes, blood flow rates to tissues, cardiac output, alveolar 
ventilation rates, and possibly membrane permeabilities. The models also utilize biochemical 
information, such as air/blood partition coefficients, and metabolic parameters. PBPK models are also 
called biologically based tissue dosimetry models.
Prevalence— The number o f cases o f a disease or condition in a population at one point in time.
Prospective Study— A type o f cohort study in which the pertinent observations are made on events 
occurring after the start o f the study. A group is followed over time.
qi *— The upper-bound estimate o f the low-dose slope o f the dose-response curve as determined by the 
multistage procedure. The qi* can be used to calculate an estimate o f carcinogenic potency, the 
incremental excess cancer risk per unit o f exposure (usually ^g/L for water, mg/kg/day for food, and 
^g/m3 for air).
Recommended Exposure Limit (REL)— A National Institute for Occupational Safety and Health 
(NIOSH) time-weighted average (TWA) concentration for up to a 10-hour workday during a 40-hour 
workweek.
Reference Concentration (RfC)— An estimate (with uncertainty spanning perhaps an order o f 
magnitude) o f a continuous inhalation exposure to the human population (including sensitive subgroups) 
that is likely to be without an appreciable risk o f deleterious noncancer health effects during a lifetime. 
The inhalation reference concentration is for continuous inhalation exposures and is appropriately 
expressed in units o f mg/m3 or ppm.
Reference Dose (RfD)— An estimate (with uncertainty spanning perhaps an order o f magnitude) o f the 
daily exposure of the human population to a potential hazard that is likely to be without risk o f deleterious 
effects during a lifetime. The RfD is operationally derived from the no-observed-adverse-effect level 
(NOAEL, from animal and human studies) by a consistent application of uncertainty factors that reflect 
various types o f data used to estimate RfDs and an additional modifying factor, which is based on a 
professional judgment o f the entire database on the chemical. The RfDs are not applicable to 
nonthreshold effects such as cancer.
Reportable Quantity (RQ)— The quantity o f a hazardous substance that is considered reportable under 
the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA). Reportable 
quantities are (1) 1 pound or greater or (2) for selected substances, an amount established by regulation 
either under CERCLA or under Section 311 o f the Clean W ater Act. Quantities are measured over a 
24-hour period.
Reproductive Toxicity— The occurrence o f adverse effects on the reproductive system that may result 
from exposure to a chemical. The toxicity may be directed to the reproductive organs and/or the related 
endocrine system. The manifestation o f such toxicity may be noted as alterations in sexual behavior, 
fertility, pregnancy outcomes, or modifications in other functions that are dependent on the integrity of 
this system.
RDX 172
Retrospective Study—A type o f cohort study based on a group o f persons known to have been exposed 
at some time in the past. Data are collected from routinely recorded events, up to the time the study is 
undertaken. Retrospective studies are limited to causal factors that can be ascertained from existing 
records and/or examining survivors o f the cohort.
Risk— The possibility or chance that some adverse effect will result from a given exposure to a chemical.
Risk Factor— An aspect o f personal behavior or lifestyle, an environmental exposure, or an inborn or 
inherited characteristic that is associated with an increased occurrence of disease or other health-related 
event or condition.
Risk Ratio— The ratio o f the risk among persons with specific risk factors compared to the risk among 
persons without risk factors. A risk ratio >1 indicates greater risk o f disease in the exposed group 
compared to the unexposed group.
Short-Term Exposure Limit (STEL)— The American Conference o f Governmental Industrial 
Hygienists (ACGIH) maximum concentration to which workers can be exposed for up to 15 minutes 
continually. No more than four excursions are allowed per day, and there must be at least 60 minutes 
between exposure periods. The daily Threshold Limit Value-Time Weighted Average (TLV-TWA) may 
not be exceeded.
Standardized Mortality Ratio (SMR)— A ratio of the observed number o f deaths and the expected 
number o f deaths in a specific standard population.
Target Organ Toxicity— This term covers a broad range o f adverse effects on target organs or 
physiological systems (e.g., renal, cardiovascular) extending from those arising through a single limited 
exposure to those assumed over a lifetime o f exposure to a chemical.
Teratogen— A chemical that causes structural defects that affect the development o f an organism.
Threshold Limit Value (TLV)— An American Conference o f Governmental Industrial Hygienists 
(ACGIH) concentration of a substance to which most workers can be exposed without adverse effect.
The TLV may be expressed as a Time Weighted Average (TWA), as a Short-Term Exposure Limit 
(STEL), or as a ceiling limit (CL).
Time-Weighted Average (TWA)— An allowable exposure concentration averaged over a normal 8-hour 
workday or 40-hour workweek.
Toxic Dose(50) (TD50)— A calculated dose of a chemical, introduced by a route other than inhalation, 
which is expected to cause a specific toxic effect in 50% o f a defined experimental animal population.
Toxicokinetic— The absorption, distribution, and elimination o f toxic compounds in the living organism.
10. GLOSSARY
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Uncertainty Factor (UF)— A factor used in operationally deriving the Minimal Risk Level (MRL) or 
Reference Dose (RfD) or Reference Concentration (RfC) from experimental data. UFs are intended to 
account for (1) the variation in sensitivity among the members o f the human population, (2) the 
uncertainty in extrapolating animal data to the case of human, (3) the uncertainty in extrapolating from 
data obtained in a study that is o f less than lifetime exposure, and (4) the uncertainty in using lowest- 
observed-adverse-effect level (LOAEL) data rather than no-observed-adverse-effect level (NOAEL) data. 
A default for each individual UF is 10; if  complete certainty in data exists, a value o f 1 can be used; 
however, a reduced UF o f 3 may be used on a case-by-case basis, 3 being the approximate logarithmic 
average o f 10 and 1.
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The Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) [42 U.S.C. 
9601 et seq.], as amended by the Superfund Amendments and Reauthorization Act (SARA) [Pub. L. 99­
499], requires that the Agency for Toxic Substances and Disease Registry (ATSDR) develop jointly with 
the U.S. Environmental Protection Agency (EPA), in order o f priority, a list o f hazardous substances most 
commonly found at facilities on the CERCLA National Priorities List (NPL); prepare toxicological 
profiles for each substance included on the priority list o f hazardous substances; and assure the initiation 
o f a research program to fill identified data needs associated with the substances.
The toxicological profiles include an examination, summary, and interpretation o f available toxicological 
information and epidemiologic evaluations o f a hazardous substance. During the development o f 
toxicological profiles, Minimal Risk Levels (MRLs) are derived when reliable and sufficient data exist to 
identify the target organ(s) o f effect or the most sensitive health effect(s) for a specific duration for a 
given route of exposure. An MRL is an estimate o f the daily human exposure to a hazardous substance 
that is likely to be without appreciable risk o f adverse noncancer health effects over a specified duration 
o f exposure. MRLs are based on noncancer health effects only and are not based on a consideration of 
cancer effects. These substance-specific estimates, which are intended to serve as screening levels, are 
used by ATSDR health assessors to identify contaminants and potential health effects that may be of 
concern at hazardous waste sites. It is important to note that MRLs are not intended to define clean-up or 
action levels.
MRLs are derived for hazardous substances using the no-observed-adverse-effect level/uncertainty factor 
approach. They are below levels that might cause adverse health effects in the people most sensitive to 
such chemical-induced effects. MRLs are derived for acute (1-14 days), intermediate (15-364 days), and 
chronic (365 days and longer) durations and for the oral and inhalation routes o f exposure. Currently, 
MRLs for the dermal route o f exposure are not derived because ATSDR has not yet identified a method 
suitable for this route o f exposure. MRLs are generally based on the most sensitive chemical-induced end 
point considered to be o f relevance to humans. Serious health effects (such as irreparable damage to the 
liver or kidneys, or birth defects) are not used as a basis for establishing MRLs. Exposure to a level 
above the MRL does not mean that adverse health effects will occur.
APPENDIX A. ATSDR MINIMAL RISK LEVELS AND WORKSHEETS
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MRLs are intended only to serve as a screening tool to help public health professionals decide where to 
look more closely. They may also be viewed as a mechanism to identify those hazardous waste sites that 
are not expected to cause adverse health effects. Most MRLs contain a degree o f uncertainty because of 
the lack o f precise toxicological information on the people who might be most sensitive (e.g., infants, 
elderly, nutritionally or immunologically compromised) to the effects o f hazardous substances. ATSDR 
uses a conservative (i.e., protective) approach to address this uncertainty consistent with the public health 
principle of prevention. Although human data are preferred, MRLs often must be based on animal studies 
because relevant human studies are lacking. In the absence o f evidence to the contrary, ATSDR assumes 
that humans are more sensitive to the effects o f hazardous substance than animals and that certain persons 
may be particularly sensitive. Thus, the resulting MRL may be as much as 100-fold below levels that 
have been shown to be nontoxic in laboratory animals.
Proposed MRLs undergo a rigorous review process: Health Effects/MRL Workgroup reviews within the 
Division o f Toxicology and Human Health Sciences (proposed), expert panel peer reviews, and agency- 
wide MRL Workgroup reviews, with participation from other federal agencies and comments from the 
public. They are subject to change as new information becomes available concomitant with updating the 
toxicological profiles. Thus, MRLs in the most recent toxicological profiles supersede previously 
published levels. For additional information regarding MRLs, please contact the Division o f Toxicology 
and Human Health Sciences (proposed), Agency for Toxic Substances and Disease Registry, 1600 Clifton 
















Final Post-Public Comment 
[ ] Inhalation [X] Oral 
[X] Acute [ ] Intermediate [ ] Chronic 
22 
Rat
Minimal Risk Level: 0.2 [X] mg/kg/day [ ] ppm
Reference: U.S. Army. 2006. Toxicology study no. 85-XC-5131-03. Subchronic oral toxicity o f RDX 
in rats. Aberdeen Proving Ground, MD: U.S. Army Center for Health Promotion and Preventive 
Medicine.
Experimental design: Groups o f six male and six female Sprague-Dawley rats were administered via 
gavage 0, 2.125, 4.25, 8.5, 17.00, 25.50, 34.00, or 42.5 mg/kg/day as a suspension o f RDX/1% methyl- 
cellulose/0.2% Tween 80 in distilled water 7 days/week for 14 days. Rats were monitored daily for toxic 
signs and morbidity. Body weights and feed consumption were measured on days 0, 1, 3, 7, and 14. 
Additional parameters used to assess toxicity included clinical chemistry (alkaline phosphatase, alanine 
aminotransferase, aspartate aminotransferase, blood urea nitrogen, calcium, sodium, potassium, chlorine, 
cholesterol, creatinine kinase, creatinine, glucose, lactate dehydrogenase, total bilirubin, total protein, 
triglycerides) and hematology (hemoglobin, hematocrit, erythrocytes, mean cell hemoglobin 
concentration, mean cell volume, mean cell hemoglobin, red blood cell distribution width, total and 
differential leukocytes, platelets, and mean platelet volume) values, organ weights (brain, heart, liver, 
kidneys, spleen, adrenals, thymus, epididymides, uterus, testes, ovaries), and gross necropsies.
Effect noted in study and corresponding doses: A significant increase in early deaths was observed at 
>25.5 mg/kg/day. Tremors and convulsions were observed in rats exposed to >17 mg/kg/day. In the 
males exposed to >17 mg/kg/day, blood stains around the mouth and nose and low arousal were also 
observed. Increased arousal, blood around the mouth and nose, barbering, and lacrimation were observed 
in females exposed to >17 mg/kg/day. No signs o f neurological alterations were observed in rats exposed 
to <8.5 mg/kg/day. Significant decreases in body weight were observed in male rats exposed to 
>17 mg/kg/day on days 1 and 7, but there were no significant alterations in male body weight at 
termination. In female rats, significant decreases in body weight gain were observed at >34 mg/kg/day on 
day 1 and in the 8.5 mg/kg/day group on day 14; however, the magnitude o f the decreased body weight 
was less than 10% and no significant alterations were observed at higher dose levels. Significant 
decreases in food consumption were also observed during the first 7 days o f exposure in males and 
females exposed to >8.5 mg/kg/day. Significant decreases in absolute liver weights and liver-to-brain 
weights and increases in blood cholesterol levels were observed in females exposed to 8.5 mg/kg/day; 
these effects were not observed at higher dose levels or in males. Due to the lack o f dose-response 
relationships for the alterations in liver weight and blood cholesterol levels, these changes observed in the
8.5 mg/kg/day female group were not considered biologically relevant. No significant alterations in 
hematological parameters or other clinical chemistry parameters or organ weights were observed.
Dose and end point used for MRL derivation: The MRL is based on a NOAELhed o f 6.45 mg/kg/day for 
tremors and convulsions in a 14-day study.
[X] NOAEL [ ] LOAEL
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PBPK modeling was used to estimate internal dose metrics for brain RDX levels and for estimating 
HEDs. Code for an RDX oral PBPK model was provided by LM Sweeney along with documentation of 
parameter values (Sweeney et al. 2012). The Sweeney et al. (2012) model is based on the rat model 
reported by Krishnan et al. (2009) with modifications made to the gastrointestinal tract parameters, to 
include two compartments (stomach and small intestine). Sweeney et al. (2012) scaled the rat model to 
the human and estimated human gastrointestinal absorption and liver metabolism parameter values based 
on optimization against serum RDX-time profiles from humans accidentally exposed to RDX. Code for 
the Sweeney et al. (2012) model was implemented in acsLX v 3.0.1.6, without modification to the human 
or rat parameter values. Performance o f the implementation was verified by comparing output to plots 
shown in Figure 2-4 o f Sweeney et al. (2012).
The model was used for interspecies extrapolation o f rat internal dosimetry to humans using the following 
procedure:
1. The rat model was used to simulate external rat dosages used in relevant bioassays and to predict 
the corresponding internal dose metric, peak concentration o f RDX in brain (CBpeak) and mean 
concentration of RDX in brain (CBmean).
2. Gavage doses (mg/kg/day) were assumed to be delivered as a single bolus each day, at the 
exposure frequency (days/week) used in the bioassay.
3. Rat model simulations were carried out for 14 days for acute exposures.
4. Rat body weights used in the simulations were the time-weighted average (TWA) body weights 
for each dose group.
5. The human model was used to predict the daily dosage (mg/kg/day) corresponding to the NOAEL 
for peak brain concentration in the rat.
6. A body weight o f 70 kg was assumed for humans.
7. Daily doses (mg/kg/day) in humans were assumed to be delivered in 12 consecutive hourly doses, 
separated by 12-hour intervals, 7 days/week.
8. Human model simulations were carried out for 14 days for acute exposures.




Table A-1. Estimated Peak and Mean Brain Concentrations in Rats Administered 





Peak brain concentration 
(mg/L)
Mean brain concentration 
(mg/L)
Males
0 0.2039 0 0
2.13 0.2044 1.602 0.6645
4.25 0.2017 3.198 1.3232
8.5 0.1915 6.351 2.6018
17 0.1826 12.619 5.1232
25.5 0.1886 19.012 7.7666
34 0.1693a 24.979 9.9956
42.5 0.1683a 31.198 12.4702
Females
0 0.1403 0 0
2.13 0.1375 1.518 0.5835
4.25 0.1397 3.042 1.1732
8.5 0.131 6.033 2.2974
17 0.1347 12.1211 4.6369
25.5 0.1374 18.214 7.0007
34 0.1250a 23.982 9.0492
42.5 0.1262a 30.016 11.3470
aDay 1 body weight used due to high mortality (100% mortality on day 1 in 42.5 mg/kg/day males and females and 
34 mg/kg/day females and 83% mortality on day 1 in 34 mg/kg/day males)
TWA = time-weighted average
Source: U.S. Army 2006
The acute-duration oral MRL was derived using the NOAEL/LOAEL approach; the lack o f incidence 
data for the neurological effects precluded using a benchmark dose approach. The U.S. Army (2006) 
study identified a NOAEL o f 8.5 mg/kg/day and LOAEL o f 17 mg/kg/day for neurological effects. The 
PBPK model was used to predict peak brain RDX concentrations and mean brain RDX concentrations 
associated with these dose levels. In animals dosed with 8.5 mg/kg/day, the model predicted peak brain 
concentrations o f 6.351 mg/L in males and 6.033 mg/L in females and mean brain concentrations o f 2.602 
and 2.297 mg/L in males and females, respectively. Mechanistic data provide strong support that the 
mode o f action for seizures involves binding to GABA receptors and there is a direct relationship between 
RDX levels in the brain and the onset o f seizures (Gust et al. 2009; Williams et al. 2011). However, there 
are insufficient data to determine whether peak brain RDX concentration or mean brain RDX 
concentration is the most appropriate internal dose metric. As presented in Table A-2, a comparison of 
the NOAEL and LOAEL values for seizures in rats exposed for intermediate or chronic durations 
suggests that peak brain concentration may be the most appropriate internal dose metric. The mean brain 
concentrations are similar for rats exposed to 8 mg/kg/day for 90 days or 2 years; however, 
seizures/convulsions were observed at this dose level in the 90-day study, but not in the 2-year study. In 
contrast to the mean concentrations, the peak brain concentration in the 90-day study was 34% higher
RDX A-6
than in the 2-year study; this difference in peak concentrations may explain the apparent difference in 
seizure threshold. Thus, peak brain concentration was selected as the internal dose metric for derivation 
o f the acute-duration oral MRL. Since the U.S. Army (2006) study did not identify gender-specific 
differences in RDX sensitivity, the peak brain concentrations were averaged for the male and females 
rats. In the rats administered 8.5 mg/kg/day RDX, the average peak brain RDX concentration was 
predicted to be 6.192 mg/L. This peak brain concentration was used to predict a HED of 
6.455 mg/kg/day using the PBPK model.
APPENDIX A
Table A-2. Comparison of NOAEL and LOAEL Values Using Different Dose 






Administered dose 4 mg/kg/day 8 mg/kg/day
Peak brain concentration 2.923 mg/L 4.051 mg/L
Mean brain concentration 1.308 mg/L 2.959 mg/L
LOAELc
Administered dose 8 mg/kg/day 40 mg/kg/day
Peak brain concentration 6.013 mg/L 18.694 mg/L
Mean brain concentration 2.615 mg/L 14.403 mg/L
aRDX administered via gavage, 7 days/week for 90 days 
bRDX administered via the diet for 2 years 
cAverage of male and female values
Uncertainty Factors used in MRL derivation:
[ ] 10 for use o f a LOAEL
[X] 3 for extrapolation from animals to humans with dosimetric adjustments 
[X] 10 for human variability
Was a conversion factor used from ppm in food or water to a mg/body weight dose? Not applicable.
If an inhalation study in animals, list conversion factors used in determining human equivalent dose: Not 
applicable.
Was a conversion used from intermittent to continuous exposure? Not applicable.
Other additional studies or pertinent information that lend support to this M RL: Human case reports have 
noted convulsions and seizures in individuals ingesting RDX (Hollander and Colbach 1969; Ketel and 
Hughes 1972; Küçükardalï et al. 2003; Merrill 1968; Stone et al. 1969; Woody et al. 1986). Several acute 
toxicity studies have reported convulsions, seizures, or tremors in rats at doses slightly higher than the 
LOAEL o f 17 mg/kg/day identified in the U.S. Army (2006) study. These LOAEL values are 
20 mg/kg/day in two gestational exposure studies (U.S. Army 1980b, 1986d) and 25 mg/kg in rats 
administered a single gavage dose (Burdette et al. 1988). In addition, decreases in motor activity and 
learning were observed in rats receiving a single gavage dose o f 12.5 mg/kg/day (U.S. Army 1985b).
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Although the potential for systemic effects has not been well investigated following acute exposure, 
intermediate-duration studies (U.S. Army 1980b, 1983a, 2006; U.S. Navy 1974b) provide support that 
neurotoxicity is the most sensitive effect o f RDX.

















[ ] Inhalation [X] Oral
[ ] Acute [X] Intermediate [ ] Chronic
50
Rat
Minimal Risk Level: 0.1 [X] mg/kg/day [ ] ppm
Reference: U.S. Army. 2006. Toxicology study no. 85-XC-5131-03. Subchronic oral toxicity o f RDX 
in rats. Aberdeen Proving Ground, MD: U.S. Army Center for Health Promotion and Preventive 
Medicine.
Experimental design: Groups o f 10 male and 10 female F344 rats were administered via gavage 0, 4, 8, 
10, 12, or 15 mg/kg/day as a suspension of RDX/1% methylcellulose/0.2% Tween 80 in distilled water 
7 days/week for 90 days. Rats were monitored weekly for toxic signs and FOB observations (home-cage, 
hand held, and open arena observations); body weights and feed consumption were also measured 
weekly. Additional parameters used to assess toxicity included neurobehavioral tests after week 11 
(motor activity, grip strength, and sensory reactivity to different types o f stimuli), ophthalmic 
examination, urinalysis (volume, color, appearance, pH, specific gravity, glucose, bilirubin, urobilinogen, 
ketone, blood, protein, nitrite, leukocytes), clinical chemistry (alkaline phosphatase, alanine 
aminotransferase, aspartate aminotransferase, blood urea nitrogen, calcium, sodium, potassium, chlorine, 
cholesterol, creatinine kinase, creatinine, glucose, lactate dehydrogenase, total bilirubin, total protein, 
triglycerides), hematology (hemoglobin, hematocrit, erythrocytes, mean cell hemoglobin concentration, 
mean cell volume, mean cell hemoglobin, red blood cell distribution width, total and differential 
leukocytes, platelets, and mean platelet volume) values, coagulation (average and activated prothrombin 
time), organ weights (brain, heart, liver, kidneys, spleen, adrenals, thymus, epididymides, uterus, testes, 
ovaries), gross necropsies, and histopathological examination o f major tissues and organs from rats 
exposed to 0 or 15 mg/kg/day. In addition, potential immunotoxicity was assessed using the following 
tests: red and white blood cell populations and spleen and thymus relative organ weights, cellularity as a 
proportion of organ weight, and proportion o f cell surface markers.
Effect noted in study and corresponding doses: Increased mortality was observed at >8 mg/kg/day; the 
number o f preterm deaths were 2/20, 5/20, 8/20, and 7/20 in the 8, 10, 12, and 15 mg/kg/day groups, 
respectively. Convulsions were observed in most animals dying early. Transient clinical signs included 
changes in arousal, blepharosis, increased salivation, blood stains around mouth and nose, rough haircoat, 
tremors, and convulsions; the incidence and severity o f these effects increased with dose. Neuromuscular 
effects were observed within the first week o f exposure in the higher dose groups and persisted 
throughout the study. Increased arousal was observed in 25, 40, and 100% of rats in the 10, 12, and 
15 mg/kg/day groups; convulsions were observed in 15, 30, 65, and 60% of rats in the 8, 10, 12, and 
15 mg/kg/day groups, respectively; and tremors were observed in 10 and 20% of rats in the 12 and 
15 mg/kg/day groups. Increased urine volume was observed in females exposed to 12 or 15 mg/kg/day; 
the investigators noted that the increased urine volume may be related to the palatability o f the suspension 
since higher dose animals were frequently observed drinking immediately after dosing. Significant 
decreases in body weight gain were observed in the male rats; however, body weights were typically 
within 10% o f controls. In the females, significant increases in body weight were observed; at 
termination, the females in the 10, 12, and 15 mg/kg/day groups weighed at least 14% more than controls.
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Significant alterations in organ weights were observed in male rats; these included increased brain weight 
at 12 and 15 mg/kg/day, decreased relative (to body weight and brain weight) testes weight at 
>10 mg/kg/day, and decreased relative (to brain weight) epididymis weight at >8 mg/kg/day. In the 
females, significant alterations in organ weights included increased spleen, liver, and kidney weights at 
10, 12 (spleen only), or 15 mg/kg/day; relative brain weight at >10 mg/kg/day; and increased relative (to 
brain) kidney, liver, and spleen weights at 10 and 15 mg/kg/day. Significant increases in mean cell 
volume were observed at 8 (males only), 10, and 12 mg/kg/day and significant decreases in cholesterol 
levels were observed in males exposed to >8 mg/kg/day. No significant increases in the incidence of 
histopathological alterations were observed. A significant increase in abnormal skin appearance (stained 
haircoat) was observed in females exposed to 15 mg/kg/day during week 12. The presence o f barbering 
was significantly increased in females exposed to 15 mg/kg/day during weeks 9 and 12. No RDX related 
alterations in immunological parameters were observed. Although the incidence o f convulsions was not 
statistically significant at 8 mg/kg/day, this dose level, which likely falls just below the NOAEL/LOAEL 
boundary, was considered a LOAEL due the seriousness o f the effect.
Dose and end point used for MRL derivation: The BMDLhed o f 4.1308 mg/kg/day for convulsions was 
used as the point o f departure for the MRL.
[ ] NOAEL [ ] LOAEL [X] BMDL10
PBPK modeling was used to estimate internal dose metrics for brain RDX levels and for estimating 
HEDs. Code for an RDX oral PBPK model was provided by LM Sweeney along with documentation of 
parameter values (Sweeney et al. 2012). The Sweeney et al. (2012) model is based on the rat model 
reported by Krishnan et al. (2009) with modifications made to the gastrointestinal tract parameters, to 
include two compartments (stomach and small intestine). Sweeney et al. (2012) scaled the rat model to 
the human and estimated human gastrointestinal absorption and liver metabolism parameter values based 
on optimization against serum RDX-time profiles from humans accidentally exposed to RDX. Code for 
the Sweeney et al. (2012) model was implemented in acsLX v 3.0.1.6, without modification to the human 
or rat parameter values. Performance o f the implementation was verified by comparing output to plots 
shown in Figure 2-4 o f Sweeney et al. (2012).
The model was used for interspecies extrapolation o f rat internal dosimetry to humans using the following 
procedure:
1. The rat model was used to simulate external rat dosages used in relevant bioassays and to predict 
the corresponding internal dose metrics, peak concentration o f RDX in brain (CBpeak) and mean 
concentration of RDX in brain (CBmean).
2. Gavage doses (mg/kg/day) were assumed to be delivered as a single bolus each day, at the 
exposure frequency (days/week) used in the bioassay.
3. Rat model simulations were carried out until steady state had been achieved for intermediate- 
duration exposures.
4. Rat body weights used in the simulations were the TWA body weights for each dose group.
5. The human model was used to predict the daily dosage (mg/kg/day) corresponding to the BMDL 
for peak brain concentration in the rat.




7. Daily doses (mg/kg/day) in humans were assumed to be delivered in 12 consecutive hourly doses, 
separated by 12-hour intervals, 7 days/week.
8. Human model simulations were carried out until steady state had been achieved for intermediate- 
duration exposures.
The peak and mean brain concentrations for each dose are presented in Table A-3.
Table A-3. Estimated Peak and Mean Brain Concentrations in Rats Administered 
RDX Via Gavage 7 Days/Week for 90 Days
Dose
(mg/kg/day)
TWA body weight 
(kg)
Peak brain concentration 
(mg/L)
Mean brain concentration 
(mg/L)
Males
0 0.2558 0 0
4 0.2435 3.090 1.3947
8 0.2362 6.154 2.7616
10 0.2418 7.718 3.4787
12 0.2446 9.277 4.1903
15 0.2579 11.683 5.3301
Females
0 0.1642 0 0
4 0.1626 2.923 1.2209
8 0.1682 5.873 2.4692
10 0.1714 7.359 3.1057
12 0.1722 8.837 3.7325
15 0.1849 11.154 4.7764
TWA = time-weighted average 
Source: U.S. Army 2006
The intermediate-duration oral MRL was derived using a benchmark dose modeling approach. Peak 
brain concentration and mean brain concentration were considered potential internal dose metrics for the 
benchmark dose modeling. Mechanistic data provide strong support that the mode o f action for seizures 
involves binding to GABA receptors and there is a direct relationship between RDX levels in the brain 
and the onset o f seizures (Gust et al. 2009; Williams et al. 2011). However, there are insufficient data to 
determine whether peak brain RDX concentration or mean brain RDX concentration is the most 
appropriate internal dose metric. As presented in Table A-4, the empirical data for seizures/convulsions 
appears to support using peak brain concentration as the internal dose metric. The mean brain 
concentrations are similar for rats exposed to 8 mg/kg/day for 90 days or 2 years; however, 
seizures/convulsions were observed at this dose level in the 90-day study, but not in the 2-year study. In 
contrast to the mean concentrations, the peak brain concentration in the 90-day study was 34% higher 




Table A-4. Comparison of NOAEL and LOAEL Values Using Different Dose 






Administered dose 4 mg/kg/day 8 mg/kg/day
Peak brain concentration 2.923 mg/L 4.051 mg/L
Mean brain concentration 1.308 mg/L 2.959 mg/L
LOAELc
Administered dose 8 mg/kg/day 40 mg/kg/day
Peak brain concentration 6.013 mg/L 18.694 mg/L
Mean brain concentration 2.615 mg/L 14.403 mg/L
aRDX administered via gavage, 7 days/week for 90 days. 
bRDX administered via the diet for 2 years. 
cAverage of male and female values.
Data for the incidence o f convulsions (summarized in Table A-5) were fit to all available dichotomous 
models in the EPA Benchmark Dose Software (BMDS) (version 2.1.2) using the extra risk option and 
using peak brain RDX concentration as the dose metric. Since the study did not identify gender-specific 
differences in RDX sensitivity, the peak brain concentrations were averaged for the male and female rats 
and these combined values were used for benchmark dose modeling. Adequate model fit was judged by 
three criteria: X  goodness-of-fit p-value (p>0.1), visual inspection o f the dose-response curve, and scaled 
residual at the data point (except the control) closest to the predefined BMR. BMDs and lower bounds on 
the BMD (BMDL) associated with a BMR of 10% extra risk were calculated for all models and are 
presented in Table A-6. As assessed by the X  goodness-of-fit statistic, all o f the models with the 
exception o f the quantal linear and 1-degree polynomial models provided adequate fit to the data. Among 
all o f the models providing adequate fit to the data, the BMDL from the model with the lowest Akaike’s 
Information Criteria (AIC) was chosen. The log-probit model provided the best fit to the convulsion 
incidence data and is presented in Figure A-1. The BMDL o f 3.9627 mg/L was used to predict a HED of 
4.131 mg/kg/day using the PBPK model.
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APPENDIX A
Table A-5. Incidence of Convulsions in Male and Female Fischer 344 Rats 
Administered RDX 7 Days/Week for 90 Days







Source: U.S. Army 2006
Table A-6. Model Predictions for the Incidence of Convulsions in Rats 
Administered RDX via Gavage for 90 Days Using Peak Brain 
Concentration as the Internal Dose Metric
Model






Gammab 0.4648 101.924 5.17803 3.79207
Logistic 0.2121 104.808 5.14052 3.99687
LogLogistic 0.4945 101.781 5.18956 3.8386
LogProbit 0.5406 101.353 5.24819 3.9627
Multistage (1-degree polynomial)c 0.3663 111.445 3.75703 2.82257
Multistage (2-degree polynomial 0.0383 102.99 NA NA
Probit 0.2696 103.851 5.11305 3.88122
Weibullb 0.352 103.06 4.87416 3.43247
Quantal-Linear 0.0383 111.445 NA NA
aValues <0.10 fail to meet conventional goodness-of-fit criteria. 
bPower restricted to >1. 
cBetas restricted to >0.
AIC = Akaike's Information Criterion; BMD = maximum likelihood estimate of the dose associated with the selected 
benchmark response; BMDL = 95% lower confidence limit on the BMD; NA = not applicable, model does not provide 
adequate fit to the data
S ource : U .S. A rm y  2 0 0 6
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Figure A-1. Fit of Log Probit Model to Data on the Incidence of Convulsions in 
Rats Administered RDX via Gavage for 90 Days Using Peak Brain RDX 
Concentration as the Dose Metric
APPENDIX A
LogProbit Model with 0.95 Confidence Level
dose
21:45 06/09 2011
Source: U.S. Army 2006
Uncertainty Factors used in MRL derivation:
[ ] 10 for use o f a LOAEL
[X] 3 for extrapolation from animals to humans with dosimetric adjustments 
[X] 10 for human variability
Was a conversion factor used from ppm in food or water to a mg/body weight dose? Not applicable.
If an inhalation study in animals, list conversion factors used in determining human equivalent dose: Not 
applicable.
Was a conversion used from intermittent to continuous exposure? Not applicable.
Other additional studies or pertinent information that lend support to this M RL: No human studies have 
examined the toxicity o f RDX following intermediate-duration exposure. Several animal studies have 
reported neurological effects, primarily convulsions, seizures, and/or tremors in rats at doses of 
>8 mg/kg/day (U.S. Army 1983a, 2006; von Oettingen et al. 1949), monkeys at 10 mg/kg/day (U.S. Navy 
1974b), and dogs at 50 mg/kg/day (von Oettingen et al. 1949). Hyperactivity was noted in rats exposed to 
100 mg/kg/day (Levine et al. 1981, 1990). The results o f the U.S. Army (2006) study suggest that there is 
a steep dose-response curve for seizure induction. The occurrences o f seizures were 0% at 4 mg/kg/day, 
20-30%  at 8 mg/kg/day, 45-50%  at 10 mg/kg/day, and 80-90%  at 12 or 15 mg/kg/day.
In addition to these neurological effects, less serious adverse health effects have been observed at similar 
or higher dose levels. Several studies have found changes in serum chemistry parameters suggestive of
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impaired liver function, although histological alterations were not generally found in the liver. Decreases 
in serum cholesterol and/or triglycerides were observed at >8 mg/kg/day (U.S. Army 1983a, 2006; Levine 
et al. 1981) and decreases in serum alanine aminotransferase levels were observed at 28 mg/kg/day (U.S. 
Army 1980b). The magnitude o f these alterations was small and not likely to be biologically significant. 
Minor hematological effects (small decreases in erythrocyte and hemoglobin levels) were observed in rats 
exposed to 40 mg/kg/day (U.S. Army 1983a) and mice exposed to 160 mg/kg/day (U.S. Army 1980b); 
however, other studies have not found significant alterations in hematological parameters (U.S. Army 
1980b, 2006; von Oettingen et al. 1949). Emesis was observed in monkeys administered via gavage 
10 mg/kg/day for 90 days (U.S. Navy 1974b); the incidence in monkeys administered 1 mg/kg/day was 
not considered to be different from the controls. There is limited evidence that RDX is a reproductive 
toxicant. Spermatic granuloma in the prostrate was observed in rats exposed to 40 mg/kg/day for 
6 months (U.S. Army 1983a). Decreases in F2 pup body weight and increases in the incidence o f renal 
cysts were observed at 16 mg/kg/day and an increase in the number of stillbirths and decreased pup 
survival were observed in the Fj generation at 50 mg/kg/day was observed in a two-generation study in 
rats (U.S. Army 1980b).

















[ ] Inhalation [X] Oral
[ ] Acute [ ] Intermediate [X] Chronic
65
Rat
Minimal Risk Level: 0.1 [X] mg/kg/day [ ] ppm
Reference: U.S. Army. 1983a. Determination o f the chronic mammalian toxicological effects o f RDX: 
Twenty-four month chronic toxicity/carcinogenicity study o f hexahydro-1,3,5-trinitro-1,3,5-triazine 
(RDX) in the Fischer 344 rat: Phase V. Vol. 1. Frederick, MD: U.S. Army Medical Research and 
Development Command. ADA160774. (author: Levine BS et al.)
Experimental design: Groups o f male and female Fischer 344 rats (75/sex/group) were exposed to 0, 0.3, 
1.5, 8.0, or 40.0 mg/kg/day RDX in the diet for 2 years. Ten animals/sex/dose were sacrificed during 
weeks 27 and 53. The following parameters were used to assess toxicity: daily observations; ophthalmic 
examinations during weeks 2, 25, 51, 76, and 103; hematology (hematocrit, hemoglogin, mean 
corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, 
erythrocyte count, total and differential leukocyte count, and platelet count) and clinical chemistry 
(glucose, blood urea nitrogen, alanine aminotransferase, bilirubin, creatinine phosphokinase, lactic 
dehydrogenase, alkaline phosphatase, triglycerides, total cholesterol, total protein, albumin, globulin, 
sodium, potassium, chloride, and calcium levels) o f blood samples collected during weeks 13, 26, 52, 78, 
and 104; organ weights (adrenal, brain, heart, kidneys, liver, ovaries, spleen, and testes), and complete 
histopathology o f major tissues and organs o f rats in the 0 or 40.0 mg/kg/day groups, and 
histopathological examination o f the brain, gonads, heart, liver, kidneys, spleen, and spinal cord o f rats in 
the 0.3, 1.5, and 8.0 mg/kg/day groups. Actual RDX doses were within 3% o f the intended dose.
Effect noted in study and corresponding doses: Deaths were observed at 40 mg/kg/day; 88% of males and 
41% of females died by week 88. The mean survival time for the 40 mg/kg/day males was 14.6 months 
compared with 22.3 months for the control males. A 20.6 month survival time was seen for the 
40 mg/kg/day females vs. 22.0 months for the control females at 40 mg/kg/day. A significant decrease in 
survival time was also observed in the males exposed to 1.5 mg/kg/day (21.0 months); however, no 
alterations in survival time was observed in the females exposed to 1.5 mg/kg/day (22.2 months) or in the 
males (22.2 months) or females (22.4 months) exposed to 8 mg/kg/day. Additionally, there were no 
significant differences in mortality incidence in the 1.5 or 8 mg/kg/day groups, as compared to controls. 
Decreased body weight gain was observed in males (20-30%) and females (10-15%) exposed to
40.0 mg/kg/day; significant decreases in body weight gain were also observed at 8.0 mg/kg/day, but the 
body weight was within 5% o f controls. Slight, but significant, reductions in food intake were observed 
in males at 40.0 mg/kg/day. Tremors and convulsions were observed prior to death at 40 mg/kg/day 
beginning after 26 weeks o f exposure. Animals were hyperreactive to approach and had increased 
fighting; hyperreactivity was first observed after 9 weeks o f exposure to 40 mg/kg/day. No adverse 
clinical signs were noted for the lower dose groups. Significant decreases in hemoglobin and erythrocyte 
counts were observed in the 40 mg/kg/day group beginning at week 26; the study investigators noted that 
the anemic state was considered slight and there was no evidence o f physiologic compensatory responses. 
Thrombocytosis was observed in rats exposed to 40 mg/kg/day and elevated platelet counts were
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observed in 8 mg/kg/day males during weeks 13 and 26. Significant decreases in blood glucose, total 
cholesterol, and triglyceride levels were observed in the 40 mg/kg/day group starting at week 13. 
Significant decreases in serum alanine aminotransferase levels were observed in males exposed to 8 or 40 
mg/kg/day at weeks 26 and 52 and in females at 40 mg/kg/day at week 26. Other clinical chemistry 
alterations included decreases in globulin and albumin levels at weeks 52 and 78 and increases in serum 
potassium levels at weeks 26, 52, and 78. A significant increase in the incidence of cataracts was 
observed in females in the 40 mg/kg/day group during weeks 78 and 104. Splenic extramedullary 
hematopoiesis and spermatic granuloma o f the prostate were observed in rats exposed to 40 mg/kg/day 
for 6 months. At 1 year, histological alterations in the urinary bladder (luminal distention and cystitis), 
kidneys (medullary papillary necrosis), and testes (germinal cell degeneration, enlarged seminal vesicles) 
were observed in males exposed to 40 mg/kg/day and in the spleen (enlarged dark-red spleens with 
histological evidence o f sinusoidal congestion) o f males and females exposed to 40 mg/kg/day. The 
following effects were observed at 2 years: suppurative inflammation o f the prostate in the 1.5, 8, and 40 
mg/kg/day groups; renal medullary papillar necrosis, renal pyelitis, and urinary bladder luminal distension 
and cystitis in males exposed to 40 mg/kg/day; splenic extramedullary hematopoiesis in female rats 
exposed to 40 mg/kg/day; and hemosiderin-like pigment in males exposed to 1.5, 8, or 40 mg/kg/day. In 
the absence of altered hematological parameters or other effects on the spleen, the increased pigment 
levels observed at 1.5 or 8 mg/kg/day were not considered adverse.
Dose and end point used for MRL derivation: The MRL is based on a NOAELhed o f 4.223 mg/kg/day 
for tremors and convulsions in a 2-year study.
[X] NOAEL [ ] LOAEL
PBPK modeling was used to estimate internal dose metrics for brain RDX levels and for estimating 
HEDs. Code for an RDX oral PBPK model was provided by LM Sweeney along with documentation of 
parameter values (Sweeney et al. 2012). The Sweeney et al. (2012) model is based on the rat model 
reported by Krishnan et al. (2009) with modifications made to the gastrointestinal tract parameters, to 
include two compartments (stomach and small intestine). Sweeney et al. (2012) scaled the rat model to 
the human and estimated human gastrointestinal absorption and liver metabolism parameter values based 
on optimization against serum RDX-time profiles from humans accidentally exposed to RDX. Code for 
the Sweeney et al. (2012) model was implemented in acsLX v 3.0.1.6, without modification to the human 
or rat parameter values. Performance o f the implementation was verified by comparing output to plots 
shown in Figure 2-4 o f Sweeney et al. (2012).
The model was used for interspecies extrapolation o f rat internal dosimetry to humans using the following 
procedure:
1. The rat model was used to simulate external rat dosages used in relevant bioassays and to predict 
the corresponding internal dose metric, peak concentration o f RDX in brain (CBpeak) and mean 
concentration of RDX in brain (CBmean).
2. Dietary doses (mg/kg/day) were assumed to be delivered in 12 consecutive hourly doses, 
separated by 12-hour intervals, at the exposure frequency (days/week) used in the bioassay.
3. Rat model simulations were carried out until steady state had been achieved for chronic-duration 
exposures.




5. The human model was used to predict the daily dosage (mg/kg/day) corresponding to the NOAEL 
for peak brain concentration in the rat.
6 . A body weight o f 70 kg was assumed for humans.
7. Daily doses (mg/kg/day) in humans were assumed to be delivered in 12 consecutive hourly doses, 
separated by 12-hour intervals, 7 days/week.
8. Human model simulations were carried out until steady state had been achieved for chronic- 
duration exposures.
The peak brain concentrations for each dose are presented in Table A-7.
Table A-7. Estimated Peak and Mean Brain Concentrations in Rats Administered 
RDX Via the Diet for 2 Years
Dose
(mg/kg/day)
TWA body weight 
(kg)
Peak brain concentration 
(mg/L)
Mean brain concentration 
(mg/L)
Males
0 0.3889 0 0
0.3 0.3904 0.165 0.122
1.5 0.3848 0.823 0.607
8 0.373 4.344 3.205
40 0.3244 20.885 15.304
Females
0 0.2302 0 0
0.3 0.2297 0.142 0.102
1.5 0.2278 0.707 0.511
8 0.2248 3.763 2.712
40 0.2218 18.694 13.502
TWA = time-weighted average 
Source: U.S. Army 1983a
The U.S. Army (1983a) study identified a NOAEL o f 8 mg/kg/day and LOAEL o f 40 mg/kg/day for 
tremors and convulsions in rats exposed to RDX in the diet for 2 years. A chronic-duration oral MRL 
was derived using the NOAEL/LOAEL approach; benchmark dose modeling could not be utilized 
because the investigators did not report incidence data for neurological signs. The NOAEL from the U.S. 
Army (1983a) study corresponds to peak brain concentrations o f 4.344 and 3.763 mg/L in males and 
females, respectively, and mean brain RDX concentrations o f 3.205 and 2.712 mg/L in males and 
females, respectively. Mechanistic data provide strong support that the mode o f action for seizures 
involves binding to GABA receptors and there is a direct relationship between RDX levels in the brain 
and the onset o f seizures (Gust et al. 2009; Williams et al. 2011). However, there are insufficient data to 
determine whether peak brain RDX concentration or mean brain RDX concentration is the most 
appropriate internal dose metric. As presented in Table A-8, a comparison o f the NOAEL and LOAEL 
values for seizures in rats exposed for intermediate or chronic durations suggests that peak brain
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concentration may be the most appropriate internal dose metric. The mean brain concentrations are 
similar for rats exposed to 8 mg/kg/day for 90 days or 2 years; however, seizures/convulsions were 
observed at this dose level in the 90-day study, but not in the 2-year study. In contrast to the mean 
concentrations, the peak brain concentration in the 90-day study was 34% higher than in the 2-year study; 
this difference in peak concentrations may explain the apparent difference in seizure threshold. Thus, 
peak brain concentration was selected as the internal dose metric for derivation o f the acute-duration oral 
MRL. Since the U.S. Army (1983a) study did not identify gender-specific differences in RDX sensitivity, 
the peak brain concentrations were averaged for the male and females rats. The average peak brain 
concentration of 4.051 mg/L was used to predict a HED o f 4.223 mg/kg/day using the PBPK model.
APPENDIX A
Table A-8. Comparison of NOAEL and LOAEL Values Using Different Dose 






Administered dose 4 mg/kg/day 8 mg/kg/day
Peak brain concentration 2.923 mg/L 4.051 mg/L
Mean brain concentration 1.308 mg/L 2.959 mg/L
LOAELc
Administered dose 8 mg/kg/day 40 mg/kg/day
Peak brain concentration 6.013 mg/L 18.694 mg/L
Mean brain concentration 2.615 mg/L 14.403 mg/L
aRDX administered via gavage, 7 days/week for 90 days. 
bRDX administered via the diet for 2 years. 
cAverage of male and female values.
Uncertainty Factors used in MRL derivation:
[ ] 10 for use o f a LOAEL
[X] 3 for extrapolation from animals to humans with dosimetric adjustments 
[X] 10 for human variability
Was a conversion factor used from ppm in food or water to a mg/body weight dose? Not applicable.
If an inhalation study in animals, list conversion factors used in determining human equivalent dose: Not 
applicable.
Was a conversion used from intermittent to continuous exposure? Not applicable.
Other additional studies or pertinent information that lend support to this M RL: No human studies have 
examined the chronic toxicity o f RDX following oral exposure. A number of human case reports have 
noted convulsions and seizures in individuals ingesting RDX (Hollander and Colbach 1969; Ketel and 
Hughes 1972; Kufukardali et al. 2003; Merrill 1968; Stone et al. 1969; Woody et al. 1986). The chronic 
oral toxicity o f RDX has been evaluated in two rat studies (U.S. Army 1983a; U.S. Navy 1976) and a 
mouse study (U.S. Army 1984c). A number o f adverse health effects have been observed in rats exposed 
to 40 mg/kg/day including tremors, convulsions, and hyperresponsiveness; decreased hematocrit,
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hemoglobin, and erythrocyte levels; hepatomegaly and decreased serum cholesterol and triglycerides; 
renal papillary necrosis and increased blood urea nitrogen levels; testicular degeneration; and cataracts 
(females only) (U.S. Army 1983a). This dose was also associated with an 88% mortality rate. In addition 
to these effects, significant increases in the incidence of suppurative inflammation were observed in the 
prostate o f rats exposed to >1.5 mg/kg/day (U.S. Army 1983a). U.S. Army (2006) noted that 
inflammation o f the prostate gland is a common condition in older rodents and is generally not due to 
toxicity; additionally, the prostate effects in the U.S. Army (1983a) study were predominantly found in 
rats dying early.
In the second rat study, no adverse effects were observed at doses as high as 10 mg/kg/day (U.S. Navy 
1976). This study did not include a histological examination of the prostate, and the animals were 
monitored weekly for overt signs o f toxicity. In mice, increases in serum cholesterol levels were 
observed in females exposed to 35 mg/kg/day and increased relative kidney weights and cytoplasmic 
vacuolization in the kidney were observed at 100 mg/kg/day. The NOAEL for the hepatic effects was 
7 mg/kg/day.
Agency Contacts (Chemical Managers): Henry Abadin
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This chapter o f the profile is a health effects summary written in nontechnical language. Its intended 
audience is the general public, especially people living in the vicinity o f a hazardous waste site or 
chemical release. If  the Public Health Statement were removed from the rest o f the document, it would 
still communicate to the lay public essential information about the chemical.
The major headings in the Public Health Statement are useful to find specific topics of concern. The 
topics are written in a question and answer format. The answer to each question includes a sentence that 
will direct the reader to chapters in the profile that will provide more information on the given topic.
Chapter 2 
Relevance to Public Health
This chapter provides a health effects summary based on evaluations of existing toxicologic, 
epidemiologic, and toxicokinetic information. This summary is designed to present interpretive, weight- 
of-evidence discussions for human health end points by addressing the following questions:
1. W hat effects are known to occur in humans?
2. W hat effects observed in animals are likely to be o f concern to humans?
3. W hat exposure conditions are likely to be o f concern to humans, especially around hazardous 
waste sites?
The chapter covers end points in the same order that they appear within the Discussion o f Health Effects 
by Route o f Exposure section, by route (inhalation, oral, and dermal) and within route by effect. Human 
data are presented first, then animal data. Both are organized by duration (acute, intermediate, chronic). 
In vitro data and data from parenteral routes (intramuscular, intravenous, subcutaneous, etc.) are also 
considered in this chapter.
The carcinogenic potential o f the profiled substance is qualitatively evaluated, when appropriate, using 
existing toxicokinetic, genotoxic, and carcinogenic data. ATSDR does not currently assess cancer 
potency or perform cancer risk assessments. Minimal Risk Levels (MRLs) for noncancer end points (if 
derived) and the end points from which they were derived are indicated and discussed.
Limitations to existing scientific literature that prevent a satisfactory evaluation of the relevance to public 
health are identified in the Chapter 3 Data Needs section.
Interpretation of Minimal Risk Levels
Where sufficient toxicologic information is available, ATSDR has derived MRLs for inhalation and oral 
routes of entry at each duration o f exposure (acute, intermediate, and chronic). These MRLs are not
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meant to support regulatory action, but to acquaint health professionals with exposure levels at which 
adverse health effects are not expected to occur in humans.
MRLs should help physicians and public health officials determine the safety o f a community living near 
a chemical emission, given the concentration o f a contaminant in air or the estimated daily dose in water. 
MRLs are based largely on toxicological studies in animals and on reports o f human occupational 
exposure.
MRL users should be familiar with the toxicologic information on which the number is based. Chapter 2, 
"Relevance to Public Health," contains basic information known about the substance. Other sections such 
as Chapter 3 Section 3.9, "Interactions with Other Substances,” and Section 3.10, "Populations that are 
Unusually Susceptible" provide important supplemental information.
MRL users should also understand the MRL derivation methodology. MRLs are derived using a 
modified version o f the risk assessment methodology that the Environmental Protection Agency (EPA) 
provides (Barnes and Dourson 1988) to determine reference doses (RfDs) for lifetime exposure.
To derive an MRL, ATSDR generally selects the most sensitive end point which, in its best judgement, 
represents the most sensitive human health effect for a given exposure route and duration. ATSDR 
cannot make this judgement or derive an MRL unless information (quantitative or qualitative) is available 
for all potential systemic, neurological, and developmental effects. If this information and reliable 
quantitative data on the chosen end point are available, ATSDR derives an MRL using the most sensitive 
species (when information from multiple species is available) with the highest no-observed-adverse-effect 
level (NOAEL) that does not exceed any adverse effect levels. When a NOAEL is not available, a 
lowest-observed-adverse-effect level (LOAEL) can be used to derive an MRL, and an uncertainty factor 
(UF) o f 10 must be employed. Additional uncertainty factors o f 10 must be used both for human 
variability to protect sensitive subpopulations (people who are most susceptible to the health effects 
caused by the substance) and for interspecies variability (extrapolation from animals to humans). In 
deriving an MRL, these individual uncertainty factors are multiplied together. The product is then 
divided into the inhalation concentration or oral dosage selected from the study. Uncertainty factors used 




Tables and Figures for Levels of Significant Exposure (LSE)
Tables and figures are used to summarize health effects and illustrate graphically levels o f exposure 
associated with those effects. These levels cover health effects observed at increasing dose 
concentrations and durations, differences in response by species, MRLs to humans for noncancer end 
points, and EPA's estimated range associated with an upper- bound individual lifetime cancer risk o f 1 in
10,000 to 1 in 10,000,000. Use the LSE tables and figures for a quick review of the health effects and to 
locate data for a specific exposure scenario. The LSE tables and figures should always be used in 
conjunction with the text. All entries in these tables and figures represent studies that provide reliable, 
quantitative estimates of NOAELs, LOAELs, or Cancer Effect Levels (CELs).
The legends presented below demonstrate the application o f these tables and figures. Representative 
examples o f LSE Table 3-1 and Figure 3-1 are shown. The numbers in the left column o f the legends 





See Sample LSE Table 3-1 (page B-6)
(1) Route of Exposure. One o f the first considerations when reviewing the toxicity o f a substance 
using these tables and figures should be the relevant and appropriate route o f exposure. Typically 
when sufficient data exist, three LSE tables and two LSE figures are presented in the document. 
The three LSE tables present data on the three principal routes o f exposure, i.e., inhalation, oral, 
and dermal (LSE Tables 3-1, 3-2, and 3-3, respectively). LSE figures are limited to the inhalation 
(LSE Figure 3-1) and oral (LSE Figure 3-2) routes. Not all substances will have data on each 
route o f exposure and will not, therefore, have all five o f the tables and figures.
(2) Exposure Period. Three exposure periods— acute (<15 days), intermediate (15-364 days), and 
chronic (365 days or more)— are presented within each relevant route o f exposure. In this 
example, an inhalation study o f intermediate exposure duration is reported. For quick reference 
to health effects occurring from a known length o f exposure, locate the applicable exposure 
period within the LSE table and figure.
(3) Health Effect. The major categories o f health effects included in LSE tables and figures are 
death, systemic, immunological, neurological, developmental, reproductive, and cancer.
NOAELs and LOAELs can be reported in the tables and figures for all effects but cancer. 
Systemic effects are further defined in the "System" column o f the LSE table (see key number 
18).
(4) Key to Figure. Each key number in the LSE table links study information to one or more data 
points using the same key number in the corresponding LSE figure. In this example, the study 
represented by key number 18 has been used to derive a NOAEL and a Less Serious LOAEL 
(also see the two "18r" data points in sample Figure 3-1).
(5) Species. The test species, whether animal or human, are identified in this column. Chapter 2, 
"Relevance to Public Health," covers the relevance o f animal data to human toxicity and 
Section 3.4, "Toxicokinetics," contains any available information on comparative toxicokinetics. 
Although NOAELs and LOAELs are species specific, the levels are extrapolated to equivalent 
human doses to derive an MRL.
(6) Exposure Frequency/Duration. The duration o f the study and the weekly and daily exposure 
regimens are provided in this column. This permits comparison of NOAELs and LOAELs from 
different studies. In this case (key number 18), rats were exposed to “Chemical x” via inhalation 
for 6 hours/day, 5 days/week, for 13 weeks. For a more complete review of the dosing regimen, 
refer to the appropriate sections of the text or the original reference paper (i.e., Nitschke et al. 
1981).
(7) System. This column further defines the systemic effects. These systems include respiratory, 
cardiovascular, gastrointestinal, hematological, musculoskeletal, hepatic, renal, and 
dermal/ocular. "Other" refers to any systemic effect (e.g., a decrease in body weight) not covered 
in these systems. In the example o f key number 18, one systemic effect (respiratory) was 
investigated.
(8) NOAEL. A NOAEL is the highest exposure level at which no harmful effects were seen in the 
organ system studied. Key number 18 reports a NOAEL o f 3 ppm for the respiratory system,
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which was used to derive an intermediate exposure, inhalation MRL of 0.005 ppm (see 
footnote "b").
(9) LOAEL. A LOAEL is the lowest dose used in the study that caused a harmful health effect. 
LOAELs have been classified into "Less Serious" and "Serious" effects. These distinctions help 
readers identify the levels o f exposure at which adverse health effects first appear and the 
gradation o f effects with increasing dose. A brief description o f the specific end point used to 
quantify the adverse effect accompanies the LOAEL. The respiratory effect reported in key 
number 18 (hyperplasia) is a Less Serious LOAEL of 10 ppm. MRLs are not derived from 
Serious LOAELs.
(10) Reference. The complete reference citation is given in Chapter 9 o f the profile.
(11) CEL. A CEL is the lowest exposure level associated with the onset o f carcinogenesis in 
experimental or epidemiologic studies. CELs are always considered serious effects. The LSE 
tables and figures do not contain NOAELs for cancer, but the text may report doses not causing 
measurable cancer increases.
(12) Footnotes. Explanations of abbreviations or reference notes for data in the LSE tables are found 
in the footnotes. Footnote "b" indicates that the NOAEL o f 3 ppm in key number 18 was used to 
derive an MRL o f 0.005 ppm.
LEGEND 
See Sample Figure 3-1 (page B-7)
LSE figures graphically illustrate the data presented in the corresponding LSE tables. Figures help the
reader quickly compare health effects according to exposure concentrations for particular exposure
periods.
(13) Exposure Period. The same exposure periods appear as in the LSE table. In this example, health 
effects observed within the acute and intermediate exposure periods are illustrated.
(14) Health Effect. These are the categories of health effects for which reliable quantitative data 
exists. The same health effects appear in the LSE table.
(15) Levels o f Exposure. Concentrations or doses for each health effect in the LSE tables are 
graphically displayed in the LSE figures. Exposure concentration or dose is measured on the log 
scale "y" axis. Inhalation exposure is reported in mg/m3 or ppm and oral exposure is reported in 
mg/kg/day.
(16) NOAEL. In this example, the open circle designated 18r identifies a NOAEL critical end point in 
the rat upon which an intermediate inhalation exposure MRL is based. The key number 18 
corresponds to the entry in the LSE table. The dashed descending arrow indicates the 
extrapolation from the exposure level o f 3 ppm (see entry 18 in the table) to the MRL of
0.005 ppm (see footnote "b" in the LSE table).
(17) CEL. Key number 38m is one o f three studies for which CELs were derived. The diamond 
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(18) Estimated Upper-Bound Human Cancer Risk Levels. This is the range associated with the upper- 
bound for lifetime cancer risk o f 1 in 10,000 to 1 in 10,000,000. These risk levels are derived 
from the EPA's Human Health Assessment Group's upper-bound estimates o f the slope o f the 
cancer dose response curve at low dose levels (qi*).
(19) Key to LSE Figure. The Key explains the abbreviations and symbols used in the figure.
SAMPLE





NOAEL Less serious Serious (ppm)
System (ppm) (ppm) Reference
7 8 9 10
i i i i































(CEL, lung tumors, 
nasal tumors)
Nitschke et al. 1981
Wong et al. 1982
NTP 1982
10 (CEL, lung tumors, NTP 1982 
hemangiosarcomas)
12 ^  a The number corresponds to entries in Figure 3-1.
b Used to derive an intermediate inhalation Minimal Risk Level (MRL) of 5x10-3 ppm; dose adjusted for intermittent exposure and divided 
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APPENDIX C. ACRONYMS, ABBREVIATIONS, AND SYMBOLS
ACGIH American Conference of Governmental Industrial Hygienists
ACOEM American College o f Occupational and Environmental Medicine
ADI acceptable daily intake
ADME absorption, distribution, metabolism, and excretion
AED atomic emission detection
AFID alkali flame ionization detector
AFOSH Air Force Office of Safety and Health
ALT alanine aminotransferase
AML acute myeloid leukemia
AOAC Association of Official Analytical Chemists
AOEC Association of Occupational and Environmental Clinics
AP alkaline phosphatase
APHA American Public Health Association
AST aspartate aminotransferase
atm atmosphere
ATSDR Agency for Toxic Substances and Disease Registry
AWQC Ambient W ater Quality Criteria
BAT best available technology
BCF bioconcentration factor
BEI Biological Exposure Index
BMD/C benchmark dose or benchmark concentration
BMDX dose that produces a X% change in response rate o f an adverse effect
BMDLX 95% lower confidence limit on the BMDX
BMDS Benchmark Dose Software
BMR benchmark response
BSC Board o f Scientific Counselors
C centigrade
CAA Clean Air Act
CAG Cancer Assessment Group o f the U.S. Environmental Protection Agency
CAS Chemical Abstract Services
CDC Centers for Disease Control and Prevention
CEL cancer effect level
CELDS Computer-Environmental Legislative Data System
CERCLA Comprehensive Environmental Response, Compensation, and Liability Act
CFR Code o f Federal Regulations
Ci curie
CI confidence interval
CL ceiling limit value
CLP Contract Laboratory Program
cm centimeter
CML chronic myeloid leukemia
CPSC Consumer Products Safety Commission
CWA Clean W ater Act
DHEW Department o f Health, Education, and Welfare
DHHS Department o f Health and Human Services
DNA deoxyribonucleic acid
DOD Department o f Defense
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DOE Department o f Energy
DOL Department o f Labor
DOT Department o f Transportation
DOT/UN/ Department o f Transportation/United Nations/
NA/IMDG North America/Intergovernmental Maritime Dangerous Goods Code 
DWEL drinking water exposure level
ECD electron capture detection
ECG/EKG electrocardiogram 
EEG electroencephalogram
EEGL Emergency Exposure Guidance Level
EPA Environmental Protection Agency
F Fahrenheit
F j first-filial generation
FAO Food and Agricultural Organization o f the United Nations
FDA Food and Drug Administration
FEMA Federal Emergency Management Agency
FIFRA Federal Insecticide, Fungicide, and Rodenticide Act
FPD flame photometric detection
fpm feet per minute
FR Federal Register




GLC gas liquid chromatography
GPC gel permeation chromatography
HPLC high-performance liquid chromatography
HRGC high resolution gas chromatography
HSDB Hazardous Substance Data Bank
IARC International Agency for Research on Cancer
IDLH immediately dangerous to life and health
ILO International Labor Organization




Koc organic carbon partition coefficient
Kow octanol-water partition coefficient
L liter
LC liquid chromatography
LC50 lethal concentration, 50% kill
LCLo lethal concentration, low
LD50 lethal dose, 50% kill




LSE Levels o f Significant Exposure






MAL maximum allowable level
mCi millicurie
MCL maximum contaminant level
MCLG maximum contaminant level goal
MF modifying factor




mmHg millimeters o f mercury
mmol millimole
mppcf millions o f particles per cubic foot
MRL Minimal Risk Level
MS mass spectrometry
NAAQS National Ambient Air Quality Standard
NAS National Academy o f Science
NATICH National Air Toxics Information Clearinghouse
NATO North Atlantic Treaty Organization
NCE normochromatic erythrocytes
NCEH National Center for Environmental Health
NCI National Cancer Institute
ND not detected
NFPA National Fire Protection Association
ng nanogram
NHANES National Health and Nutrition Examination Survey
NIEHS National Institute of Environmental Health Sciences
NIOSH National Institute for Occupational Safety and Health
NIOSHTIC NIOSH's Computerized Information Retrieval System




NOES National Occupational Exposure Survey
NOHS National Occupational Hazard Survey
NPD nitrogen phosphorus detection
NPDES National Pollutant Discharge Elimination System
NPL National Priorities List
NR not reported
NRC National Research Council
NS not specified
NSPS New Source Performance Standards
NTIS National Technical Information Service
NTP National Toxicology Program
ODW Office of Drinking Water, EPA
OERR Office of Emergency and Remedial Response, EPA
OHM/TADS Oil and Hazardous Materials/Technical Assistance Data Sys
OPP Office of Pesticide Programs, EPA
OPPT Office of Pollution Prevention and Toxics, EPA
OPPTS Office of Prevention, Pesticides and Toxic Substances, EPA
OR odds ratio
OSHA Occupational Safety and Health Administration
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OSW Office of Solid Waste, EPA
OTS Office of Toxic Substances
OW Office of W ater
OWRS Office of W ater Regulations and Standards, EPA
PAH polycyclic aromatic hydrocarbon
PBPD physiologically based pharmacodynamic
PBPK physiologically based pharmacokinetic
PCE polychromatic erythrocytes
PEL permissible exposure limit
pg picogram
PHS Public Health Service
PID photo ionization detector
pmol picomole
PMR proportionate mortality ratio
ppb parts per billion
ppm parts per million
ppt parts per trillion
PSNS pretreatment standards for new sources
RBC red blood cell





RTECS Registry o f Toxic Effects of Chemical Substances
SARA Superfund Amendments and Reauthorization Act
SCE sister chromatid exchange
SGOT serum glutamic oxaloacetic transaminase
SGPT serum glutamic pyruvic transaminase
SIC standard industrial classification
SIM selected ion monitoring
SMCL secondary maximum contaminant level
SMR standardized mortality ratio
SNARL suggested no adverse response level
SPEGL Short-Term Public Emergency Guidance Level
STEL short term exposure limit
STORET Storage and Retrieval
TD50 toxic dose, 50% specific toxic effect
TLV threshold limit value
TOC total organic carbon
TPQ threshold planning quantity
TRI Toxics Release Inventory




USDA United States Department o f Agriculture
USGS United States Geological Survey
VOC volatile organic compound
WBC white blood cell




> greater than or equal to
= equal to
< less than








q i* cancer slope factor- negative
+ positive
(+) weakly positive result
(-) weakly negative result
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aerobic................................................................................................................................................. 69, 113, 114, 115
alanine aminotransferase....................................................................................................................... 11, 16, 19, 51
ambient a i r .......................................................................................................................................................... 123, 124
anaerobic..................................................................................................................... 9, 69, 107, 113, 114, 115, 122
aspartate aminotransferase......................................................................................................................................... 51
bioaccumulation..................................................................................................................................................... 9, 111
bioavailability............................................................................................................................................. 66, 95, 123
bioconcentration fac to r............................................................................................................................................. 111
biodegradation....................................................................................................................9, 107, 113, 114, 115, 126
biom arker................................................................................................................................ 84, 85, 86, 94, 127, 140
body weight effects..............................................................................................................................................53, 62
breast m ilk............................................................................................................................................................. 4, 120
cancer.....................................................................................................................................................4, 22, 57, 83, 92
carcinogen.......................................................................................................................................................4, 12, 145
carcinogenic....................................................................................................................................... 11, 12, 21, 22, 57
carcinogenicity............................................................................................................................................ 11, 92, 113
carcinom as............................................................................................................................................. 11, 57, 92, 145
cardiovascular................................................................................................................................................ 22, 49, 58
cardiovascular effects.................................................................................................................................... 23, 49, 58
cholinesterase................................................................................................................................................................79
clearance........................................................................................................................................................................73
death...............................................................................................................................  13, 19, 21, 22, 23, 25, 58, 90
deoxyribonucleic acid (see D N A ).....................................................................................................................62, 63
dermal effects..................................................................................................................................................23, 52, 61
developmental effects...................................................................................  11, 25, 56, 57, 62, 82, 84, 91, 93, 96




fetus...............................................................................................................................................................4, 68, 82, 84
gastrointestinal effects..................................................................................................................................23, 50, 58
general population.......................................................................................................................................9, 107, 119
genotoxic................................................................................................................................................................21, 64
genotoxicity.....................................................................................................................................................62, 64, 92
groundwater....................................................2, 9, 105, 107, 111, 112, 115, 117, 119, 122, 123, 124, 137, 138
half-life............................................................................................................................................9, 85, 107, 113, 122
hematological effects.................................................................................................................................... 23, 50, 61
hepatic effects................................................................................................................................................ 23, 51, 61
hydrolysis...............................................................................................................................  107, 112, 135, 136, 139
immune system ............................................................................................................................................................ 93








m icronuclei............................................................................................................................................................. 64, 92
m ilk .............................................................................................................................................................................4, 68
musculoskeletal effects.........................................................................................................................................51, 61
neoplastic.......................................................................................................................................................................92
neurobehavioral.......................................................................................................................................  16, 54, 82, 94
neurological effects...............................  10, 14, 15, 17, 24, 53, 54, 55, 56, 62, 79, 81, 88, 90, 91, 94, 96, 143
neurotransmitter........................................................................................................................................................... 80
nuclear.......................................................................................................................................................................... 121
ocular effects........................................................................................................................................... 49, 52, 58, 62
partition coefficients..............................................................................................................................73, 74, 75, 76
pharmacodynamic........................................................................................................................................................70
pharmacokinetic.................................................................................................................. 15, 70, 71, 72, 83, 92, 93
photolysis....................................................................................................................................9, 107, 112, 113, 122
placenta...................................................................................................................................................................... 4, 68
rate constant...........................................................................................................................................73, 75, 77, 111
renal effects........................................................................................................................................ 22, 23, 52, 58, 61
reproductive effects...........................................................................................................................25, 55, 56, 62, 91




systemic effects................................................................................................................... 14, 22, 49, 58, 88, 90, 91
T 3 .............................................................................................................................................................................. 26, 59
T 4 .................................................................................................................................................................................. 100
toxicokinetic............................................................................................................................... 21, 65, 81, 84, 95, 96
trem ors....................................................................................................................  10, 14, 15, 17, 18, 20, 54, 90, 91
tum ors........................................................................................................................................................................ 4, 92
vapor pressure.............................................................................................................................................................137
volatilization............................................................................................................................................................... 110
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